



Pfizer Inc.

# 2025 CDP Corporate Questionnaire 2025

Word version

**Important: this export excludes unanswered questions**

This document is an export of your organization's CDP questionnaire response. It contains all data points for questions that are answered or in progress. There may be questions or data points that you have been requested to provide, which are missing from this document because they are currently unanswered. Please note that it is your responsibility to verify that your questionnaire response is complete prior to submission. CDP will not be liable for any failure to do so.

[Read full terms of disclosure](#)

# Contents

<b>C1. Introduction.....</b>	<b>8</b>
(1.1) In which language are you submitting your response? .....	8
(1.2) Select the currency used for all financial information disclosed throughout your response. ....	8
(1.3) Provide an overview and introduction to your organization. ....	8
(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years. ....	9
(1.4.1) What is your organization's annual revenue for the reporting period? .....	10
(1.5) Provide details on your reporting boundary. ....	10
(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)? .....	11
(1.7) Select the countries/areas in which you operate. ....	13
(1.8) Are you able to provide geolocation data for your facilities? .....	14
(1.8.1) Please provide all available geolocation data for your facilities. ....	14
(1.24) Has your organization mapped its value chain? .....	16
(1.24.1) Have you mapped where in your direct operations or elsewhere in your value chain plastics are produced, commercialized, used, and/or disposed of? .....	17
<b>C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities.....</b>	<b>18</b>
(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities? .....	18
(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts? .....	19
(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities?.....	20
(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities. ....	20
(2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed? .....	29
(2.3) Have you identified priority locations across your value chain? .....	30
(2.4) How does your organization define substantive effects on your organization? .....	31
(2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health? .....	33
(2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities. ....	34

### **C3. Disclosure of risks and opportunities..... 36**

(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?.....	36
(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future. ....	38
(3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks.....	45
(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?.....	46
(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)? .....	46
(3.5.1) Select the carbon pricing regulation(s) which impact your operations. ....	46
(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by. ....	46
(3.5.3) Complete the following table for each of the tax systems you are regulated by. ....	48
(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by? .....	49
(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future? .....	50
(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future. ....	50
(3.6.2) Provide the amount and proportion of your financial metrics in the reporting year that are aligned with the substantive effects of environmental opportunities. ....	59

### **C4. Governance ..... 61**

(4.1) Does your organization have a board of directors or an equivalent governing body?.....	61
(4.1.1) Is there board-level oversight of environmental issues within your organization?.....	62
(4.1.2) Identify the positions (do not include any names) of the individuals or committees on the board with accountability for environmental issues and provide details of the board's oversight of environmental issues. ....	62
(4.2) Does your organization's board have competency on environmental issues? .....	65
(4.3) Is there management-level responsibility for environmental issues within your organization?.....	66
(4.3.1) Provide the highest senior management-level positions or committees with responsibility for environmental issues (do not include the names of individuals). ....	66
(4.5) Do you provide monetary incentives for the management of environmental issues, including the attainment of targets? .....	71
(4.5.1) Provide further details on the monetary incentives provided for the management of environmental issues (do not include the names of individuals). ....	72
(4.6) Does your organization have an environmental policy that addresses environmental issues? .....	74
(4.6.1) Provide details of your environmental policies. ....	74
(4.10) Are you a signatory or member of any environmental collaborative frameworks or initiatives? .....	78

(4.11) In the reporting year, did your organization engage in activities that could directly or indirectly influence policy, law, or regulation that may (positively or negatively) impact the environment? .....	79
(4.11.2) Provide details of your indirect engagement on policy, law, or regulation that may (positively or negatively) impact the environment through trade associations or other intermediary organizations or individuals in the reporting year. ....	81
(4.12) Have you published information about your organization's response to environmental issues for this reporting year in places other than your CDP response? .....	85
(4.12.1) Provide details on the information published about your organization's response to environmental issues for this reporting year in places other than your CDP response. Please attach the publication. ....	85

## **C5. Business strategy..... 90**

(5.1) Does your organization use scenario analysis to identify environmental outcomes? .....	90
(5.1.1) Provide details of the scenarios used in your organization's scenario analysis. ....	90
(5.1.2) Provide details of the outcomes of your organization's scenario analysis. ....	99
(5.2) Does your organization's strategy include a climate transition plan? .....	101
(5.3) Have environmental risks and opportunities affected your strategy and/or financial planning? .....	104
(5.3.1) Describe where and how environmental risks and opportunities have affected your strategy. ....	104
(5.3.2) Describe where and how environmental risks and opportunities have affected your financial planning. ....	107
(5.4) In your organization's financial accounting, do you identify spending/revenue that is aligned with your organization's climate transition? .....	108
(5.4.1) Quantify the amount and percentage share of your spending/revenue that is aligned with your organization's climate transition. ....	109
(5.9) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year? .....	110
(5.10) Does your organization use an internal price on environmental externalities? .....	111
(5.10.1) Provide details of your organization's internal price on carbon. ....	111
(5.11) Do you engage with your value chain on environmental issues? .....	114
(5.11.1) Does your organization assess and classify suppliers according to their dependencies and/or impacts on the environment? .....	115
(5.11.2) Does your organization prioritize which suppliers to engage with on environmental issues? .....	117
(5.11.5) Do your suppliers have to meet environmental requirements as part of your organization's purchasing process? .....	118
(5.11.6) Provide details of the environmental requirements that suppliers have to meet as part of your organization's purchasing process, and the compliance measures in place. ....	120
(5.11.7) Provide further details of your organization's supplier engagement on environmental issues. ....	123
(5.11.9) Provide details of any environmental engagement activity with other stakeholders in the value chain. ....	126
(5.13) Has your organization already implemented any mutually beneficial environmental initiatives due to CDP Supply Chain member engagement? .....	133

<b>C6. Environmental Performance - Consolidation Approach .....</b>	<b>134</b>
(6.1) Provide details on your chosen consolidation approach for the calculation of environmental performance data.....	134
<b>C7. Environmental performance - Climate Change.....</b>	<b>135</b>
(7.1) Is this your first year of reporting emissions data to CDP? .....	135
(7.1.1) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data?.....	135
(7.1.2) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year? .....	135
(7.1.3) Have your organization's base year emissions and past years' emissions been recalculated as a result of any changes or errors reported in 7.1.1 and/or 7.1.2?....	136
(7.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions. ....	137
(7.3) Describe your organization's approach to reporting Scope 2 emissions. ....	137
(7.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure? .....	138
(7.4.1) Provide details of the sources of Scope 1, Scope 2, or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure. ....	138
(7.5) Provide your base year and base year emissions. ....	140
(7.6) What were your organization's gross global Scope 1 emissions in metric tons CO <sub>2</sub> e?.....	149
(7.7) What were your organization's gross global Scope 2 emissions in metric tons CO <sub>2</sub> e?.....	149
(7.8) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions. ....	150
(7.8.1) Disclose or restate your Scope 3 emissions data for previous years. ....	161
(7.9) Indicate the verification/assurance status that applies to your reported emissions. ....	164
(7.9.1) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.....	164
(7.9.2) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements. ....	165
(7.9.3) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements. ....	168
(7.10) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year? .....	169
(7.10.1) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year. ....	169
(7.10.2) Are your emissions performance calculations in 7.10 and 7.10.1 based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure? .....	172
(7.12) Are carbon dioxide emissions from biogenic carbon relevant to your organization? .....	173
(7.12.1) Provide the emissions from biogenic carbon relevant to your organization in metric tons CO <sub>2</sub> . ....	173

(7.15) Does your organization break down its Scope 1 emissions by greenhouse gas type? .....	173
(7.15.1) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used global warming potential (GWP). .....	173
(7.16) Break down your total gross global Scope 1 and 2 emissions by country/area. ....	177
(7.17) Indicate which gross global Scope 1 emissions breakdowns you are able to provide. ....	202
(7.17.1) Break down your total gross global Scope 1 emissions by business division. ....	202
(7.20) Indicate which gross global Scope 2 emissions breakdowns you are able to provide. ....	203
(7.20.1) Break down your total gross global Scope 2 emissions by business division. ....	203
(7.22) Break down your gross Scope 1 and Scope 2 emissions between your consolidated accounting group and other entities included in your response. ....	203
(7.23) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response?.....	204
(7.27) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges? .....	205
(7.28) Do you plan to develop your capabilities to allocate emissions to your customers in the future? .....	205
(7.29) What percentage of your total operational spend in the reporting year was on energy? .....	205
(7.30) Select which energy-related activities your organization has undertaken. ....	206
(7.30.1) Report your organization's energy consumption totals (excluding feedstocks) in MWh. ....	206
(7.30.6) Select the applications of your organization's consumption of fuel. ....	210
(7.30.7) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type. ....	211
(7.30.9) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year. ....	218
(7.30.16) Provide a breakdown by country/area of your electricity/heat/steam/cooling consumption in the reporting year. ....	220
(7.30.17) Provide details of your organization's renewable electricity purchases in the reporting year by country/area. ....	275
(7.30.18) Provide details of your organization's low-carbon heat, steam, and cooling purchases in the reporting year by country/area. ....	289
(7.30.19) Provide details of your organization's renewable electricity generation by country/area in the reporting year.....	291
(7.30.20) Describe how your organization's renewable electricity sourcing strategy directly or indirectly contributes to bringing new capacity into the grid in the countries/areas in which you operate. ....	305
(7.30.21) In the reporting year, has your organization faced barriers or challenges to sourcing renewable electricity?.....	305
(7.30.22) Provide details of the country/area-specific challenges to sourcing renewable electricity faced by your organization in the reporting year.....	305
(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations. ....	306
(7.52) Provide any additional climate-related metrics relevant to your business.....	308

(7.53) Did you have an emissions target that was active in the reporting year? .....	310
(7.53.1) Provide details of your absolute emissions targets and progress made against those targets. ....	310
(7.54) Did you have any other climate-related targets that were active in the reporting year? .....	333
(7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production. ....	334
(7.54.2) Provide details of any other climate-related targets, including methane reduction targets. ....	336
(7.54.3) Provide details of your net-zero target(s). ....	339
(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases. ....	342
(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings. ....	342
(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below. ....	342
(7.55.3) What methods do you use to drive investment in emissions reduction activities? .....	344
(7.73) Are you providing product level data for your organization's goods or services? .....	345
(7.74) Do you classify any of your existing goods and/or services as low-carbon products? .....	345
(7.74.1) Provide details of your products and/or services that you classify as low-carbon products. ....	345
(7.79) Has your organization retired any project-based carbon credits within the reporting year? .....	347

## **C9. Environmental performance - Water security..... 348**

(9.1) Are there any exclusions from your disclosure of water-related data? .....	348
(9.1.1) Provide details on these exclusions. ....	348
(9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored? .....	349
(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change? .....	356
(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change. ....	360
(9.2.7) Provide total water withdrawal data by source. ....	361
(9.2.8) Provide total water discharge data by destination. ....	365
(9.2.9) Within your direct operations, indicate the highest level(s) to which you treat your discharge. ....	367
(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year. ....	372
(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities? .....	373

(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year. ....	374
(9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified? .....	401
(9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member? .....	403
(9.5) Provide a figure for your organization’s total water withdrawal efficiency. ....	404
(9.13) Do any of your products contain substances classified as hazardous by a regulatory authority? .....	404
(9.14) Do you classify any of your current products and/or services as low water impact? .....	404
(9.15) Do you have any water-related targets? .....	405
(9.15.1) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories. ....	405
(9.15.2) Provide details of your water-related targets and the progress made. ....	407
<b>C10. Environmental performance - Plastics .....</b>	<b>410</b>
(10.1) Do you have plastics-related targets, and if so what type? .....	410
(10.2) Indicate whether your organization engages in the following activities. ....	410
(10.4) Provide the total weight of plastic durable goods and durable components produced, sold and/or used, and indicate the raw material content. ....	413
(10.5) Provide the total weight of plastic packaging sold and/or used and indicate the raw material content. ....	414
(10.5.1) Indicate the circularity potential of the plastic packaging you sold and/or used.....	414
<b>C13. Further information &amp; sign off .....</b>	<b>416</b>
(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party? .....	416
(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used? .....	416
(13.3) Provide the following information for the person that has signed off (approved) your CDP response. ....	419



## C1. Introduction

### (1.1) In which language are you submitting your response?

Select from:

☒ English

### (1.2) Select the currency used for all financial information disclosed throughout your response.

Select from:

☒ USD

### (1.3) Provide an overview and introduction to your organization.

#### (1.3.2) Organization type

Select from:

☒ Publicly traded organization

#### (1.3.3) Description of organization

*Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The company was incorporated under the laws of the State of Delaware on June 2, 1942. Pfizer's approach to responsible business growth is closely aligned with our purpose and corporate strategy. Through a comprehensive assessment, we identified 30 key topics, which we organized into six priority areas: product innovation, climate change, equitable access and pricing, product quality and safety, diversity, equity and inclusion, and business ethics. These priorities are embedded in our Blueprint Strategy and integrated into our Enterprise Risk Management (ERM) process. Pfizer's environmental sustainability program is focused on mitigating climate impact, conserving natural resources, and reducing waste including:*

- *Reducing the greenhouse gas (GHG) emissions associated with our operations. This includes application of engineering and sustainability innovations to how we design and operate our sites (e.g., manufacturing, labs, offices, etc.) and manage our operations (e.g., product transportation, business travel, renewable energy, etc.).*

- Reducing water withdrawal associated with our operations and being effective stewards of the water we use
- Decreasing waste generated from our operations through a multifaceted approach including source reduction, waste minimization, recycling, and other opportunities to reuse materials we cannot recycle ourselves
- Applying scientific innovation and operational efficiency to reduce the environmental impact of our medicines throughout the product lifecycle
- Integrating environmental sustainability criteria into our supplier selection and management processes; and
- Engaging with key suppliers of goods and services to drive the adoption of science-based GHG reduction goals.

*With senior leader support and collaboration at all levels, we aim to improve health outcomes, build trust, create shared value, and make a positive impact on society for years to come. Further information can be found at [www.Pfizer.com](http://www.Pfizer.com) or through Pfizer's social media including X (formerly known as Twitter) @Pfizer and @Pfizer News, LinkedIn, YouTube and Facebook.com/Pfizer. Disclosure Notice: The information contained in this 2025 CDP submittal is as of September 12, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this response as the result of new information or future events or developments. This response contains forward-looking information about, among other things, potential environmental impacts to Pfizer, including regulatory, physical, and business risks and opportunities, and information related to environmental sustainability strategies and goals, all of which involve substantial risks, uncertainties and assumptions. Such risks, uncertainties and assumptions include, among other things, the uncertainties inherent in determining potential impacts from climate change; changes to existing, or implementation of new regulations; projected financial impact and management cost; projected performance on climate change related goals; and the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer's business and prospects, adverse developments in Pfizer's markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally. Pfizer's past performance in attaining reductions in GHG emissions is not an indication of future performance. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results" and in its subsequent reports on Forms 10-Q and 8-K, all of which are filed with the SEC and are available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com).*

#### **(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years.**

##### **(1.4.1) End date of reporting year**

12/31/2024

##### **(1.4.2) Alignment of this reporting period with your financial reporting period**

Select from:

☒ Yes

##### **(1.4.3) Indicate if you are providing emissions data for past reporting years**

Select from:

☒ Yes

(1.4.4) Number of past reporting years you will be providing Scope 1 emissions data for

Select from:

☒ 1 year

(1.4.5) Number of past reporting years you will be providing Scope 2 emissions data for

Select from:

☒ 1 year

(1.4.6) Number of past reporting years you will be providing Scope 3 emissions data for

Select from:

☒ 1 year

(1.4.1) What is your organization’s annual revenue for the reporting period?

\$63,627,000,000

(1.5) Provide details on your reporting boundary.

	Is your reporting boundary for your CDP disclosure the same as that used in your financial statements?
	Select from: <input checked="" type="checkbox"/> Yes

**(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?**

**ISIN code - bond**

**(1.6.1) Does your organization use this unique identifier?**

*Select from:*

☒ No

**ISIN code - equity**

**(1.6.1) Does your organization use this unique identifier?**

*Select from:*

☒ Yes

**(1.6.2) Provide your unique identifier**

US7170811035

**CUSIP number**

**(1.6.1) Does your organization use this unique identifier?**

*Select from:*

☒ Yes

**(1.6.2) Provide your unique identifier**

717081103

**Ticker symbol**

**(1.6.1) Does your organization use this unique identifier?**

Select from:

☒ Yes

## (1.6.2) Provide your unique identifier

PFE

### SEDOL code

## (1.6.1) Does your organization use this unique identifier?

Select from:

☒ No

### LEI number

## (1.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

## (1.6.2) Provide your unique identifier

765LHXWGK1KXCLTFYQ30

### D-U-N-S number

## (1.6.1) Does your organization use this unique identifier?

Select from:

☒ No

### Other unique identifier

## (1.6.1) Does your organization use this unique identifier?

Select from:

☒ No

### **(1.7) Select the countries/areas in which you operate.**

Select all that apply

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Peru     | <input checked="" type="checkbox"/> Italy     |
| <input checked="" type="checkbox"/> Chile    | <input checked="" type="checkbox"/> Japan     |
| <input checked="" type="checkbox"/> China    | <input checked="" type="checkbox"/> Spain     |
| <input checked="" type="checkbox"/> Egypt    | <input checked="" type="checkbox"/> Brazil    |
| <input checked="" type="checkbox"/> India    | <input checked="" type="checkbox"/> Canada    |
| <input checked="" type="checkbox"/> France   | <input checked="" type="checkbox"/> Norway    |
| <input checked="" type="checkbox"/> Greece   | <input checked="" type="checkbox"/> Poland    |
| <input checked="" type="checkbox"/> Israel   | <input checked="" type="checkbox"/> Serbia    |
| <input checked="" type="checkbox"/> Latvia   | <input checked="" type="checkbox"/> Sweden    |
| <input checked="" type="checkbox"/> Mexico   | <input checked="" type="checkbox"/> Turkey    |
| <input checked="" type="checkbox"/> Algeria  | <input checked="" type="checkbox"/> Czechia   |
| <input checked="" type="checkbox"/> Austria  | <input checked="" type="checkbox"/> Denmark   |
| <input checked="" type="checkbox"/> Belarus  | <input checked="" type="checkbox"/> Ecuador   |
| <input checked="" type="checkbox"/> Belgium  | <input checked="" type="checkbox"/> Estonia   |
| <input checked="" type="checkbox"/> Croatia  | <input checked="" type="checkbox"/> Finland   |
| <input checked="" type="checkbox"/> Germany  | <input checked="" type="checkbox"/> Tunisia   |
| <input checked="" type="checkbox"/> Hungary  | <input checked="" type="checkbox"/> Ukraine   |
| <input checked="" type="checkbox"/> Ireland  | <input checked="" type="checkbox"/> Bulgaria  |
| <input checked="" type="checkbox"/> Morocco  | <input checked="" type="checkbox"/> Colombia  |
| <input checked="" type="checkbox"/> Romania  | <input checked="" type="checkbox"/> Pakistan  |
| <input checked="" type="checkbox"/> Portugal | <input checked="" type="checkbox"/> Argentina |
| <input checked="" type="checkbox"/> Slovakia | <input checked="" type="checkbox"/> Australia |
| <input checked="" type="checkbox"/> Slovenia | <input checked="" type="checkbox"/> Indonesia |

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> Thailand   | <input checked="" type="checkbox"/> Lithuania    |
| <input checked="" type="checkbox"/> Viet Nam   | <input checked="" type="checkbox"/> Singapore    |
| <input checked="" type="checkbox"/> Costa Rica   | <input checked="" type="checkbox"/> Philippines  |
| <input checked="" type="checkbox"/> Kazakhstan   | <input checked="" type="checkbox"/> Puerto Rico  |
| <input checked="" type="checkbox"/> Luxembourg   | <input checked="" type="checkbox"/> Switzerland  |
| <input checked="" type="checkbox"/> Netherlands  | <input checked="" type="checkbox"/> Saudi Arabia |
| <input checked="" type="checkbox"/> New Zealand  | <input checked="" type="checkbox"/> South Africa |
| <input checked="" type="checkbox"/> Taiwan, China  |  |
| <input checked="" type="checkbox"/> Republic of Korea                                    |  |
| <input checked="" type="checkbox"/> Russian Federation                                   |  |
| <input checked="" type="checkbox"/> United States of America                             |  |
| <input checked="" type="checkbox"/> United Kingdom of Great Britain and Northern Ireland |  |

## **(1.8) Are you able to provide geolocation data for your facilities?**

### **(1.8.1) Are you able to provide geolocation data for your facilities?**

Select from:

- ☒ Yes, for some facilities

### **(1.8.2) Comment**

*While we have geolocation data available, due to the large number of facilities included within the scope of this disclosure we are only providing data for the facility relevant to the Supply Chain member requesting our water response.*

## **(1.8.1) Please provide all available geolocation data for your facilities.**

**Row 1**

#### (1.8.1.1) Identifier

*Newbridge*

#### (1.8.1.2) Latitude

*53.1858*

#### (1.8.1.3) Longitude

*-6.7794*

#### (1.8.1.4) Comment

*Geolocation data provided for the facility relevant to the CDP Supply chain member requesting Water Security information.*

### Row 2

#### (1.8.1.1) Identifier

*Kalamazoo*

#### (1.8.1.2) Latitude

*42.2106*

#### (1.8.1.3) Longitude

*-85.5571*

#### (1.8.1.4) Comment

*Geolocation data provided for the facility relevant to the CDP Supply chain member requesting Water Security information.*

### Row 3



### **(1.8.1.1) Identifier**

*McPherson*

### **(1.8.1.2) Latitude**

*38.3875*

### **(1.8.1.3) Longitude**

*-97.6347*

### **(1.8.1.4) Comment**

*Geolocation data provided for the facility relevant to the CDP Supply chain member requesting Water Security information.*

## **(1.24) Has your organization mapped its value chain?**

### **(1.24.1) Value chain mapped**

*Select from:*

☒ Yes, we have mapped or are currently in the process of mapping our value chain

### **(1.24.2) Value chain stages covered in mapping**

*Select all that apply*

☒ Upstream value chain

### **(1.24.3) Highest supplier tier mapped**

*Select from:*

☒ Tier 1 suppliers

### **(1.24.4) Highest supplier tier known but not mapped**

Select from:

☒ Tier 2 suppliers

### (1.24.7) Description of mapping process and coverage

*Pfizer sets high standards for responsible supply chain management, guided by robust governance processes. This helps ensure the safety and quality of the medicines and vaccines we produce and aligns with our core value of Equity. Compliance with laws is our baseline expectation, and we also establish other risk-based assessment criteria to help assure our suppliers are responsibly managing environmental, health, and safety (EHS) risks and maintaining a robust supply chain, including establishing a comprehensive supply chain management system. We collect information regarding our suppliers' business entities and business locations. This information is maintained in our enterprise systems.*

#### (1.24.1) Have you mapped where in your direct operations or elsewhere in your value chain plastics are produced, commercialized, used, and/or disposed of?

	Plastics mapping	Value chain stages covered in mapping
	<p>Select from:</p> <p><input checked="" type="checkbox"/> Yes, we have mapped or are currently in the process of mapping plastics in our value chain</p>	<p>Select all that apply</p> <p><input checked="" type="checkbox"/> Upstream value chain</p>

## C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities

(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities?

### Short-term

(2.1.1) From (years)

0

(2.1.3) To (years)

5

(2.1.4) How this time horizon is linked to strategic and/or financial planning

*Pfizer uses a 0-5 year timeframe to assess short-term environmental dependencies, impacts, risks and opportunities. This timeframe is useful to inform business planning and identify capital needs.*

### Medium-term

(2.1.1) From (years)

5

(2.1.3) To (years)

10

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer uses a 5-10 year timeframe in assessing environmental dependencies, impacts, risks and opportunities. This time horizon aligns with Pfizer's current near-term climate targets and informs strategy and investment needed as we strive to achieve our emission reduction targets.

Long-term

(2.1.1) From (years)

10

(2.1.2) Is your long-term time horizon open ended?

Select from:

☒ No

(2.1.3) To (years)

30

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer defines long-term as 10-30 years for assessing environmental dependencies, impacts, risks and opportunities. This timeframe aligns with the Corporate Net-Zero Standard as well as decarbonization timelines established by many government healthcare agencies globally.

(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts?

	Process in place	Dependencies and/or impacts evaluated in this process
	Select from: <input checked="" type="checkbox"/> Yes	Select from: <input checked="" type="checkbox"/> Both dependencies and impacts

**(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities?**

	Process in place	Risks and/or opportunities evaluated in this process	Is this process informed by the dependencies and/or impacts process?
	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select from:</i> <input checked="" type="checkbox"/> Both risks and opportunities	<i>Select from:</i> <input checked="" type="checkbox"/> Yes

**(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities.**

**Row 1**

**(2.2.2.1) Environmental issue**

*Select all that apply*

☒ Climate change

**(2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue**

*Select all that apply*

☒ Dependencies

☒ Impacts

☒ Risks

☒ Opportunities

**(2.2.2.3) Value chain stages covered**

*Select all that apply*

- ☒ Direct operations
- ☒ Upstream value chain
- ☒ Downstream value chain

#### **(2.2.2.4) Coverage**

*Select from:*

- ☒ Full

#### **(2.2.2.5) Supplier tiers covered**

*Select all that apply*

- ☒ Tier 1 suppliers

#### **(2.2.2.7) Type of assessment**

*Select from:*

- ☒ Qualitative and quantitative

#### **(2.2.2.8) Frequency of assessment**

*Select from:*

- ☒ More than once a year

#### **(2.2.2.9) Time horizons covered**

*Select all that apply*

- ☒ Short-term
- ☒ Medium-term
- ☒ Long-term

#### **(2.2.2.10) Integration of risk management process**

Select from:

- ☒ Integrated into multi-disciplinary organization-wide risk management process

### (2.2.2.11) Location-specificity used

Select all that apply

- ☒ Site-specific
- ☒ Local
- ☒ National

### (2.2.2.12) Tools and methods used

Enterprise Risk Management

- ☒ Enterprise Risk Management
- ☒ Internal company methods

International methodologies and standards

- ☒ ISO 14001 Environmental Management Standard
- ☒ Other international methodologies and standards, please specify :The International Best Track Archive for Climate Stewardship (IBTrACS)

Databases

- ☒ Nation-specific databases, tools, or standards
- ☒ Other databases, please specify :World Resources Institute, NASA, European Space Agency

Other

- ☒ Desk-based research
- ☒ External consultants
- ☒ Scenario analysis
- ☒ Other, please specify :World Climate Research Programme (WCRP) Coupled Model Intercomparison Project (CMIP6)

### (2.2.2.13) Risk types and criteria considered

### Acute physical

- ☑ Drought
- ☑ Avalanche
- ☑ Landslide
- ☑ Wildfires
- ☑ Heat waves
- ☑ Flood (coastal, fluvial, pluvial, ground water)
- ☑ Storm (including blizzards, dust, and sandstorms)

### Chronic physical

- ☑ Heat stress
- ☑ Soil erosion
- ☑ Solifluction
- ☑ Water stress
- ☑ Sea level rise
- ☑ Temperature variability
- ☑ Water quality at a basin/catchment level
- ☑ Precipitation or hydrological variability
- ☑ Increased severity of extreme weather events
- ☑ Water availability at a basin/catchment level

### Policy

- ☑ Carbon pricing mechanisms
- ☑ Changes to international law and bilateral agreements
- ☑ Changes to national legislation

### Market

- ☑ Availability and/or increased cost of raw materials
- ☑ Changing customer behavior

### Reputation

- ☑ Impact on human health

- ☑ Subsidence
- ☑ Cold wave/frost
- ☑ Glacial lake outburst
- ☑ Cyclones, hurricanes, typhoons
- ☑ Heavy precipitation (rain, hail, snow/ice)

- ☑ Coastal erosion
- ☑ Soil degradation
- ☑ Permafrost thawing
- ☑ Ocean acidification
- ☑ Changing wind patterns
- ☑ Changing temperature (air, freshwater, marine water)
- ☑ Changing precipitation patterns and types (rain, hail, snow/ice)



- ☒ Increased partner and stakeholder concern and partner and stakeholder negative feedback

#### Technology

- ☒ Transition to lower emissions technology and products

#### Liability

- ☒ Exposure to litigation
- ☒ Non-compliance with regulations

### (2.2.2.14) Partners and stakeholders considered

Select all that apply

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> NGOs      | <input checked="" type="checkbox"/> Regulators        |
| <input checked="" type="checkbox"/> Customers | <input checked="" type="checkbox"/> Local communities |
| <input checked="" type="checkbox"/> Employees |   |
| <input checked="" type="checkbox"/> Investors |   |
| <input checked="" type="checkbox"/> Suppliers |   |

### (2.2.2.15) Has this process changed since the previous reporting year?

Select from:

- ☒ No

### (2.2.2.16) Further details of process

*Pfizer assesses climate change risk as part of our enterprise-level EHS and business continuity risk management processes. We conduct structured evaluations of risks with the potential to have a substantive impact on Pfizer and the effectiveness of controls through our Operational Risk Review (ORR) process. Under our ORR process, cross-functional program leaders and subject matter experts assess potential climate-related risks to Pfizer's direct operations and full value chain across four risk areas (external and reputational, physical, regulatory and legal, and market and technology). Acute and chronic physical risks related to climate change are managed through Pfizer's Loss Prevention and Business Resilience teams at the enterprise and local levels. Pfizer uses natural hazard analysis and mapping tools to monitor short-, medium- and long-term physical threats to internal operations and for more than 5,000 contract manufacturers and material suppliers. To gain insight into Pfizer's current and projected resilience to acute and chronic physical risks and opportunities, we conducted a TCFD-aligned risk assessment using a panel of criteria and hazards developed in partnership with a global sustainability consultancy. The qualitative scenario analyses for physical risk were guided using IPCC-aligned predictive modeling and usage of a blend of national and global datasets, setting a foundation for further engagement with internal stakeholders spanning*

across Pfizer's operational geographical footprint. After a validation process with internal stakeholders, we assigned impact ratings using Pfizer methodology applied in our Enterprise Risk Management (ERM) framework. Twenty risks and opportunities with the highest potential for impact were prioritized for further comprehensive assessment. Risks identified through these assessments are prioritized based on potential severity and the effectiveness of existing controls and, if necessary, risk mitigation actions are identified. This information is reviewed as part of the ORR, and mitigation of risk is monitored through Pfizer's Loss Prevention and Business Resilience programs and escalated to company leadership as needed to inform business strategy. Key risks identified through these processes are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC). PGS QRC reports key risks to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors. The PGS QRC risk management process also informs Pfizer's ERM program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM program provides a framework for the identification and management of significant risks. Pfizer also monitors progress on climate commitments throughout the year. Issues or events that may impact our ability to achieve established commitments are identified and escalated.

## Row 2

### (2.2.2.1) Environmental issue

Select all that apply

☒ Water

### (2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☒ Dependencies

☒ Impacts

☒ Risks

☒ Opportunities

### (2.2.2.3) Value chain stages covered

Select all that apply

☒ Direct operations

☒ Upstream value chain

### (2.2.2.4) Coverage

*Select from:*

☒ Full

#### **(2.2.2.5) Supplier tiers covered**

*Select all that apply*

☒ Tier 1 suppliers

#### **(2.2.2.7) Type of assessment**

*Select from:*

☒ Qualitative and quantitative

#### **(2.2.2.8) Frequency of assessment**

*Select from:*

☒ More than once a year

#### **(2.2.2.9) Time horizons covered**

*Select all that apply*

☒ Short-term

☒ Medium-term

☒ Long-term

#### **(2.2.2.10) Integration of risk management process**

*Select from:*

☒ Integrated into multi-disciplinary organization-wide risk management process

#### **(2.2.2.11) Location-specificity used**

*Select all that apply*

☒ Site-specific

- ☒ Local

### (2.2.2.12) Tools and methods used

Commercially/publicly available tools

- ☒ WRI Aqueduct
- ☒ Other commercially/publicly available tools, please specify :WBCSD Global Water Tool

Enterprise Risk Management

- ☒ Enterprise Risk Management
- ☒ Internal company methods

International methodologies and standards

- ☒ IPCC Climate Change Projections

Other

- ☒ External consultants
- ☒ Internal company methods
- ☒ Scenario analysis
- ☒ Other, please specify :Swiss RE CatNet; FEMA Flood Zone Maps

### (2.2.2.13) Risk types and criteria considered

Acute physical

- ☒ Cyclones, hurricanes, typhoons
- ☒ Drought
- ☒ Flood (coastal, fluvial, pluvial, ground water)
- ☒ Pollution incident
- ☒ Storm (including blizzards, dust, and sandstorms)

Chronic physical

- ☒ Water stress
- ☒ Increased severity of extreme weather events

- ☒ Sea level rise
- ☒ Groundwater depletion
- ☒ Declining water quality
- ☒ Water quality at a basin/catchment level

- ☒ Water availability at a basin/catchment level
- ☒ Changing precipitation patterns and types (rain, hail, snow/ice)
- ☒ Increased levels of environmental pollutants in freshwater bodies

#### Policy

- ☒ Changes to national legislation
- ☒ Introduction of regulatory standards for previously unregulated contaminants
- ☒ Poor enforcement of environmental regulation
- ☒ Regulation of discharge quality/volumes
- ☒ Statutory water withdrawal limits/changes to water allocation

#### Market

- ☒ Changing customer behavior
- ☒ Inadequate access to water, sanitation, and hygiene services (WASH)

#### Reputation

- ☒ Impact on human health
- ☒ Stakeholder conflicts concerning water resources at a basin/catchment level

### (2.2.2.14) Partners and stakeholders considered

*Select all that apply*

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> NGOs      | <input checked="" type="checkbox"/> Regulators                                     |
| <input checked="" type="checkbox"/> Customers | <input checked="" type="checkbox"/> Local communities                              |
| <input checked="" type="checkbox"/> Employees | <input checked="" type="checkbox"/> Water utilities at a local level               |
| <input checked="" type="checkbox"/> Investors | <input checked="" type="checkbox"/> Other water users at the basin/catchment level |
| <input checked="" type="checkbox"/> Suppliers |  |

### (2.2.2.15) Has this process changed since the previous reporting year?

*Select from:*

- ☒ No

## (2.2.2.16) Further details of process

*Pfizer uses multiple tools to assess water-related risks. We use the World Resources Institute (WRI) Aqueduct, World Business Council for Sustainable Development (WBCSD), and Intergovernmental Panel on Climate Change (IPCC) Global Water tools to identify water-related risks with the potential to have substantive financial or strategic impact to the business. For WRI Aqueduct, we consider all the tool indicators in our assessment, including those related to water scarcity, water quality, environmental flows, and the accessibility of water. We perform a site-level assessment of water-related system operations and program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). Our process assesses short, medium and long-term acute and chronic water risks. As part of the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations. Sites are also mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans. These assessments are conducted annually, or more frequently if there are significant changes to a facility. Subject matter experts conduct focused reviews for sites determined to be at higher risk. To gain insight into Pfizer's current and projected resilience to acute and chronic water-related risks and opportunities, we conducted a TCFD-aligned risk assessment using a panel of criteria and hazards developed in partnership with a multi-national sustainability advisory firm. We further refined our assessment process in 2023, expanding the scope of hazards considered and improving data quality by evaluating impacts at the asset level. The qualitative scenario analyses for physical risk were guided using IPCC-aligned predictive modeling and usage of a blend of national and global datasets, setting a foundation for further engagement with internal stakeholders spanning across Pfizer's operational geographical footprint. After a validation process with internal stakeholders, we assigned impact ratings using Pfizer methodology applied in our Enterprise Risk Management (ERM) framework. The conclusions of these risk assessment activities are used to inform an annual review of water-related risk through our EHS Operational Risk Review process (ORR). Key risks are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC). PGS QRC reports key risks to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors. The PGS QRC risk management process also informs Pfizer's ERM program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM program provides a framework for the identification and management of significant risks. Pfizer's Water Stewardship Position Statement, published in 2022, states our commitment to assessing water stress of our internal sites and key suppliers. Our position statement can be found on our website at: [Pfizer\\_Water\\_Stewardship\\_Public\\_Position\\_Statement\\_2022.pdf](#).*

## (2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed?

### (2.2.7.1) Interconnections between environmental dependencies, impacts, risks and/or opportunities assessed

Select from:

☒ Yes

### (2.2.7.2) Description of how interconnections are assessed

*The assessment of potential interconnections between environmental dependencies, impacts, risks and opportunities is integrated into our enterprise-level EHS and business continuity risk management processes. For example, a reliable supply of good quality water is critical to Pfizer's manufacturing operations, so water quality and availability in the short-, medium- and long-term timeframes are taken into consideration when assigning a weighting to water-related risk for these sites.*

*Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans.*

## **(2.3) Have you identified priority locations across your value chain?**

### **(2.3.1) Identification of priority locations**

*Select from:*

☒ Yes, we have identified priority locations

### **(2.3.2) Value chain stages where priority locations have been identified**

*Select all that apply*

☒ Direct operations

### **(2.3.3) Types of priority locations identified**

Locations with substantive dependencies, impacts, risks, and/or opportunities

☒ Locations with substantive dependencies, impacts, risks, and/or opportunities relating to water

### **(2.3.4) Description of process to identify priority locations**

*Pfizer uses multiple tools to assess climate- and water-related risks. We use the WRI Aqueduct, WBCSD, and IPCC Global Water tools to identify water-related risks with the potential to have substantive financial or strategic impact to the business. For WRI Aqueduct, we consider all the tool indicators in our assessment, including those related to water scarcity, water quality, environmental flows, and the accessibility of water. We perform a site-level assessment of water-related system operations and program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). Our process assesses short, medium and long-term acute and chronic water risks. As part of the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations. Sites are also mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans. These assessments are conducted annually, or more frequently if there are significant changes to a facility. Subject matter experts conduct focused reviews for sites determined to be at higher risk. To improve our understanding of Pfizer's resilience to the impacts of climate change, we conducted an in-depth assessment of our potential exposure to physical risks and opportunities that could have a potential impact on our business using scenario*

analysis informed by data modelling insights from a global sustainability consultancy. Through this process we assessed risks, opportunities and impacts, with consideration of key sensitivities, site aspects, exposures, drivers and uncertainties.

### **(2.3.5) Will you be disclosing a list/spatial map of priority locations?**

Select from:

☒ Yes, we will be disclosing the list/geospatial map of priority locations

### **(2.3.6) Provide a list and/or spatial map of priority locations**

Q2.3\_Priority locations across value chain.pdf

## **(2.4) How does your organization define substantive effects on your organization?**

### **Risks**

### **(2.4.1) Type of definition**

Select all that apply

☒ Qualitative

☒ Quantitative

### **(2.4.2) Indicator used to define substantive effect**

Select from:

☒ Other, please specify :Any costs (operating and/or capital)

### **(2.4.3) Change to indicator**

Select from:

☒ Absolute increase

### **(2.4.5) Absolute increase/ decrease figure**

\$100,000,000



## (2.4.6) Metrics considered in definition

Select all that apply

- ☒ Frequency of effect occurring
- ☒ Time horizon over which the effect occurs
- ☒ Likelihood of effect occurring

## (2.4.7) Application of definition

*For the purposes of this response, Pfizer defines “substantive” environmental risk as any climate-related or water security-related impact that could adversely impact the company’s business or financial condition or disrupt, delay or inhibit the supply of products designated as financially critical, medically necessary, and/or medically significant. For environmental risks that can be evaluated financially, Pfizer generally applies a threshold of \$100MM for considering a risk substantive in this context. We also consider certain market, reputational, regulatory and technology risks to Pfizer as part of the assessment. Pfizer applies these criteria when assessing both direct and indirect environmental risks and opportunities. For the avoidance of doubt, CDP’s phrasing of “substantive” and our response to questions presenting “substantive” climate- or water-related risks should not be considered to relate to matters or facts that could be deemed “material” to a reasonable investor as referred to under US securities laws, similar requirements of other jurisdictions, or other voluntary frameworks. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US SEC, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of “material” matters.*

## Opportunities

### (2.4.1) Type of definition

Select all that apply

- ☒ Qualitative
- ☒ Quantitative

### (2.4.2) Indicator used to define substantive effect

Select from:

- ☒ Revenue

### (2.4.3) Change to indicator

Select from:

- ☒ Absolute increase

#### (2.4.5) Absolute increase/ decrease figure

\$100,000,000

#### (2.4.6) Metrics considered in definition

Select all that apply

- ☒ Frequency of effect occurring
- ☒ Time horizon over which the effect occurs
- ☒ Likelihood of effect occurring

#### (2.4.7) Application of definition

*For the purposes of this response, Pfizer defines a “substantive” environmental opportunity as one that could potentially result in a reduction in operating expenses or an increase in revenue. Pfizer generally applies a threshold of \$100MM for considering an opportunity substantive in this context. We also consider certain market, reputational, product, operational efficiency, and business resilience opportunities in our assessment. Pfizer applies these criteria when assessing both direct and indirect environmental opportunities. For the avoidance of doubt, CDP’s phrasing of “substantive” and our response to questions presenting “substantive” climate- or water-related risks and opportunities should not be considered to relate to matters or facts that could be deemed “material” to a reasonable investor as referred to under US securities laws, similar requirements of other jurisdictions, or other voluntary frameworks. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US SEC, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of “material” matters.*

### (2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health?

#### (2.5.1) Identification and classification of potential water pollutants

Select from:

- ☒ Yes, we identify and classify our potential water pollutants

## (2.5.2) How potential water pollutants are identified and classified

*Mitigating our impact on water resources includes working to ensure that our operations do not adversely affect human health or the environment. We are committed to compliance with all applicable laws and regulations. We work to meet all applicable local water quality requirements and are committed to engaging our suppliers to embed responsible environmental standards into their operations. We are also committed to limiting the discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes. As an active member of the AMR Industry Alliance (AMRIA), Pfizer is committed to following the responsible manufacturing practices set out in the Antibiotic Manufacturing Standard, including the application of industry published targets (Predicted No Effect Concentrations (PNECs)) for antibiotics. For new projects, a risk assessment is performed during the capital project approval process to evaluate environmental impacts, e.g., wastewater discharges. Additionally, every major change to our manufacturing processes is reviewed through Pfizer's management of change process to address, among other things, wastewater management practices including consideration of the relevant PNEC.*

## (2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities.

### Row 1

#### (2.5.1.1) Water pollutant category

Select from:

☒ Other synthetic organic compounds

#### (2.5.1.2) Description of water pollutant and potential impacts

*Pfizer is committed to limiting discharges to wastewater from our manufacturing processes, including organic compounds and active pharmaceutical ingredients, using environmental risk assessment methodologies, wastewater discharge control practices and technologies, and responsible waste management.*

#### (2.5.1.3) Value chain stage

Select all that apply

☒ Direct operations

☒ Upstream value chain

☒ Downstream value chain

☒ Other, please specify :Product use phase

#### (2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

- ☒ Upgrading of process equipment/methods
- ☒ Beyond compliance with regulatory requirements
- ☒ Reduction or phase out of hazardous substances
- ☒ Provision of best practice instructions on product use
- ☒ Implementation of integrated solid waste management systems
- ☒ Requirement for suppliers to comply with regulatory requirements
- ☒ Industrial and chemical accidents prevention, preparedness, and response
- ☒ Discharge treatment using sector-specific processes to ensure compliance with regulatory requirements
- ☒ Assessment of critical infrastructure and storage condition (leakages, spillages, pipe erosion etc.) and their resilience
- ☒ Other, please specify :Requirement for suppliers to comply with standards beyond regulatory requirements

#### (2.5.1.5) Please explain

*Pfizer is committed to minimizing our impact on water resources and to ensuring our operations protect human health and the environment. We are committed to compliance with all applicable laws and local water quality requirements, including managing wastewater in line with permit requirements. Our global Water Stewardship Standard requires sites to assess and control risks to water from hazardous substances. Reducing pharmaceuticals in the environment remains a key priority. We are committed to managing wastewater responsibly at our sites and collaborating with suppliers to do the same. As part of the AMR Industry Alliance (AMRIA), we support efforts to mitigate antimicrobial resistance through responsible manufacturing. In 2024, we helped to advance AMRIA's Antibiotic Manufacturing Standard certification program. Our Catania, Italy site earned the British Standards Institution (BSI) Kitemark™ quality certification to the Antibiotic Manufacturing Standard for drug product manufacturing, and our Ringaskiddy, Ireland site received certification for API production. Additionally, one contract manufacturer achieved certification for both API and drug product used to make one of our antibiotics. We continue to expand certification efforts across our internal network and with external partners.*

### C3. Disclosure of risks and opportunities

**(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?**

#### Climate change

##### (3.1.1) Environmental risks identified

Select from:

☒ Yes, only within our direct operations

##### (3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain

Select from:

☒ Environmental risks exist, but none with the potential to have a substantive effect on our organization

##### (3.1.3) Please explain

*Pfizer assessed approximately 5,000 suppliers, based on their geographical location without considering adaptation or mitigation measures, against 9 key climate hazards (extreme heat, extreme cold, flooding (river, extreme rainfall, and coastal), tropical cyclones, rainfall-induced landslides, water stress and drought, and wildfires). While a number of these supplier locations were identified as being at elevated risk for one or more of these hazards by 2030 under a high carbon scenario, none were identified as having an overall elevated score when averaged across all nine climate hazards assessed. Pfizer's Loss Prevention and Business Continuity programs will continue to monitor risks to identify potential supply chain vulnerabilities and establish contingency plans designed to maintain supply, e.g., alternative sourcing options and holding multiple weeks of buffer inventory (depending on product). Pfizer maintains resources for assessing and establishing business continuity arrangements such as the activation of alternative supply chains. Supply chain and business continuity professionals are retained as staff and consultants to ensure these plans are updated at least annually, exercised at least annually, and key colleagues on site are trained on their content and implementation.*

#### Water

##### (3.1.1) Environmental risks identified

Select from:

☒ No

### **(3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain**

Select from:

☒ Environmental risks exist, but none with the potential to have a substantive effect on our organization

### **(3.1.3) Please explain**

*Pfizer uses a comprehensive risk assessment methodology to identify and evaluate water-related risks with the potential to have substantive financial or strategic impact to the business. These assessments are refreshed annually, or more frequently if there are significant changes to a facility. We have also completed detailed asset-level scenario analyses to assess potential medium- and long-term water-related risks. Based on the findings of these assessments, we consider our current business model and strategy to be resilient and have not identified any water-related risks that pose a substantive risk to our overall operations.*

## **Plastics**

### **(3.1.1) Environmental risks identified**

Select from:

☒ No

### **(3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain**

Select from:

☒ No standardized procedure

### **(3.1.3) Please explain**

*Pfizer's use of plastics does not pose environmental risks within our direct operations or value chain due to our commitment to responsible sourcing, controlled usage, and effective waste management practices. Plastics are used in equipment required for R&D and manufacturing (especially aseptic manufacturing) but are primarily used in packaging and product delivery systems, where their application is regulated and optimized for safety, efficiency, and minimal environmental impact. Pfizer*

*employs rigorous environmental risk assessments that have not identified plastics as a substantive concern to our operations to date. This is supported by our commitment to sustainable design, including efforts to reduce plastic use, increase recyclability, and eliminate substances of concern.*

**(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.**

## Climate change

### (3.1.1.1) Risk identifier

*Select from:*

☒ Risk1

### (3.1.1.3) Risk types and primary environmental risk driver

Policy

☒ Carbon pricing mechanisms

### (3.1.1.4) Value chain stage where the risk occurs

*Select from:*

☒ Direct operations

### (3.1.1.6) Country/area where the risk occurs

*Select all that apply*

☒ Chile  
☒ China  
☒ India  
☒ Italy  
☒ Japan

☒ Spain  
☒ Brazil  
☒ Canada  
☒ Greece  
☒ Mexico

- ☒ Sweden
- ☒ Austria
- ☒ Belgium
- ☒ Croatia
- ☒ Finland
- ☒ Portugal
- ☒ Argentina
- ☒ Australia
- ☒ Indonesia
- ☒ Singapore

- ☒ Germany
- ☒ Ireland
- ☒ Morocco
- ☒ Colombia
- ☒ Pakistan
- ☒ Netherlands
- ☒ Taiwan, China
- ☒ United States of America
- ☒ United Kingdom of Great Britain and Northern Ireland

### (3.1.1.9) Organization-specific description of risk

*According to the 2025 World Bank "State and Trends of Carbon Pricing" report, carbon pricing is increasingly recognized as an essential policy instrument to deliver the transition to a low-carbon economy. Approximately 28% of global emissions are currently covered by carbon pricing instruments and governments continue to evaluate carbon pricing policies to reduce emissions. Although not financially substantive to Pfizer at this time, the implementation of carbon pricing schemes could increase our cost of operations. The World Bank suggests that a carbon price of \$50-100 /mtCO<sub>2</sub>e by 2030 will be required to limit global warming below 2C, and in the Network for Greening the Financial System's most recent update in November 2024, scenarios consistent with a transition toward net-zero by 2050 include a carbon price of around \$300/mtCO<sub>2</sub>e by 2035. Pfizer has facilities in many regions where carbon pricing schemes currently exist or are being considered, including 20 in the Americas, 13 in Asia-Pacific, 2 in Africa, and 20 in Europe. We currently have 4 sites that are active under the EU ETS. Of the countries that have not implemented carbon taxes, the U.S., which accounts for around two-thirds of Pfizer's global Scope 1&2 emissions, represents the area of greatest potential impact. To mitigate the impact from carbon fees, including increases in the cost of goods within our supply chain, Pfizer continues to focus on energy demand reduction through our emission reduction goals.*

### (3.1.1.11) Primary financial effect of the risk

Select from:

- ☒ Increased indirect [operating] costs

### (3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Medium-term



### (3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☒ Very likely

### (3.1.1.14) Magnitude

Select from:

☒ Medium-low

### (3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

*These risks could increase operating costs, including the cost of our electricity and energy use, or otherwise increase compliance costs. Our supply chain is subject to these same transitional and physical risks and would likely pass along any increased operating costs to their customers (including Pfizer).*

### (3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☒ Yes

### (3.1.1.21) Anticipated financial effect figure in the medium-term – minimum (currency)

\$35,000,000

### (3.1.1.22) Anticipated financial effect figure in the medium-term – maximum (currency)

\$70,000,000

### (3.1.1.25) Explanation of financial effect figure

*Operations in the United States account for approximately two-thirds of Pfizer's global Scope 1&2 GHG emissions. Pfizer performed scenario analysis to determine the potential impact to Pfizer if the United States implements a federal carbon pricing scheme consistent with World Bank recommendations. The cost to Pfizer for Scope 1 emissions, calculated using 2024 Scope 1 emissions data for facilities located in the United States multiplied by \$50/mt CO<sub>2</sub>e as the minimum potential carbon tax and \$100/mt CO<sub>2</sub>e as the maximum potential carbon tax, could range from approximately \$18M to \$35M per year assuming no changes to onsite sources of GHG emissions by 2030. The cost associated with Scope 2 emissions, calculated using 2024 Scope 2 emissions data for facilities located in the United States*

multiplied by \$50/mt CO<sub>2</sub>e as the minimum potential carbon tax and \$100/mt CO<sub>2</sub>e as the maximum potential carbon tax, could range from approximately \$17M to \$34M per year by 2030 based on GHG emissions forecasts and varying rates of adoption of green technologies across the US electrical grid. Our calculation assumes that purchased environmental attribute credits will not be allowed to be used to offset GHG emissions for the purposes of any federal carbon assessments, which is consistent with the European Union ETS. Pfizer's combined total cost for US Scope 1&2 emissions therefore could range from approximately \$35M to \$70M per year by 2030, an increase of 14% to 28% over current global energy spend.

#### (3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☒ Establish organization-wide targets

#### (3.1.1.27) Cost of response to risk

\$35,000,000

#### (3.1.1.28) Explanation of cost calculation

The annual cost of response provided (\$35M) includes an estimated \$4M in staffing and consulting costs and approximately \$31M incremental OPEX/CAPEX investment to identify, evaluate and advance energy efficiency and decarbonization projects. The estimated OPEX and CAPEX spend is derived from 2024 project data entered by sites in Pfizer's enterprise environmental reporting system. The portion of that spend associated with emissions reduction was estimated based on project type, and the resulting values were aggregated to provide total projected incremental OPEX and CAPEX spend. The estimated \$4M in staffing and consulting costs was added to the \$31M project spend to arrive at the \$35M estimate. Our annual energy efficiency and decarbonization investment, which is integrated within our annual operating planning cycle, may change in the future subject to market and technological developments as we seek opportunities to decarbonize our company operations.

#### (3.1.1.29) Description of response

Pfizer evaluates climate change risk as part of its Operating Risk Review process. We monitor regulatory risks arising from current and/or expected local, state, regional, national, or international regulations or legislation related to climate change and evaluate the impact on an ongoing basis. Pfizer manages risk associated with emerging regulations and/or carbon pricing initiatives through effective GHG emission reduction goals and internal energy efficiency targets to reduce potential costs associated with the purchase or generation of energy. In 2024 we invested \$31M, not including staffing costs for internal energy conservation program management, to implement or begin implementing 232 projects across the company that are expected to result in an annual GHG emissions reduction of over 30,000 mt CO<sub>2</sub>e and an estimated annual savings of \$8M.

### Climate change

### (3.1.1.1) Risk identifier

Select from:

☒ Risk2

### (3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☒ Tornado

### (3.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations

### (3.1.1.6) Country/area where the risk occurs

Select all that apply

☒ United States of America

### (3.1.1.9) Organization-specific description of risk

*Climate change presents risks to our operations, including more frequent and severe weather events that could impact our facilities and those of our suppliers. Pfizer conducts comprehensive risk assessments to evaluate acute and chronic physical climate risks across our sites and key supplier locations. We use advanced modeling tools like NathanRE and ERM's Climate Impact Platform to assess short-, medium-, and long-term risks from major climate hazards. Many Pfizer sites in the U.S. are in regions prone to severe storms, including tornadoes. NathanRE modeling, confirmed by site-specific risk assessments, indicates high tornado risk for several Midwest facilities: four manufacturing sites (two in Michigan, one in Wisconsin, one in Kansas), one R&D site in Missouri, and two logistics centers (Wisconsin and Tennessee). We also identified five manufacturing sites, four R&D locations, one office, and three storage facilities across North America with medium tornado risk, including sites in Massachusetts (2), North Carolina (5), Ohio (1), Connecticut (2), New Jersey (1), and New York (2). In July 2023, our Rocky Mount, NC manufacturing site—located in a medium-risk region—was damaged by a tornado but returned to full operation by mid-2024. While future climate-related risks may affect operations or supply chains, we've implemented mitigation measures including business continuity plans, structural resilience actions, and active weather monitoring and crisis response protocols.*

### (3.1.1.11) Primary financial effect of the risk

Select from:

☒ Other, please specify :Inventory losses, disruption in production capacity, and increased indirect costs

#### (3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Short-term

#### (3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☒ About as likely as not

#### (3.1.1.14) Magnitude

Select from:

☒ Medium-low

#### (3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

*While it is unlikely that a severe weather event would result in the complete loss of a Pfizer facility, a tornado strike at one of our sites in the U.S. could result in significant operational disruptions, including physical damage to buildings, equipment, and infrastructure. This may lead to temporary or prolonged shutdowns, delays in production or research activities, and interruptions in the distribution of critical medicines. Damage to utilities and transportation networks could further hinder recovery efforts. Additionally, such an event could impact employee safety, increase costs related to repairs and business continuity, and strain supply chain resilience—especially if the affected site plays a key role in manufacturing or logistics.*

#### (3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☒ Yes

#### (3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

\$50,000,000

### (3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

\$500,000,000

### (3.1.1.25) Explanation of financial effect figure

*Given that it is unlikely that a severe weather event, such as a tornado, would result in the complete loss of a Pfizer facility, the potential financial impact estimate is based on a percentage of the total insurable value of facilities identified as being at risk. This approach reflects our actual experience, which shows that such events typically cause partial damage rather than total loss. As a result, while the estimate provides a conservative view of potential exposure, the actual financial impact is expected to be significantly lower.*

### (3.1.1.26) Primary response to risk

Policies and plans

☒ Other policies or plans, please specify :Maintain business resilience and loss prevention plans

### (3.1.1.27) Cost of response to risk

\$5,400,000

### (3.1.1.28) Explanation of cost calculation

*The estimated cost of response includes approximately \$2M in staffing costs to manage business continuity programs at the site and corporate level and approximately \$3.4M for subscriptions and services to perform loss prevention assessments at sites and maintain access to predictive tools to facilitate risk assessment.*

### (3.1.1.29) Description of response

*Pfizer's primary controls for the management of acute and chronic physical risks are our infrastructure and systems. Our facilities are primarily located in areas with limited exposure to most physical risks and we have robust processes in place to identify and mitigate potential vulnerabilities. Through our Loss Prevention and Business Resilience programs we maintain plans to minimize business disruption, including alternative sourcing options and buffer inventory (depending on product). Pfizer maintains resources for assessing and establishing business continuity arrangements. Business continuity professionals are retained as staff and consultants to help ensure these plans are updated and exercised at least annually, and key colleagues on site are trained on the plans' content and implementation.*

**(3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks.**

**Climate change**

**(3.1.2.1) Financial metric**

*Select from:*

☒ Other, please specify :Cost of sales, partially offset by insurance recoveries.

**(3.1.2.2) Amount of financial metric vulnerable to transition risks for this environmental issue (unit currency as selected in 1.2)**

\$70,000,000

**(3.1.2.3) % of total financial metric vulnerable to transition risks for this environmental issue**

*Select from:*

☒ Less than 1%

**(3.1.2.4) Amount of financial metric vulnerable to physical risks for this environmental issue (unit currency as selected in 1.2)**

\$500,000,000

**(3.1.2.5) % of total financial metric vulnerable to physical risks for this environmental issue**

*Select from:*

☒ Less than 1%

**(3.1.2.7) Explanation of financial figures**

*The proportion of Pfizer's revenue potentially exposed to transition risk reflects the maximum estimated impact of the United States — where 68% of our Scope 1 and 2 emissions originate — adopting carbon taxes within the next 5 to 10 years. The exposure to physical risk was estimated based on a percentage of the total insurable value of at-risk facilities, reflecting the likelihood of partial damage rather than total loss from severe weather events.*

**(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?**

	Water-related regulatory violations
	Select from: <input checked="" type="checkbox"/> No

**(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?**

Select from:

☒ Yes

**(3.5.1) Select the carbon pricing regulation(s) which impact your operations.**

Select all that apply

☒ EU ETS

☒ Ireland carbon tax

☒ Spain carbon tax

☒ Other carbon tax, please specify :Canada Carbon Tax, Croatia Carbon Tax, Germany Carbon Tax

**(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by.**

## EU ETS

### (3.5.2.1) % of Scope 1 emissions covered by the ETS

13.05

### (3.5.2.2) % of Scope 2 emissions covered by the ETS

0

### (3.5.2.3) Period start date

01/01/2024

### (3.5.2.4) Period end date

12/31/2024

### (3.5.2.5) Allowances allocated

16591

### (3.5.2.6) Allowances purchased

52131

### (3.5.2.7) Verified Scope 1 emissions in metric tons CO2e

80013

### (3.5.2.8) Verified Scope 2 emissions in metric tons CO2e

0

### (3.5.2.9) Details of ownership



Select from:  
☒ Facilities we own and operate

(3.5.2.10) Comment

N/A

(3.5.3) Complete the following table for each of the tax systems you are regulated by.

Ireland carbon tax

(3.5.3.1) Period start date

01/01/2024

(3.5.3.2) Period end date

12/31/2024

(3.5.3.3) % of total Scope 1 emissions covered by tax

11

(3.5.3.4) Total cost of tax paid

\$226,369

Spain carbon tax

(3.5.3.1) Period start date

01/01/2024

(3.5.3.2) Period end date

12/31/2024

**(3.5.3.3) % of total Scope 1 emissions covered by tax**

0.3

**(3.5.3.4) Total cost of tax paid**

\$12,329

**Other carbon tax, please specify**

**(3.5.3.1) Period start date**

01/01/2024

**(3.5.3.2) Period end date**

12/31/2024

**(3.5.3.3) % of total Scope 1 emissions covered by tax**

2

**(3.5.3.4) Total cost of tax paid**

\$465,171

**(3.5.3.5) Comment**

*Includes taxes in Canada (Manitoba Federal Carbon Charge), Germany (German Fuel Emissions Trading Act) and Croatia (excise duties on energy purchases)*

**(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?**

Pfizer's strategy is to set corporate GHG reduction goals which in turn drive the sites to implement energy reduction projects and equipment upgrades to reduce their carbon footprint. Through three successive emissions reduction goals, Pfizer reduced GHG emissions by more than 60% from 2000 through 2020. We have established a near-term goal to further reduce GHG emissions by 46% by 2030 from a 2019 baseline and aim to achieve the voluntary Net-Zero Standard by 2040. Pfizer's Scope 1 and 2 GHG emissions in 2024 were approximately 3% lower than 2023 and 15% lower than the 2019 baseline. By reducing our carbon footprint, we help minimize the impact of the carbon pricing requirements that apply to our operations. For example, our site in Kalamazoo, Michigan, completed 11 projects in 2024 to reduce GHG emissions by approximately 11,700 mtCO<sub>2</sub>e annually, and our sites in Ireland collectively completed 17 projects during the year to reduce GHG emissions by approximately 2,400 mtCO<sub>2</sub>e annually. Reducing GHG emissions from our manufacturing and R&D facilities is a key element of our efforts to reach net-zero emissions by 2040. We are actively working to create more energy-efficient and healthy workplaces that can support colleagues' health and well-being. In 2024, Pfizer's Ringaskiddy Clinical Manufacturing Facility in Cork, Ireland, and Pfizer's office in Madrid, Spain, received LEED Gold recognition, and our office in Vienna, Austria, was awarded Platinum status. Pfizer's New York headquarters was awarded both LEED Platinum and WELL Platinum certifications. Pfizer invests in no- and low-carbon technologies at our sites and through Virtual Power Purchase Agreements (VPPAs) that enable sourcing of renewable energy. VPPAs covering solar projects in Spain and the United States, coming online in 2025, are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe. Pfizer's fleet of vehicles, the majority of which are used by our commercial teams to facilitate education and engagement with healthcare providers, accounted for approximately 12% percent of our total Scope 1 GHG emissions in 2024. Pfizer is working to transition our fleet to battery electric vehicles (BEVs) and, where feasible, other low-emission vehicle options. We are also supporting fuel management and efficient driving choices for internal combustion vehicles until they can be retired. We have BEVs on the road in 10 markets, with plans for additional markets in 2025 and beyond.

**(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?**

	Environmental opportunities identified
Climate change	Select from: <input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized
Water	Select from: <input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized

**(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.**

## Climate change

### (3.6.1.1) Opportunity identifier

Select from:

☒ Opp1

### (3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☒ Increased efficiency of production and/or distribution processes

### (3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations

### (3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ China  
☒ India  
☒ Italy  
☒ Japan  
☒ Spain  
☒ Belgium  
☒ Croatia  
☒ Germany  
☒ Ireland  
☒ Morocco  
☒ United States of America

☒ Brazil  
☒ Canada  
☒ Mexico  
☒ Sweden  
☒ Austria  
☒ Tunisia  
☒ Argentina  
☒ Australia  
☒ Indonesia  
☒ Singapore

### **(3.6.1.8) Organization specific description**

*Pfizer continually seeks to drive efficiency improvements within our operations. By replacing and/or optimizing efficiency of production, HVAC, and utility equipment such as boilers, we strive to reduce energy consumption and GHG emissions and lower our operating costs. Pfizer aims to achieve the voluntary Net-Zero Standard by 2040 and has near-term commitments to reduce Scope 1 and 2 emissions 46% from a 2019 baseline. We expect to achieve these targets in part by investing in equipment optimization and replacement at our sites. We have established internal targets to drive project implementation at our manufacturing facilities, and manufacturing leadership monitors progress toward these targets. We completed over 230 emission reduction projects at 32 sites around the world in 2024, investing approximately \$31M in both OPEX and CAPEX expenditures to reduce emissions by nearly 30,500 mt CO2e annually. These projects are projected to reduce operating costs by approximately \$7.7M annually, with approximately 15% of savings resulting from replacement and optimization of chillers, approximately 22% from the replacement and optimization of HVAC systems, and the rest from a combination of boiler, compressed air, steam, lighting, and other improvement projects.*

### **(3.6.1.9) Primary financial effect of the opportunity**

*Select from:*

☒ Reduced indirect (operating) costs

### **(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization**

*Select all that apply*

☒ Short-term

### **(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon**

*Select from:*

☒ Virtually certain (99–100%)

### **(3.6.1.12) Magnitude**

*Select from:*

☒ Medium-low

### **(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons**

*Savings from the implementation of emissions reduction projects are projected to have low impact on Pfizer's financial position, financial performance and cash flows.*

### (3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

### (3.6.1.17) Anticipated financial effect figure in the short-term - minimum (currency)

0

### (3.6.1.18) Anticipated financial effect figure in the short-term – maximum (currency)

\$125,000,000

### (3.6.1.23) Explanation of financial effect figures

*The estimated financial impact of approximately \$125 million reflects the total projected savings from all energy-related projects completed in 2024, as well as those expected to be completed between 2025 and 2030. Estimated annual savings for each project are used to calculate total savings, beginning the year after each project's completion and continuing through the end of 2030.*

### (3.6.1.24) Cost to realize opportunity

\$220,000,000

### (3.6.1.25) Explanation of cost calculation

*The cost to realize the opportunity outlined above includes approximately \$220 million in incremental OPEX and CAPEX investments to identify, evaluate, and implement energy efficiency and decarbonization projects completed in 2024 and planned for implementation between 2025 and 2030. These projects typically have a payback period of 4-10 years or less and have a lifetime greater than 6 years.*

### (3.6.1.26) Strategy to realize opportunity

*Pfizer's Environmental Impact Reduction Standard requires all sites to develop a systematic approach to conserve energy and improve efficiency. Sites identified as medium and large energy users are required to establish environmental sustainability teams and to develop and maintain sustainability master plans that include prioritized emission reduction opportunities. Project implementation is monitored at the corporate level with performance reports provided to company leadership quarterly. Pfizer has historically invested each year to reduce energy demand through end-of-life asset replacement, efficiency improvements, and installation of renewable technologies. In 2024, we invested approximately \$31M in both OPEX (\$6.2M) and CAPEX (\$24.8M) expenditures (incremental) in energy efficiency projects. These projects are projected to reduce operating costs by approximately \$7.7M annually. Projects with the most significant annual savings include HVAC*

upgrades at our sites in Andover, Massachusetts; Kalamazoo, Michigan; and Rocky Mount, North Carolina, as well as chiller, cooling, and compressed air system improvements in Kalamazoo, Michigan. Additionally, a boiler conversion from diesel to natural gas was completed at our site in Vizag, India. Projects completed in 2024 are expected to reduce Pfizer's Scope 1 and 2 emissions by nearly 30,500 mt CO2e annually. Furthermore, between 2025 and 2030, we anticipate completing over 340 additional projects, representing an incremental investment of more than \$190 million. These projects are expected to generate over \$78 million in additional savings, calculated from the year following each project's completion through 2030.

## Water

### (3.6.1.1) Opportunity identifier

Select from:

☒ Opp2

### (3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☒ Reduced water usage and consumption

### (3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations

### (3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ Italy

☒ Japan

☒ Spain

☒ Brazil

☒ Mexico

☒ Ireland

☒ Australia

☒ United States of America

### (3.6.1.6) River basin where the opportunity occurs

Select all that apply

☒ Other, please specify :Multiple river basins

#### **(3.6.1.8) Organization specific description**

*Pfizer requires our manufacturing and research and development sites to maintain site master plans that identify opportunities to reduce their environmental footprint. Sites are expected to set annual performance targets and to identify, prioritize, and implement water conservation projects to offset increases due to increased production. Project information is entered into a global database where it is monitored by sustainability champions at the site, business, and corporate levels. Progress is reported to business leadership quarterly.*

#### **(3.6.1.9) Primary financial effect of the opportunity**

Select from:

☒ Reduced indirect (operating) costs

#### **(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization**

Select all that apply

☒ Short-term

#### **(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon**

Select from:

☒ Virtually certain (99–100%)

#### **(3.6.1.12) Magnitude**

Select from:

☒ Low

#### **(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons**

*While not considered substantive as defined for the purposes of this submittal, we have included this opportunity as it may be of interest to our stakeholders. Savings from the implementation of water conservation projects are projected to have minimal impact on Pfizer's financial position, financial performance and cash flows.*



### (3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

### (3.6.1.17) Anticipated financial effect figure in the short-term - minimum (currency)

0

### (3.6.1.18) Anticipated financial effect figure in the short-term – maximum (currency)

\$960,000

### (3.6.1.23) Explanation of financial effect figures

*The estimated financial impact of approximately \$960,000 reflects the total projected savings from all water-related projects completed in 2024, as well as those expected to be completed between 2025 and 2030. Estimated annual savings for each project are used to calculate total savings, beginning the year after each project's completion and continuing through the end of 2030.*

### (3.6.1.24) Cost to realize opportunity

\$280,000

### (3.6.1.25) Explanation of cost calculation

*The cost to realize the opportunity outlined above includes approximately \$280,000 in incremental OPEX and CAPEX investments to identify, evaluate, and implement water conservation projects completed in 2024 and planned for implementation between 2025 and 2030.*

### (3.6.1.26) Strategy to realize opportunity

*The availability of and access to clean water is a basic human need globally that must be addressed locally. Pfizer's Water Stewardship position statement describes our commitment to being good stewards of the water we use to make medicines and vaccines, particularly in water-stressed areas. To this end, we completed water stress assessments at all Pfizer sites to identify water quality, scarcity, and availability risks across our network and are developing action plans for sites with elevated risk scores. These plans include elements such as quantifying water use, implementing mitigation plans and establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities. We will measure progress at our internal sites while engaging with our key suppliers in water stressed areas to encourage them to develop and implement similar action plans.*

## Climate change

### (3.6.1.1) Opportunity identifier

Select from:

☒ Opp3

### (3.6.1.3) Opportunity type and primary environmental opportunity driver

Markets

☒ Use of public sector incentives

### (3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Downstream value chain

### (3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ United Kingdom of Great Britain and Northern Ireland

### (3.6.1.8) Organization specific description

*An increasing number of national healthcare systems and countries have announced targets to become Net-Zero, including in their supply chain, i.e., the suppliers and pharmaceutical products used by healthcare providers. Healthcare systems may, therefore, prefer or require suppliers to provide low-carbon products. Pfizer's current and potential customers increasingly request information and data to assess our environmental commitments and performance. Pfizer has been requested to provide 2024 GHG emissions and environmental sustainability program information to over 20 customers in Europe and the United States and for several hospital tenders in Europe. We anticipate that Pfizer's commitment to ambitious climate action may help to position us favorably in supplier selection processes.*

### (3.6.1.9) Primary financial effect of the opportunity

Select from:

☒ Increased revenues resulting from increased demand for products and services

### (3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☒ Long-term

### (3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☒ Very likely (90–100%)

### (3.6.1.12) Magnitude

Select from:

☒ Medium-low

### (3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

*This opportunity has the potential to have a substantive impact on Pfizer's revenue but is not yet quantifiable.*

### (3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

### (3.6.1.21) Anticipated financial effect figure in the long-term - minimum (currency)

0

### (3.6.1.22) Anticipated financial effect figure in the long-term – maximum (currency)

\$100,000,000

### (3.6.1.23) Explanation of financial effect figures

*Pfizer continues to see increased requests for environmental information for more products and by more customers. We performed scenario analysis to determine the potential impact to Pfizer if customers' decarbonization demands influenced purchasing decisions. For example, England's National Health Service (NHS) publicly declared its intention to be net-zero for Scopes 1, 2 and 3 by 2045 and set a long-term target to stop purchasing from suppliers that do not meet or exceed the NHS commitment to net-zero by 2030. (Reference: Delivering a 'Net-Zero' National Health Service; October 2020). Pfizer's commitment to ambitious climate action may help us meet or exceed NHS's expectation. If so, we would expect to potentially maintain or increase our share of NHS purchasing decisions. The potential financial impact is a placeholder that represents our acknowledgement that the impact could be substantive but is not yet quantifiable until NHS develops its sustainable purchasing criteria and uncertainty in projecting future product needs to satisfy NHS criteria.*

#### **(3.6.1.24) Cost to realize opportunity**

\$55,200,000

#### **(3.6.1.25) Explanation of cost calculation**

*The approximate cost to maintain Pfizer's Net-Zero program was calculated based on the estimated annual incremental capital spend associated with emission reduction activities for projects completed in 2024 (\$24.8M) and the estimated staff and consulting costs to implement corporate goals, manage programs, report performance and support sustainable science initiatives (\$30.4M).*

#### **(3.6.1.26) Strategy to realize opportunity**

*We recognize global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Pfizer is continuing its near-term goal to reduce company greenhouse gas (GHG) emissions by 46% compared with a 2019 baseline, aligned with a 1.5°C trajectory, and to drive action by encouraging suppliers to also set science-based GHG emissions reduction goals. We have further committed to reduce GHG emissions by working to achieve the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in the standard. By 2040 Pfizer aims to decrease its company GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by reducing the energy demand of our operations, transitioning away from fossil fuels, sourcing renewable electricity, and engaging suppliers to catalyze equivalent action.*

### **(3.6.2) Provide the amount and proportion of your financial metrics in the reporting year that are aligned with the substantive effects of environmental opportunities.**

#### **Climate change**

##### **(3.6.2.1) Financial metric**

Select from:

☒ OPEX

### (3.6.2.2) Amount of financial metric aligned with opportunities for this environmental issue (unit currency as selected in 1.2)

\$7,700,000

### (3.6.2.3) % of total financial metric aligned with opportunities for this environmental issue

Select from:

☒ Less than 1%

### (3.6.2.4) Explanation of financial figures

*The OPEX savings associated with the implementation of energy conservation projects in 2024 was well below 1% of total OPEX spend.*

## Water

### (3.6.2.1) Financial metric

Select from:

☒ OPEX

### (3.6.2.2) Amount of financial metric aligned with opportunities for this environmental issue (unit currency as selected in 1.2)

\$90,000

### (3.6.2.3) % of total financial metric aligned with opportunities for this environmental issue

Select from:

☒ Less than 1%

### (3.6.2.4) Explanation of financial figures

*The OPEX savings associated with the implementation of water conservation projects in 2024 was well below 1% of total OPEX spend.*

## C4. Governance

### (4.1) Does your organization have a board of directors or an equivalent governing body?

#### (4.1.1) Board of directors or equivalent governing body

Select from:

☒ Yes

#### (4.1.2) Frequency with which the board or equivalent meets

Select from:

☒ More frequently than quarterly

#### (4.1.3) Types of directors your board or equivalent is comprised of

Select all that apply

☒ Executive directors or equivalent

☒ Independent non-executive directors or equivalent

#### (4.1.4) Board diversity and inclusion policy

Select from:

☒ Yes, and it is publicly available

#### (4.1.5) Briefly describe what the policy covers

*For the purposes of this response, we are defining policy broadly to include Pfizer Inc. Corporate Governance Principles. Pursuant to its charter, the Governance Committee of the Board is responsible for considering a diverse pool of candidates to fill positions on the Board; however, the company does not have a formal policy on Board diversity.*

#### (4.1.6) Attach the policy (optional)

*corporate-governance-principles-last-revised-april-2024.pdf*

**(4.1.1) Is there board-level oversight of environmental issues within your organization?**

	Board-level oversight of this environmental issue
Climate change	Select from: <input checked="" type="checkbox"/> Yes
Water	Select from: <input checked="" type="checkbox"/> Yes

**(4.1.2) Identify the positions (do not include any names) of the individuals or committees on the board with accountability for environmental issues and provide details of the board's oversight of environmental issues.**

**Climate change**

**(4.1.2.1) Positions of individuals or committees with accountability for this environmental issue**

Select all that apply

- ☒ Board chair
- ☒ Chief Executive Officer (CEO)
- ☒ Board-level committee

**(4.1.2.2) Positions' accountability for this environmental issue is outlined in policies applicable to the board**

Select from:

- ☒ Yes

#### (4.1.2.3) Policies which outline the positions' accountability for this environmental issue

Select all that apply

- ☒ Other policy applicable to the board, please specify :Committee charters, available at <https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/>

#### (4.1.2.4) Frequency with which this environmental issue is a scheduled agenda item

Select from:

- ☒ Scheduled agenda item in some board meetings – at least annually

#### (4.1.2.5) Governance mechanisms into which this environmental issue is integrated

Select all that apply

- ☒ Overseeing the setting of corporate targets ☒ Overseeing and guiding the development of a business strategy
- ☒ Monitoring progress towards corporate targets
- ☒ Approving and/or overseeing employee incentives
- ☒ Overseeing reporting, audit, and verification processes
- ☒ Monitoring the implementation of a climate transition plan

#### (4.1.2.7) Please explain

*Pfizer's CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for guiding Pfizer's climate strategy and approving environmental sustainability-related public goals. In June 2022 he committed to accelerating the decarbonization of Pfizer's value chain, aiming to achieve the voluntary Net-Zero standard by 2040. Pfizer's management reports progress on our Net-Zero goal quarterly to the CEO and Chairman of the Board, who in turn informs the Board of Directors. The Board of Directors is fully engaged and supportive of Pfizer's sustainability program. The Governance Committee of the Board (GC) is primarily responsible for oversight of our sustainability strategy and reporting. Throughout 2024, the GC received updates from the Chief Sustainability Officer (CSO) and other company leaders regarding our sustainability priorities and progress and changes in the sustainability external environment. Pfizer's Compensation Committee of the Board of Directors is responsible for establishing annual and long-term performance goals and reviewing and certifying performance-based compensation plans. For 2024, the Committee approved the addition of a sustainability modifier that included a GHG emissions reduction metric to Pfizer's annual performance-based variable bonus program to support Pfizer's commitment to reducing GHG emissions.*

## Water

#### (4.1.2.1) Positions of individuals or committees with accountability for this environmental issue



Select all that apply

- ☒ Board chair
- ☒ Chief Executive Officer (CEO)
- ☒ Board-level committee

#### (4.1.2.2) Positions' accountability for this environmental issue is outlined in policies applicable to the board

Select from:

- ☒ Yes

#### (4.1.2.3) Policies which outline the positions' accountability for this environmental issue

Select all that apply

- ☒ Other policy applicable to the board, please specify :Committee charters, available at <https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/>

#### (4.1.2.4) Frequency with which this environmental issue is a scheduled agenda item

Select from:

- ☒ Scheduled agenda item in some board meetings – at least annually

#### (4.1.2.5) Governance mechanisms into which this environmental issue is integrated

Select all that apply

- ☒ Overseeing and guiding the development of a business strategy
- ☒ Monitoring the implementation of the business strategy

#### (4.1.2.7) Please explain

*Pfizer's enterprise EHS risk program is managed by the Safety and Environmental Operations team in partnership with Legal and with active engagement from a cross disciplinary team of leaders representing Engineering, Facilities, Sourcing, and scientific and manufacturing lines. Through our Operational Risk Review process, key risks are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC). PGS QRC reports on priority risks and mitigation, including those related to environmental issues, to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors. The PGS QRC risk management process also informs Pfizer's Enterprise Risk Management (ERM) program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM process assesses on an annual basis our operations and risk management priorities, including risks related to environmental*

issues and the long-term sustainability of the business. Each risk is prioritized and assigned to a member or members, as appropriate, of Pfizer's Executive Leadership Team. The Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer's ERM program. Periodically, the Regulatory and Compliance Committee and the Audit Committee hold joint sessions to discuss risks relevant to both Committees' areas of risk oversight, including an annual discussion of the ERM program. Throughout 2024, the Board was kept informed of its committees' risk oversight and other activities through reports by the committee chairs to the full Board. Our cross-functional Sustainability Steering Committee, chaired by our CSO, advised on key issues and guided the integration and implementation of Pfizer's non-financial reporting related to sustainability. This Committee was overseen by a dedicated Executive Sustainability Committee, chaired by the Executive Leadership Team member leading Corporate Affairs, who reports directly to the Chairman and CEO. Our sustainability governance has as its foundation oversight by the Board of Directors, commitment and accountability by leadership, and engagement by colleagues across the company. Diverse perspectives from internal and external stakeholders inform our sustainability strategy and priorities. The Board of Directors is fully engaged and supportive of Pfizer's sustainability program. The GC of the Board is primarily responsible for oversight of our sustainability strategy and reporting. Throughout the year, the GC receives updates from company leaders regarding our sustainability priorities and progress and changes in the sustainability external environment.

## **(4.2) Does your organization's board have competency on environmental issues?**

### **Climate change**

#### **(4.2.1) Board-level competency on this environmental issue**

Select from:

☒ Yes

#### **(4.2.2) Mechanisms to maintain an environmentally competent board**

Select all that apply

☒ Having at least one board member with expertise on this environmental issue

#### **(4.2.3) Environmental expertise of the board member**

Experience

☒ Executive-level experience in a role focused on environmental issues

☒ Experience in an organization that is exposed to environmental-scrutiny and is going through a sustainability transition

## Water

### (4.2.1) Board-level competency on this environmental issue

Select from:

☒ Yes

### (4.2.2) Mechanisms to maintain an environmentally competent board

Select all that apply

☒ Other, please specify :Pfizer's BoD is composed of a diverse group of esteemed medical professionals, scientists, academics, and business leaders with skills, experience and academic training that provides them with competence to oversee environmental matters.

### (4.3) Is there management-level responsibility for environmental issues within your organization?

	Management-level responsibility for this environmental issue
Climate change	Select from: <input checked="" type="checkbox"/> Yes
Water	Select from: <input checked="" type="checkbox"/> Yes

### (4.3.1) Provide the highest senior management-level positions or committees with responsibility for environmental issues (do not include the names of individuals).

Climate change

#### (4.3.1.1) Position of individual or committee with responsibility

Executive level

- ☒ Chief Executive Officer (CEO)

#### (4.3.1.2) Environmental responsibilities of this position

Dependencies, impacts, risks and opportunities

- ☒ Managing environmental dependencies, impacts, risks, and opportunities

Policies, commitments, and targets

- ☒ Monitoring compliance with corporate environmental policies and/or commitments
- ☒ Setting corporate environmental policies and/or commitments
- ☒ Setting corporate environmental targets

Strategy and financial planning

- ☒ Developing a business strategy which considers environmental issues

#### (4.3.1.4) Reporting line

Select from:

- ☒ Reports to the board directly

#### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

- ☒ Quarterly

#### (4.3.1.6) Please explain

*The CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for guiding Pfizer's climate strategy and approving environmental sustainability-related public goals. In June 2022 he committed to accelerating the decarbonization of Pfizer's value chain, aiming to achieve*

*the voluntary Net-Zero standard by 2040. Pfizer's Strategy & Consulting team collects and reports progress on Pfizer's GHG reduction targets to the CEO and Chairman of the Board, who in turn reports them to the Board of Directors.*

## Water

### (4.3.1.1) Position of individual or committee with responsibility

Executive level

☒ Chief Executive Officer (CEO)

### (4.3.1.2) Environmental responsibilities of this position

Dependencies, impacts, risks and opportunities

☒ Managing environmental dependencies, impacts, risks, and opportunities

Strategy and financial planning

☒ Developing a business strategy which considers environmental issues

### (4.3.1.4) Reporting line

Select from:

☒ Reports to the board directly

### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

☒ Half-yearly

### (4.3.1.6) Please explain

*The PGS QRC provides updates on priority risks and mitigation, including those related to climate change and pharmaceuticals in the environment, to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors twice each year. The PGS QRC risk management process also informs Pfizer's Enterprise Risk Management (ERM) program, overseen by the Audit Committee of the Board of Directors.*

## Climate change

### (4.3.1.1) Position of individual or committee with responsibility

Executive level

☒ President

### (4.3.1.2) Environmental responsibilities of this position

Policies, commitments, and targets

☒ Monitoring compliance with corporate environmental policies and/or commitments

Strategy and financial planning

☒ Implementing a climate transition plan

☒ Implementing the business strategy related to environmental issues

☒ Managing annual budgets related to environmental issues

☒ Managing major capital and/or operational expenditures relating to environmental issues

### (4.3.1.4) Reporting line

Select from:

☒ Reports to the Chief Executive Officer (CEO)

### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

☒ Not reported to the board

### (4.3.1.6) Please explain

*Pfizer's Executive Vice President, Chief Global Supply and Quality Officer, leads Pfizer's Global Supply division (PGS), and is responsible for implementation of Pfizer's Net-Zero strategy. He also sponsors Pfizer's Net Zero Core Team, which provides cross-functional oversight for the development and execution of strategies and programs aligned with Pfizer's net-zero commitments. Product manufacturing at our internal network of sites, managed by PGS, accounts for approximately 70%*

of the company's energy consumption and Scope 1 & 2 GHG emissions. The EVP, Chief Global Supply and Quality Officer, has operational control over PGS operations and strategy, including OPEX/CAPEX investment in emission reduction projects and oversight of Pfizer's manufacturing supply chain which accounts for the majority of our Scope 3 emissions. Environmental sustainability has been integrated into the overarching PGS strategy and GHG emissions reduction is monitored as a key performance indicator (KPI). Performance against this goal is included in a monthly dashboard reviewed by the PGS Executive Leadership Team.

## Climate change

### (4.3.1.1) Position of individual or committee with responsibility

Committee

☒ Sustainability committee

### (4.3.1.2) Environmental responsibilities of this position

Policies, commitments, and targets

☒ Monitoring compliance with corporate environmental policies and/or commitments

Strategy and financial planning

☒ Developing a business strategy which considers environmental issues

### (4.3.1.4) Reporting line

Select from:

☒ Other, please specify :Reports to the Executive Sustainability Committee which is composed of Executive Leadership Team members

### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

☒ Quarterly

### (4.3.1.6) Please explain

In 2024, our cross-functional Sustainability Steering Committee, chaired by our CSO, advised on key issues and guided the integration and implementation of Pfizer's non-financial reporting related to sustainability. This Committee was overseen by a dedicated Executive Sustainability Committee, chaired by the Executive

Leadership Team member leading Corporate Affairs, who reported directly to the Chairman and CEO. Our sustainability governance has as its foundation oversight by the Board of Directors, commitment and accountability by leadership, and engagement by colleagues across the company. Diverse perspectives from internal and external stakeholders inform our sustainability strategy and priorities. The Board of Directors is engaged and supportive of Pfizer's sustainability program. The GC of the Board is primarily responsible for oversight of our sustainability strategy and reporting. Throughout the year, the GC receives updates from company leaders regarding our sustainability priorities and progress and changes in the sustainability external environment.

## **(4.5) Do you provide monetary incentives for the management of environmental issues, including the attainment of targets?**

### **Climate change**

#### **(4.5.1) Provision of monetary incentives related to this environmental issue**

Select from:

☒ Yes

#### **(4.5.2) % of total C-suite and board-level monetary incentives linked to the management of this environmental issue**

0.01

#### **(4.5.3) Please explain**

In 2024, Pfizer's performance-based variable short-term incentive program, applicable to the CEO and Named Executive Officers, included a 5% ESG modifier. This modifier was based on the achievement of targets for three KPIs, including a GHG emissions reduction target. Short-term incentives represent approximately 15-18% of total executive compensation. The total percentage of incentives linked to climate change in 2024 was 0.003% but has been entered as 0.01% as the system does not accommodate a third decimal place. Note that this modifier was assessed as neutral based on 2024 performance and did not result in a compensation adjustment.

### **Water**

#### **(4.5.1) Provision of monetary incentives related to this environmental issue**

Select from:

☒ No, and we do not plan to introduce them in the next two years



**(4.5.1) Provide further details on the monetary incentives provided for the management of environmental issues (do not include the names of individuals).**

## **Climate change**

### **(4.5.1.1) Position entitled to monetary incentive**

Facility/Unit/Site management

☒ Site manager

### **(4.5.1.2) Incentives**

*Select all that apply*

☒ Bonus - % of salary

### **(4.5.1.3) Performance metrics**

Targets

☒ Progress towards environmental targets

☒ Achievement of environmental targets

Emission reduction

☒ Reduction in absolute emissions

### **(4.5.1.4) Incentive plan the incentives are linked to**

*Select from:*

☒ Short-Term Incentive Plan, or equivalent, only (e.g. contractual annual bonus)

### **(4.5.1.5) Further details of incentives**

Site-specific targets for energy consumption and GHG emission reduction projects are included in goals against which monetary awards are determined.

#### **(4.5.1.6) How the position's incentives contribute to the achievement of your environmental commitments and/or climate transition plan**

*Pfizer's manufacturing sites account for approximately 70% of the company's energy consumption and Scope 1 & 2 GHG emissions. Pfizer is aiming to achieve the voluntary Net-Zero Standard by 2040 and has a near-term goal to reduce Scope 1 and 2 emissions 46% from a 2019 baseline. We expect to achieve this target in part by investing in equipment optimization and replacement at our sites. We have established site-specific targets to drive project implementation at our manufacturing facilities, and progress toward these targets is factored into annual performance assessments.*

### **Climate change**

#### **(4.5.1.1) Position entitled to monetary incentive**

Board or executive level

☒ Chief Executive Officer (CEO)

#### **(4.5.1.2) Incentives**

Select all that apply

☒ Bonus - % of salary

#### **(4.5.1.3) Performance metrics**

Targets

☒ Progress towards environmental targets

☒ Achievement of environmental targets

Emission reduction

☒ Reduction in absolute emissions

#### **(4.5.1.4) Incentive plan the incentives are linked to**

Select from:

☒ Short-Term Incentive Plan, or equivalent, only (e.g. contractual annual bonus)

(4.5.1.5) Further details of incentives

*In 2024, Pfizer’s performance-based variable bonus program, applicable to the CEO and Executive Leadership Team as well as approximately 50% of Pfizer colleagues, included a 5% ESG modifier. This modifier was based on three KPIs, including a GHG emissions reduction target.*

(4.5.1.6) How the position’s incentives contribute to the achievement of your environmental commitments and/or climate transition plan

*The inclusion of sustainability modifiers in Pfizer's 2024 Global Performance Plan served to further embed robust sustainability management into our strategic decisions, business operations, and governance and supported continued focus on implementation of our climate strategy.*

(4.6) Does your organization have an environmental policy that addresses environmental issues?

	Does your organization have any environmental policies?
	Select from: <input checked="" type="checkbox"/> Yes

(4.6.1) Provide details of your environmental policies.

Row 1

(4.6.1.1) Environmental issues covered

Select all that apply

- ☒ Climate change

#### (4.6.1.2) Level of coverage

Select from:

- ☒ Organization-wide

#### (4.6.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain

#### (4.6.1.4) Explain the coverage

*At Pfizer, we recognize global climate change as one of the defining issues of our time requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. In our Climate Change position statement, we affirm our commitment to collaborating to reduce GHG emissions across our value chain, including our near-term goal to reduce company GHG emissions by 46% compared with a 2019 baseline, aligned with a 1.5°C trajectory, and to drive action by encouraging suppliers to also set science-based GHG emissions reduction goals. Pfizer's corporate environmental, health and safety (EHS) policy and corporate EHS standards further reinforce this commitment by establishing a global framework for risk mitigation, regulatory compliance, and sustainability integration across operations. In addition, Pfizer's Blue Book—our publicly available Code of Conduct—outlines our commitment to promoting gender equality and respecting internationally recognized human rights. It also provides detailed mechanisms for raising concerns, including a grievance and whistleblower system to report non-compliance with our environmental policy and to escalate potential greenwashing concerns. The Blue Book is accessible on our website.*

#### (4.6.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to take environmental action beyond regulatory compliance
- ☒ Commitment to stakeholder engagement and capacity building on environmental issues

Climate-specific commitments

- ☒ Commitment to 100% renewable energy
- ☒ Commitment to net-zero emissions

#### Social commitments

- ☒ Commitment to promote gender equality and women's empowerment
- ☒ Commitment to respect internationally recognized human rights

#### Additional references/Descriptions

- ☒ Description of environmental requirements for procurement
- ☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns
- ☒ Description of membership and financial support provided to organizations that seek to influence public policy
- ☒ Recognition of environmental linkages and trade-offs
- ☒ Reference to timebound environmental milestones and targets

### (4.6.1.6) Indicate whether your environmental policy is in line with global environmental treaties or policy goals

*Select all that apply*

- ☒ Yes, in line with the Paris Agreement

### (4.6.1.7) Public availability

*Select from:*

- ☒ Publicly available

### (4.6.1.8) Attach the policy

*Climate\_Change\_Position\_Statement\_December\_2024.pdf*

## Row 2

### (4.6.1.1) Environmental issues covered

*Select all that apply*

- ☒ Water

#### (4.6.1.2) Level of coverage

Select from:

- ☒ Organization-wide

#### (4.6.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain

#### (4.6.1.4) Explain the coverage

*Our Water Stewardship Position Statement acknowledges the global significance of access to clean water and reiterates Pfizer's commitment to conserving water. Specifically, in water-stressed areas, conservation includes minimizing water withdrawal, mitigating potential impact on water quality from our own operations and those of our supply chain, and responsibly managing discharges to water. Pfizer's corporate environmental, health and safety (EHS) policy and corporate EHS standards further reinforce this commitment by establishing a global framework for risk mitigation, regulatory compliance, and sustainability integration across operations. In addition, Pfizer's Blue Book—our publicly available Code of Conduct—outlines our commitment to promoting gender equality and respecting internationally recognized human rights. It also provides detailed mechanisms for raising concerns, including a grievance and whistleblower system to report non-compliance with our environmental policy and to escalate potential greenwashing concerns. The Blue Book is accessible on our website.*

#### (4.6.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to take environmental action beyond regulatory compliance

Water-specific commitments

- ☒ Commitment to reduce water consumption volumes
- ☒ Commitment to reduce water withdrawal volumes
- ☒ Commitment to reduce or phase out hazardous substances
- ☒ Commitment to control/reduce/eliminate water pollution
- ☒ Commitment to the conservation of freshwater ecosystems
- ☒ Commitment to water stewardship and/or collective action

#### Social commitments

- ☒ Commitment to promote gender equality and women's empowerment
- ☒ Commitment to respect internationally recognized human rights

#### Additional references/Descriptions

- ☒ Acknowledgement of the human right to water and sanitation
- ☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns
- ☒ Description of membership and financial support provided to organizations that seek to influence public policy
- ☒ Recognition of environmental linkages and trade-offs
- ☒ Reference to timebound environmental milestones and targets

### **(4.6.1.6) Indicate whether your environmental policy is in line with global environmental treaties or policy goals**

*Select all that apply*

- ☒ Yes, in line with Sustainable Development Goal 6 on Clean Water and Sanitation

### **(4.6.1.7) Public availability**

*Select from:*

- ☒ Publicly available

### **(4.6.1.8) Attach the policy**

*Pfizer\_Water\_Stewardship\_Public\_Position\_Statement\_2022.pdf*

## **(4.10) Are you a signatory or member of any environmental collaborative frameworks or initiatives?**

### **(4.10.1) Are you a signatory or member of any environmental collaborative frameworks or initiatives?**

*Select from:*

☒ Yes

#### (4.10.2) Collaborative framework or initiative

Select all that apply

- ☒ RE100
- ☒ Science-Based Targets Initiative (SBTi)
- ☒ Task Force on Climate-related Financial Disclosures (TCFD)
- ☒ UN Global Compact
- ☒ Other, please specify :AMR Industry Alliance (AMRIA)

#### (4.10.3) Describe your organization's role within each framework or initiative

*RE100: Pfizer is a member of Renewable Energy 100 (RE100) and has a goal to achieve 100% renewable electricity by 2030. SBTi: In 2015, we were one of the first companies to have our then GHG emissions reduction goal validated by the Science Based Targets Initiative (SBTi), and we remain committed to developing and implementing a science-based climate action strategy. Our current near-term climate targets have been validated by the SBTi. TCFD: As described in our Climate Change Position Statement, we conduct robust risk assessments to safeguard resiliency of our research, manufacturing, and commercial activities and to transparently report on our progress, risks, and opportunities aligned with Task Force on Climate-related Financial Disclosure (TCFD) recommendations. UN Global Compact: Pfizer is proud to have been one of the early signatories to the United Nations (UN) Global Compact, an initiative that calls on companies to align strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and to take actions that advance societal goals. AMR Industry Alliance (AMRIA): Pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be important environmental issues for our industry. Pfizer is an active member of the AMR Industry Alliance (AMRIA), one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance.*

**(4.11) In the reporting year, did your organization engage in activities that could directly or indirectly influence policy, law, or regulation that may (positively or negatively) impact the environment?**

#### (4.11.1) External engagement activities that could directly or indirectly influence policy, law, or regulation that may impact the environment

Select all that apply

- ☒ Yes, we engaged indirectly through, and/or provided financial or in-kind support to a trade association or other intermediary organization or individual whose activities could influence policy, law, or regulation



#### **(4.11.2) Indicate whether your organization has a public commitment or position statement to conduct your engagement activities in line with global environmental treaties or policy goals**

Select from:

- ☒ Yes, we have a public commitment or position statement in line with global environmental treaties or policy goals

#### **(4.11.3) Global environmental treaties or policy goals in line with public commitment or position statement**

Select all that apply

- ☒ Paris Agreement
- ☒ Sustainable Development Goal 6 on Clean Water and Sanitation

#### **(4.11.4) Attach commitment or position statement**

*Pfizer - Climate & Water Position Statements.pdf*

#### **(4.11.5) Indicate whether your organization is registered on a transparency register**

Select from:

- ☒ Yes

#### **(4.11.6) Types of transparency register your organization is registered on**

Select all that apply

- ☒ Mandatory government register

#### **(4.11.7) Disclose the transparency registers on which your organization is registered & the relevant ID numbers for your organization**

*For the US, Pfizer's Federal Lobbying ID numbers are: House: 313540000; Senate: 31326-12. For the EU Transparency Register, Pfizer's ID is: 4263301811-33*

#### **(4.11.8) Describe the process your organization has in place to ensure that your external engagement activities are consistent with your environmental commitments and/or transition plan**

*Our climate and water-related engagement activities with policy makers, trade associations, and other organizations are guided by our Climate Change Position Statement and our Water Stewardship Position Statement, which outline Pfizer's approach to these environmental issues and the policies that will help support Pfizer's climate change and water stewardship strategy. Our support of these organizations and any tax-exempt organizations that write and endorse model legislation is evaluated annually by the company's U.S. Government Relations leaders based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to Pfizer. In addition to their positions on health care policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizer. If concerns arise about a particular issue, we convey our concerns, as appropriate, through our colleagues who serve on the boards and committees of these groups. We believe there is value in making sure our positions on issues important to Pfizer and our industry are communicated and understood within those organizations. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members.*

**(4.11.2) Provide details of your indirect engagement on policy, law, or regulation that may (positively or negatively) impact the environment through trade associations or other intermediary organizations or individuals in the reporting year.**

**Row 1**

**(4.11.2.1) Type of indirect engagement**

Select from:

☒ Indirect engagement via a trade association

**(4.11.2.4) Trade association**

North America

☒ US Chamber of Commerce

**(4.11.2.5) Environmental issues relevant to the policies, laws, or regulations on which the organization or individual has taken a position**

Select all that apply

☒ Climate change

**(4.11.2.6) Indicate whether your organization's position is consistent with the organization or individual you engage with**

Select from:

☒ Mixed

#### **(4.11.2.7) Indicate whether your organization attempted to influence the organization or individual's position in the reporting year**

Select from:

☒ No, we did not attempt to influence their position

#### **(4.11.2.8) Describe how your organization's position is consistent with or differs from the organization or individual's position, and any actions taken to influence their position**

*Pfizer recognizes climate change as one of the defining issues of our time requiring collective action to mitigate the potential risks it poses. As such, Pfizer committed to further reducing GHG emissions aligned with science by aiming to achieve the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in the standard and reporting transparently on our progress. Pfizer appreciates that voluntary measures often offer the greatest opportunity for companies to design innovative solutions that work best for their situation, product range, and investment timelines. Tackling climate change, however, will require action from all parties across all sectors, and Pfizer supports policy efforts that are science- and market-based to encourage and advance such action. The company also seeks to engage its value chain partners to support them in achieving science aligned reductions in GHG emissions. The Chamber acknowledges the severity of the climate threat and that steps need to be taken to address the crisis. The organization recognizes the role that business and market-driven solutions can play in slowing the effects of climate change. In addition, governments and technological solutions should be leveraged but solutions must be realistic, durable, and reinforce U.S. economic competitiveness. On climate change, both Pfizer and the Chamber favor market-based and technology-based solutions. Pfizer is committed to taking responsible climate action and reducing environmental impact; the Chamber also advocates for corporations to take such actions. The Chamber has been criticized for its history of opposition to legislation targeting climate change and reliance on an "all of the above" approach which may prolong dependence on fossil fuels. For these reasons, there is misalignment between Pfizer and the Chamber on this topic. In 2024, Pfizer's policy engagement through the Chamber was limited to topics related to EU CSRD and CSDDD, where our positions were aligned, and therefore Pfizer did not need to influence the Chamber on these topics. Pfizer participates in the Energy, Environment, Climate & Sustainability Committee and the ESG Working Group through which we provide comments on relevant topics consistent with our Climate Change Position Statement and commitment to transparency.*

#### **(4.11.2.9) Funding figure your organization provided to this organization or individual in the reporting year (currency)**

\$464,016

#### **(4.11.2.10) Describe the aim of this funding and how it could influence policy, law or regulation that may impact the environment**

*Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. The funding figure reported represents the portion of Pfizer's dues used for US federal lobbying activity in 2024 as reported by the trade association.*

**(4.11.2.11) Indicate if you have evaluated whether your organization’s engagement is aligned with global environmental treaties or policy goals**

Select from:

☒ Yes, we have evaluated, and it is aligned

**(4.11.2.12) Global environmental treaties or policy goals aligned with your organization’s engagement on policy, law or regulation**

Select all that apply

☒ Paris Agreement

**Row 2**

**(4.11.2.1) Type of indirect engagement**

Select from:

☒ Indirect engagement via a trade association

**(4.11.2.4) Trade association**

Europe

☒ Other trade association in Europe, please specify :European Federation of Pharmaceutical Industries and Associations (EFPIA)

**(4.11.2.5) Environmental issues relevant to the policies, laws, or regulations on which the organization or individual has taken a position**

Select all that apply

☒ Water

#### (4.11.2.6) Indicate whether your organization's position is consistent with the organization or individual you engage with

Select from:

☒ Consistent

#### (4.11.2.7) Indicate whether your organization attempted to influence the organization or individual's position in the reporting year

Select from:

☒ Yes, and they have changed their position

#### (4.11.2.8) Describe how your organization's position is consistent with or differs from the organization or individual's position, and any actions taken to influence their position

*The joint AESGP – EFPIA – EGA Position Paper on Pharmaceuticals in the Environment (PiE) (<https://www.efpia.eu/media/25274/eps-position-paper-october-2015.pdf>) states: “The European pharmaceutical industry, represented by the Association of the European Self-Medication Industry (AESGP), the European Federation of Pharmaceutical Industries (EFPIA), and the European Generic and Biosimilar Medicines Association (EGA), recognizes and understands the concerns raised by stakeholders as regards the presence of pharmaceuticals in the environment (PiE). For this reason, we have come together to develop the Eco-Pharmaco-Stewardship (EPS) concept, a proposal that strives to protect patients’ access to medicines while appropriately considering environmental aspects.” On PiE, both Pfizer and EFPIA propose actions in three areas: 1. Encouraging further research to assess the impact of PiE; 2. Manage pharmaceutical sites’ effluents effectively; 3. Monitor environmental impact through extended Environmental Risk Assessment (eERA). Pfizer has collaborated with EFPIA in shaping their position on water issues by providing multidisciplinary input including technical, legal, and government affair expertise.*

#### (4.11.2.9) Funding figure your organization provided to this organization or individual in the reporting year (currency)

\$858,062

#### (4.11.2.10) Describe the aim of this funding and how it could influence policy, law or regulation that may impact the environment

*The fees disclosed represent Pfizer's total 2024 membership contributions to EFPIA. This funding supports EFPIA's role as a trade association representing the pharmaceutical industry in Europe, enabling coordinated engagement with EU institutions on science-based, innovation-friendly policy frameworks. Through EFPIA, Pfizer contributes to shaping environmental policy discussions on topics such as climate change, pharmaceuticals in the environment (PiE), water stewardship, and chemical legislation. This funding enables EFPIA to advocate for balanced, evidence-based regulation that protects public health and the environment while supporting continued access to medicines and innovation.*

#### **(4.11.2.11) Indicate if you have evaluated whether your organization's engagement is aligned with global environmental treaties or policy goals**

*Select from:*

☒ Yes, we have evaluated, and it is aligned

#### **(4.11.2.12) Global environmental treaties or policy goals aligned with your organization's engagement on policy, law or regulation**

*Select all that apply*

☒ Sustainable Development Goal 6 on Clean Water and Sanitation

#### **(4.12) Have you published information about your organization's response to environmental issues for this reporting year in places other than your CDP response?**

*Select from:*

☒ Yes

**(4.12.1) Provide details on the information published about your organization's response to environmental issues for this reporting year in places other than your CDP response. Please attach the publication.**

#### **Row 1**

##### **(4.12.1.1) Publication**

*Select from:*

☒ In voluntary sustainability reports

##### **(4.12.1.3) Environmental issues covered in publication**

*Select all that apply*

- ☒ Climate change
- ☒ Water
- ☒ Biodiversity

#### (4.12.1.4) Status of the publication

Select from:

- ☒ Complete

#### (4.12.1.5) Content elements

Select all that apply

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> Strategy              | <input checked="" type="checkbox"/> Value chain engagement                                  |
| <input checked="" type="checkbox"/> Governance            | <input checked="" type="checkbox"/> Dependencies & Impacts                                  |
| <input checked="" type="checkbox"/> Emission targets      | <input checked="" type="checkbox"/> Water accounting figures                                |
| <input checked="" type="checkbox"/> Emissions figures     | <input checked="" type="checkbox"/> Other, please specify : <b>Waste accounting figures</b> |
| <input checked="" type="checkbox"/> Risks & Opportunities |   |

#### (4.12.1.6) Page/section reference

*Planet section, pp 28-36; Environmental performance, pp. 53-54*

#### (4.12.1.7) Attach the relevant publication

*Pfizer\_2024\_Impact\_Report\_02JUN2025.pdf*

#### (4.12.1.8) Comment

*Pfizer's 2024 Impact Report is available online at: [https://cdn.pfizer.com/pfizercom/Pfizer\\_2024\\_Impact\\_Report\\_02JUN2025.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2024_Impact_Report_02JUN2025.pdf)*

### Row 2

#### (4.12.1.1) Publication

Select from:

☒ In mainstream reports, in line with environmental disclosure standards or frameworks

#### (4.12.1.2) Standard or framework the report is in line with

Select all that apply

☒ TCFD

#### (4.12.1.3) Environmental issues covered in publication

Select all that apply

☒ Climate change

#### (4.12.1.4) Status of the publication

Select from:

☒ Complete

#### (4.12.1.5) Content elements

Select all that apply

☒ Risks & Opportunities

#### (4.12.1.6) Page/section reference

*Responsible Business Growth, p. 29*

#### (4.12.1.7) Attach the relevant publication

*10K\_Final.pdf*

#### (4.12.1.8) Comment

*Pfizer's 2024 10-K Report is available online at: [https://s206.q4cdn.com/795948973/files/doc\\_financials/2024/ar/10K\\_Final.pdf](https://s206.q4cdn.com/795948973/files/doc_financials/2024/ar/10K_Final.pdf)*



### Row 3

#### (4.12.1.1) Publication

Select from:

☒ In voluntary communications

#### (4.12.1.3) Environmental issues covered in publication

Select all that apply

☒ Climate change

#### (4.12.1.4) Status of the publication

Select from:

☒ Complete

#### (4.12.1.5) Content elements

Select all that apply

☒ Public policy engagement

☒ Strategy

#### (4.12.1.6) Page/section reference

Full document

#### (4.12.1.7) Attach the relevant publication

Climate\_Change\_Position\_Statement\_December\_2024.pdf

#### (4.12.1.8) Comment

Pfizer's Climate Change Position Statement is available online at: [https://cdn.pfizer.com/pfizercom/about/Climate\\_Change\\_Position\\_Statement\\_December\\_2024.pdf](https://cdn.pfizer.com/pfizercom/about/Climate_Change_Position_Statement_December_2024.pdf)

## Row 4

### (4.12.1.1) Publication

Select from:

☒ In voluntary communications

### (4.12.1.3) Environmental issues covered in publication

Select all that apply

☒ Water

### (4.12.1.4) Status of the publication

Select from:

☒ Complete

### (4.12.1.5) Content elements

Select all that apply

☒ Strategy

☒ Value chain engagement

### (4.12.1.6) Page/section reference

Full document

### (4.12.1.7) Attach the relevant publication

*Pfizer\_Water\_Stewardship\_Public\_Position\_Statement\_2022.pdf*

### (4.12.1.8) Comment

*Pfizer's Water Stewardship Position Statement is available online at:*

*[https://cdn.pfizer.com/pfizercom/Pfizer\\_Water\\_Stewardship\\_Public\\_Position\\_Statement\\_2022.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf)*

## C5. Business strategy

### (5.1) Does your organization use scenario analysis to identify environmental outcomes?

#### Climate change

##### (5.1.1) Use of scenario analysis

Select from:

☒ Yes

##### (5.1.2) Frequency of analysis

Select from:

☒ More than once a year

#### Water

##### (5.1.1) Use of scenario analysis

Select from:

☒ Yes

##### (5.1.2) Frequency of analysis

Select from:

☒ More than once a year

### (5.1.1) Provide details of the scenarios used in your organization's scenario analysis.

#### Climate change

#### (5.1.1.1) Scenario used

Physical climate scenarios

☒ RCP 2.6

#### (5.1.1.2) Scenario used    SSPs used in conjunction with scenario

*Select from:*

☒ SSP1

#### (5.1.1.3) Approach to scenario

*Select from:*

☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

*Select from:*

☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

*Select all that apply*

☒ Acute physical

☒ Chronic physical

#### (5.1.1.6) Temperature alignment of scenario

*Select from:*

☒ 1.6°C - 1.9°C

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2050

#### (5.1.1.9) Driving forces in scenario

Direct interaction with climate

☒ On asset values, on the corporate

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This physical risk scenario is aligned to the current commitments under the Paris Agreement. The world shifts towards a more sustainable path, emphasizing more inclusive development, driven by an increasing commitment to achieving development goals. Key parameters and assumptions: global Net-Zero is reached in 2050; renewables account for more than half of the energy supply by 2050; and there are few challenges to climate mitigation and adaptation.*

#### (5.1.1.11) Rationale for choice of scenario

*Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net Zero target, international and national climate policy milestones, and the expected lifetime of our assets.*

### Water

#### (5.1.1.1) Scenario used

Water scenarios

☒ WRI Aqueduct

#### (5.1.1.3) Approach to scenario

Select from:

- ☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

Select from:

- ☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

Select all that apply

- ☒ Acute physical
- ☒ Chronic physical
- ☒ Policy
- ☒ Reputation
- ☒ Liability

#### (5.1.1.7) Reference year

2023

#### (5.1.1.8) Timeframes covered

Select all that apply

- ☒ 2025

#### (5.1.1.9) Driving forces in scenario

Local ecosystem asset interactions, dependencies and impacts

- ☒ Climate change (one of five drivers of nature change)

Stakeholder and customer demands

- ☒ Impact of nature footprint on reputation
- ☒ Impact of nature service delivery on consumer
- ☒ Sensitivity to inequity of nature impacts

Direct interaction with climate

☒ On asset values, on the corporate

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*No additional assumptions, uncertainties or constraints beyond those inherent in WRI's Aqueduct Tool (version 4.0).*

#### (5.1.1.11) Rationale for choice of scenario

*WRI's Aqueduct Tool is used to identify potential baseline/short-term risks and assess the adequacy of site Water Stewardship plans. Medium- and long-term water-related risks are assessed as part of the climate change physical risk analysis using the RCP 2.6 and RCP 8.5 scenarios.*

### Climate change

#### (5.1.1.1) Scenario used

Physical climate scenarios

☒ RCP 8.5

#### (5.1.1.2) Scenario used    SSPs used in conjunction with scenario

Select from:

☒ SSP5

#### (5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

Select from:

- ☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

Select all that apply

- ☒ Acute physical
- ☒ Chronic physical

#### (5.1.1.6) Temperature alignment of scenario

Select from:

- ☒ 4.0°C and above

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

Select all that apply

- ☒ 2030
- ☒ 2050

#### (5.1.1.9) Driving forces in scenario

Direct interaction with climate

- ☒ On asset values, on the corporate

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This is a physical risk high emissions scenario with no additional climate policy (business-as-usual). The push for economic and social development is coupled with the exploitation of abundant fossil fuel resources and the adoption of resource and energy intensive lifestyles around the world. Key parameters and assumptions: energy demand triples by 2100, dominated by fossil fuels; current atmospheric CO2 levels double by 2050; there are many challenges to climate mitigation, with few challenges to adaptation.*



### (5.1.1.11) Rationale for choice of scenario

*Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.*

## Climate change

### (5.1.1.1) Scenario used

Climate transition scenarios

☒ NGFS scenarios framework, please specify :Net-Zero 2050

### (5.1.1.3) Approach to scenario

*Select from:*

☒ Qualitative and quantitative

### (5.1.1.4) Scenario coverage

*Select from:*

☒ Organization-wide

### (5.1.1.5) Risk types considered in scenario

*Select all that apply*

☒ Policy

☒ Market

☒ Reputation

☒ Technology

☒ Liability

### (5.1.1.6) Temperature alignment of scenario

Select from:

☒ 1.5°C or lower

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2040

☒ 2050

#### (5.1.1.9) Driving forces in scenario

Stakeholder and customer demands

☒ Consumer sentiment

Regulators, legal and policy regimes

☒ Global regulation

☒ Global targets

Relevant technology and science

☒ Other relevant technology and science driving forces, please specify :New technologies to enable decarbonization

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This is an ambitious transition risk scenario that limits global warming to 1.5 °C through stringent climate policies and innovation, reaching Net-Zero greenhouse gas emissions around 2050. Key parameters and assumptions include the immediate introduction of ambitious climate policy and that global Net-Zero is reached in 2050. IPCC's SSP2 'Middle of the Road' socioeconomic assumptions were adjusted for COVID-19 impact.*

#### (5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

## Climate change

### (5.1.1.1) Scenario used

Climate transition scenarios

☒ NGFS scenarios framework, please specify :Current Policies

### (5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

### (5.1.1.4) Scenario coverage

Select from:

☒ Organization-wide

### (5.1.1.5) Risk types considered in scenario

Select all that apply

☒ Policy

☒ Market

☒ Reputation

☒ Technology

☒ Liability

### (5.1.1.6) Temperature alignment of scenario

Select from:

☒ 3.0°C - 3.4°C

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

*Select all that apply*

☒ 2030

☒ 2040

☒ 2050

#### (5.1.1.9) Driving forces in scenario

Regulators, legal and policy regimes

☒ Global regulation

☒ Global targets

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This transition risk scenario assumes that only currently implemented policies are preserved, with an expected temperature outcome of ~3°C. This scenario assumes that emissions peak in 2080. IPCC's SSP2 'Middle of the Road' socioeconomic assumptions were adjusted for COVID-19 impact.*

#### (5.1.1.11) Rationale for choice of scenario

*Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.*

### (5.1.2) Provide details of the outcomes of your organization's scenario analysis.

## Climate change

### (5.1.2.1) Business processes influenced by your analysis of the reported scenarios

Select all that apply

- ☒ Risk and opportunities identification, assessment and management
- ☒ Resilience of business model and strategy

### (5.1.2.2) Coverage of analysis

Select from:

- ☒ Organization-wide

### (5.1.2.3) Summarize the outcomes of the scenario analysis and any implications for other environmental issues

*Physical Risk: Scenario analysis indicated that by 2030, under a high emissions scenario, almost half of Pfizer's manufacturing and R&D sites assessed are at a high risk of water scarcity and drought, and several of our manufacturing sites are at high risk of flooding. Risk remains high through 2050. Potential financial impacts include increased capital expenditures, increased direct (operating) costs, decreased asset value or asset useful life leading to write-offs, and decreased revenues due to reduced production capacity. Also, while scenario analysis does not show extreme heat as presenting a high risk to Pfizer in the near term, by 2050, under a high emissions scenario, approximately 14% of the manufacturing and R&D sites assessed were at a high risk of extreme heat. Extreme heat may increase potential financial risk for Pfizer by increasing operating costs associated with running air conditioning and backup generators, and/or reducing revenue due to production shutdowns. In 2024, we used the output of this analysis to drive the development and implementation of site-specific mitigation plans to address identified climate risks. Transition (Policy): Pfizer is increasingly exposed to the cost of carbon in our operations and could be exposed to pass-through costs in the supply chain. The potential risk of increased direct and indirect (operating) costs was rated high for 2030, 2040, and 2050 under a Net-Zero scenario where carbon pricing mechanisms are expected to increase. Additionally, a transition away from fossil fuels may result in volatile energy and fuel prices, potentially increasing direct costs for Pfizer, especially in 2040 and beyond. Transition (Technology): A growing need to decarbonize to meet both our Net-Zero goal and external stakeholder pressure will require investment to decarbonize capital assets. Technology risk was rated medium for 2030 and high for 2040 and 2050, with potential financial impacts of increased capital expenditures, decreased asset value or asset useful life leading to write-offs, and asset impairment or early retirement of existing assets. Transition (Market): A number of national healthcare systems and countries have announced Net-Zero targets which may result in increasing pressure for suppliers to decarbonize products across their life cycle including Scope 3 emissions. As ~80% of Pfizer's emissions are Scope 3, there is additional complexity in producing low-carbon products as it relies on suppliers decarbonizing their operations. Risk was rated medium for 2030 and high for 2040 and 2050, with a potential impact of decreased revenues due to reduced demand for products and services. Pfizer manages transition risks associated with emerging regulations, carbon pricing initiatives, and customer expectations through effective GHG emission reduction goals and internal energy efficiency targets to reduce potential costs associated with the purchase or generation of energy. In 2024 we invested \$31M in CAPEX and OPEX spend, not including staffing costs for internal energy conservation program management, to implement or begin implementing projects to reduce GHG emissions across the company. While a number of risks and opportunities with the potential to impact financial performance and position were identified through our analysis, we concluded that Pfizer's current business model and strategy is resilient under the assessed scenarios.*

## Water

### (5.1.2.1) Business processes influenced by your analysis of the reported scenarios

Select all that apply

- ☒ Risk and opportunities identification, assessment and management
- ☒ Resilience of business model and strategy

### (5.1.2.2) Coverage of analysis

Select from:

- ☒ Organization-wide

### (5.1.2.3) Summarize the outcomes of the scenario analysis and any implications for other environmental issues

*Through scenario analysis we have currently identified six manufacturing and two R&D facilities that are currently exposed to water stress risks, and one additional manufacturing facility that is projected to be exposed to water stress risk in the 2030 and 2050 time horizons. These risks were determined not to be substantive and will continue to be monitored and managed through our Water Stewardship and Business Resilience programs. We are currently working to validate scenario analysis results for additional facilities within our direct operations and supply chain.*

## (5.2) Does your organization's strategy include a climate transition plan?

### (5.2.1) Transition plan

Select from:

- ☒ Yes, we have a climate transition plan which aligns with a 1.5°C world

### (5.2.3) Publicly available climate transition plan

Select from:

- ☒ Yes

#### (5.2.4) Plan explicitly commits to cease all spending on, and revenue generation from, activities that contribute to fossil fuel expansion

Select from:

☒ No, and we do not plan to add an explicit commitment within the next two years

#### (5.2.6) Explain why your organization does not explicitly commit to cease all spending on and revenue generation from activities that contribute to fossil fuel expansion

*Pfizer uses fossil fuels and fossil fuel-based materials in our operations to manufacture pharmaceuticals. Through our Net Zero goal we anticipate our demand for these materials will not increase and will decrease over time. Therefore, we do not anticipate our use to contribute to fossil fuel expansion. Pfizer is a member of RE100 and has committed to achieve 100% renewable electricity by 2030. Transitioning away from fossil fuels is part of our strategy to achieve the Net-Zero standard.*

#### (5.2.7) Mechanism by which feedback is collected from shareholders on your climate transition plan

Select from:

☒ We have a different feedback mechanism in place

#### (5.2.8) Description of feedback mechanism

*Pfizer has established a strategic plan to advance our Net-Zero goal and therefore our responses in this questionnaire align to CDP's expectations of a transition plan per CDP guidance. Our annual Impact Report provides stakeholders with prior-year GHG emissions data and updates on our progress toward achieving Net-Zero. Each year, Pfizer strives to engage with investors who, in the aggregate, hold approximately 50% of our outstanding stock. We share our Impact Report with these investors and invite them to meet with representatives of Pfizer's sustainability team and Investor Relations. These meetings offer an opportunity to gather feedback and address specific questions related to our responsible business strategy and performance. In addition to these annual engagements, we maintain ongoing dialogue with investors on sustainability issues through one-on-one conversations, surveys, questionnaires, and targeted communications—for example, via our Responsible Business website.*

#### (5.2.9) Frequency of feedback collection

Select from:

☒ More frequently than annually

#### (5.2.10) Description of key assumptions and dependencies on which the transition plan relies

Pfizer's Net-Zero transition plan is grounded in the assumption that emerging technologies—particularly those enabling low/no-carbon heat and steam generation—will become available and scalable within the required timeframe. Our strategy depends on the evolution of regulatory frameworks that support decarbonization and incentivize innovation. We assume continued progress across sectors in electrification infrastructure, renewable energy markets, and the development of alternative fuels. Our internal decarbonization efforts rely on the successful implementation of Net-Zero design guidelines and master plans across our global network, as well as employee engagement and behavioral change. A key dependency is the active participation of our value chain. Approximately 80% of our emissions are Scope 3, and we rely on suppliers to adopt science-aligned targets and implement emissions-reduction strategies. As of the end of 2024, 65% of our suppliers (by spend) had adopted or committed to science-based targets, exceeding our 2025 goal of 64%. We also depend on reliable logistics systems and the availability of low-emission fuels and electric vehicles to reduce transportation-related emissions. Our plan assumes that voluntary corporate action will remain a key driver of climate progress, but we also call on governments to enact ambitious climate policies to stabilize global temperature rise at 1.5°C.

#### **(5.2.11) Description of progress against transition plan disclosed in current or previous reporting period**

Pfizer has made measurable progress across key elements of our Net-Zero transition plan, including internal operations, supplier engagement, logistics, business travel, and product life cycle innovation. **Internal Operations (Scope 1 & 2):** We've launched Net-Zero site master plans across our internal manufacturing, R&D, and commercial facilities, creating a pipeline of decarbonization projects. Our strategy includes: integrating Net-Zero attributes into new construction and renovations, implementing energy efficiency projects and analytics, replacing aging assets with energy-efficient alternatives, electrifying infrastructure to support low/zero-carbon utilities, transitioning our sales fleet to electric and low-emission vehicles. These efforts, combined with renewable electricity procurement, are expected to reduce Scope 1&2 emissions by 46% by 2030 (vs. 2019). Fleet and site upgrades alone are projected to reduce Scope 1 emissions by 20–25%. As of the end of 2024, our combined Scope 1 and 2 emissions were 15% below our 2019 baseline. **Supplier Engagement (Scope 3):** We set a 2025 target for 64% of suppliers (by spend) to adopt science-aligned targets. As of 2024, 65% had done so. We continue to engage suppliers through surveys, direct outreach, and collaborative initiatives to drive climate action across our value chain. **Transportation & Logistics (Scope 3):** We aim to reduce upstream transportation and distribution emissions by 10% by 2025 (vs. 2019). In 2024, we shifted shipments from air to ocean where feasible, adopted biofuels in select transport lanes with certified emissions factors, piloted electric medium-duty freight vehicles in regions with supporting infrastructure, and advanced circularity initiatives to reduce waste and emissions. As of the end of 2024, our emissions associated with upstream transportation and distribution were 23% lower than our 2019 baseline. **Business Travel (Scope 3):** We set a 2025 target of 25% reduction in travel-related emissions from a 2019 baseline. As of 2024, emissions were down 55% from 2019. We've embedded sustainable travel messaging in booking tools, collaborated with suppliers on low-emission options, and educated employees on purposeful travel. We're exploring internal policy revisions to further align travel with long-term emissions reduction goals. **Product Life Cycle Innovation (Scope 1, 2 & 3):** Our Sustainable Medicines Program drives process innovation aimed at reducing GHG impacts across the product life cycle. We're advancing life cycle assessments (LCAs) across modalities—small molecules, biologics, vaccines, and devices—to identify and help address emissions hotspots. These insights inform manufacturing improvements and product design decisions. Pfizer's progress reflects a science-based, cross-functional approach to climate action. While challenges remain, our achievements to date demonstrate our commitment to delivering on our Net-Zero ambition while continuing to serve patients globally.

#### **(5.2.13) Other environmental issues that your climate transition plan considers**

Select all that apply

☒ No other environmental issue considered



### **(5.3) Have environmental risks and opportunities affected your strategy and/or financial planning?**

#### **(5.3.1) Environmental risks and/or opportunities have affected your strategy and/or financial planning**

*Select from:*

☒ Yes, both strategy and financial planning

#### **(5.3.2) Business areas where environmental risks and/or opportunities have affected your strategy**

*Select all that apply*

☒ Products and services

☒ Upstream/downstream value chain

☒ Investment in R&D

☒ Operations

### **(5.3.1) Describe where and how environmental risks and opportunities have affected your strategy.**

#### **Products and services**

##### **(5.3.1.1) Effect type**

*Select all that apply*

☒ Opportunities

##### **(5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area**

*Select all that apply*

☒ Climate change

☒ Water

##### **(5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area**

*Pfizer has leveraged our achievements in green chemistry, success with our public GHG emission reduction goals and water stewardship program, and commitment to science-based targets to develop substantiated environmental information which has been shared with potential customers/retailers and governmental tenders in response to their requests for such information. We anticipate that our goal to achieve Net-Zero GHG emissions, as well as our ability to provide environmental footprint details for our products, will become increasingly important to our customers in the next 3-5 years.*

## Upstream/downstream value chain

### (5.3.1.1) Effect type

*Select all that apply*

☒ Risks

### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

*Select all that apply*

☒ Climate change

### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*As one of the first companies to receive validation of our then current GHG emission reduction goal by the Science Based Target Initiative (SBTi) in 2015, Pfizer remains committed to ambitious long-term actions aligned with science. As part of our near-term targets, approved by SBTi, we aim to use our influence to catalyze similar reductions across our value chain. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We are therefore urging all our suppliers to commit to ambitious, science-based GHG reduction targets and have integrated environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes. As a result of our engagement efforts, 65% of our suppliers of goods and services by spend have committed to science-based emission reduction targets. By 2040 Pfizer aims to decrease its company GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by reducing the energy demand of our operations, transitioning away from fossil fuels, sourcing renewable electricity, and engaging suppliers to catalyze equivalent action.*

## Investment in R&D

### (5.3.1.1) Effect type

*Select all that apply*

☒ Opportunities

### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

☒ Water

### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*Pfizer is committed to developing medicines that not only improve patient health but also have a reduced environmental impact throughout the product lifecycle when compared to traditional research, development, manufacturing, and supply methods. Building on our long history of applying green chemistry principles and promoting them across the industry, we continue to innovate in sustainable science. Our approach aims to encompass the entire product lifecycle, from early-stage research through manufacturing and end-of-life management. We are integrating sustainable product design principles within our R&D processes, aiming to systematically conserve energy, reduce water and raw material usage, minimize waste, and embrace circular solutions where possible. We continue to educate our colleagues, define key metrics and performance targets, and encourage innovation through collaboration and partnerships. As part of these efforts, Pfizer is committed to reducing the environmental impact of our medicines and vaccines throughout their lifecycle. To support this goal and our net-zero ambitions, we have conducted over 20 life cycle assessments (LCAs) measuring impacts across a range of product modalities, including small molecules, large molecules, vaccines, and medical devices. These LCAs provide valuable insights into the environmental impacts at each stage of a product's life. We share these insights with our scientists, researchers, and engineers to support sustainable innovation and impact reduction. As a founding member of the Pharmaceutical Life-Cycle Assessment (Pharma LCA) Consortium, Pfizer is contributing to industry-wide efforts to develop a coordinated approach for assessing and communicating the environmental impact of pharmaceutical products. The Consortium's ultimate goal is to develop a sector-wide standard for LCAs that will allow pharmaceutical companies and their stakeholders to make informed choices about product development and patient care.*

## Operations

### (5.3.1.1) Effect type

Select all that apply

☒ Opportunities

### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

☒ Water

### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*We are reducing our environmental footprint by expanding the use of renewable energy, enhancing energy efficiency at manufacturing and R&D facilities around the globe, and increasing our fleet of electric vehicles, among other measures. We continue to collaborate with our partners to drive the adoption of science-based GHG reduction targets through our value chain. Reducing GHG emissions from our manufacturing and R&D facilities is a key element of our efforts to reach net-zero emissions by 2040. We are actively working to create more energy-efficient and healthy workplaces that can support colleagues' health and well-being. In 2024, Pfizer's Ringaskiddy Clinical Manufacturing Facility in Cork, Ireland, and Pfizer's office in Madrid, Spain, received LEED® Gold recognition, and our office in Vienna, Austria, was awarded Platinum status. Pfizer's New York headquarters was awarded both LEED® Platinum and WELL Platinum certifications. Pfizer invests in no- and low-carbon technologies at our sites and through VPPAs that enable sourcing of renewable energy. VPPAs covering solar projects in Spain and the United States, coming online in 2025, are expected to generate renewable energy credits (RECs) to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe. In 2024, we enhanced our water stewardship efforts by: 1. Enhancing and updating our baseline requirements for responsible water management at Pfizer sites, including focusing on responsible water use in pharmaceutical development and production, minimizing potential environmental impacts from water use and wastewater effluent, and setting internal requirements for ground and surface water protection. The standard sets expectations for sites to evaluate water usage and potential impact on local water resources, ecosystems, communities, and human health. 2. Based on water stress assessments completed in 2023 for all Pfizer sites, we completed detailed water risk assessments at several sites. Resulting action plans include, where needed, elements such as protecting water quality, improving wastewater treatment, evaluating recycling practices, and engaging with surrounding communities.*

## **(5.3.2) Describe where and how environmental risks and opportunities have affected your financial planning.**

### **Row 1**

#### **(5.3.2.1) Financial planning elements that have been affected**

*Select all that apply*

- ☒ Revenues
- ☒ Indirect costs
- ☒ Capital expenditures
- ☒ Assets

#### **(5.3.2.2) Effect type**

*Select all that apply*

- ☒ Risks
- ☒ Opportunities

### (5.3.2.3) Environmental issues relevant to the risks and/or opportunities that have affected these financial planning elements

Select all that apply

☒ Climate change

☒ Water

### (5.3.2.4) Describe how environmental risks and/or opportunities have affected these financial planning elements

*Climate-related risks and opportunities have influenced Pfizer's business strategy and are incorporated into financial planning. Assets: Physical climate risks such as water scarcity, flooding, and extreme heat—identified through scenario analysis—have influenced asset management decisions. For example, under a high-emissions scenario, nearly half of Pfizer's manufacturing and R&D sites are projected to face high water stress by 2030, with several also at risk of flooding or extreme heat by 2050. These risks have prompted asset-level assessments and the development of mitigation plans, including infrastructure upgrades and resilience investments, to protect asset value and extend useful life. Revenues: Environmental performance is increasingly a factor in customer engagement and procurement decisions. Pfizer has received a growing number of requests for environmental data from customers, with associated revenues exceeding \$100 million. While the precise influence on purchasing decisions is still being quantified, this trend is now factored into revenue forecasts and customer relationship strategies. Indirect Costs and Capital Expenditures: Operational costs are affected by both physical and transition risks. For example, extreme heat may increase energy consumption for cooling and backup systems, while regulatory and stakeholder expectations drive ongoing investments in sustainability reporting, risk engineering, and supply chain resilience. These costs are recurring and incorporated into annual budgets. Pfizer invests in no- and low-carbon technologies at our sites and through VPPAs that enable sourcing of renewable energy. VPPAs covering solar projects in Spain and the United States, coming online in 2025, are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Environmental considerations are embedded in Pfizer's capital planning. Sites are required to maintain master plans identifying emissions reduction opportunities, which are reviewed through the capital project appropriation process.*

**(5.4) In your organization's financial accounting, do you identify spending/revenue that is aligned with your organization's climate transition?**

	Identification of spending/revenue that is aligned with your organization's climate transition	Methodology or framework used to assess alignment with your organization's climate transition
	<i>Select from:</i> <input checked="" type="checkbox"/> Yes	<i>Select all that apply</i> <input checked="" type="checkbox"/> Other methodology or framework

**(5.4.1) Quantify the amount and percentage share of your spending/revenue that is aligned with your organization's climate transition.**

**Row 1**

#### **(5.4.1.1) Methodology or framework used to assess alignment**

*Select from:*

☒ Other, please specify :Internal tracking of emission reduction plan-related OPEX and CAPEX spend

#### **(5.4.1.5) Financial metric**

*Select from:*

☒ Revenue/Turnover

#### **(5.4.1.6) Amount of selected financial metric that is aligned in the reporting year (currency)**

\$31,000,000

#### **(5.4.1.7) Percentage share of selected financial metric aligned in the reporting year (%)**

0.05

#### **(5.4.1.8) Percentage share of selected financial metric planned to align in 2025 (%)**

0

#### **(5.4.1.9) Percentage share of selected financial metric planned to align in 2030 (%)**

0

#### **(5.4.1.12) Details of the methodology or framework used to assess alignment with your organization's climate transition**

*Pfizer integrates climate transition considerations directly into our capital allocation and operational planning processes. We track spending on net-zero initiatives by embedding them into our financial and strategic decision-making frameworks. This includes: - Net-zero master plans that prioritize emission reduction opportunities. - Design standards applied to capital project concepts to ensure alignment with net-zero goals. - Lifecycle cost analysis to evaluate long-term sustainability and financial impact. - Net-zero tracking tags within our capital management systems to monitor investments. - Inclusion of physical and financial climate risk considerations in capital allocation and financing decisions. These tools help ensure that net-zero projects are not only considered but actively prioritized in both operational and capital planning cycles, enabling transparent tracking of climate-related spending. Expenses and capital spending related to our emissions reduction plan in 2024 were not material to our consolidated financial statements. While we anticipate incurring additional capital and operational expenditures to achieve our climate goals, we do not currently expect these costs to have a material impact on our financial position in the near term (i.e., through 2025 or 2030). As such, the percentage shares of revenue for these periods has been reported as zero.*

### **(5.9) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year?**

#### **(5.9.1) Water-related CAPEX (+/- % change)**

0

#### **(5.9.2) Anticipated forward trend for CAPEX (+/- % change)**

0

#### **(5.9.3) Water-related OPEX (+/- % change)**

0

#### (5.9.4) Anticipated forward trend for OPEX (+/- % change)

0

#### (5.9.5) Please explain

*Capital and operating expenditures have remained relatively flat across the organization. Water costs represent less than 1% of Pfizer's CAPEX and OPEX spend. These costs include payments for utilities as well as investments in water conservation projects. OPEX spend includes spend related to purchased water, chilled water and water filtration and treatment supplies. CAPEX spend includes water-related capital projects, including project management.*

#### (5.10) Does your organization use an internal price on environmental externalities?

	Use of internal pricing of environmental externalities	Environmental externality priced
	Select from: <input checked="" type="checkbox"/> Yes	Select all that apply <input checked="" type="checkbox"/> Carbon

#### (5.10.1) Provide details of your organization's internal price on carbon.

##### Row 1

#### (5.10.1.1) Type of pricing scheme

Select from:

☒ Shadow price

#### (5.10.1.2) Objectives for implementing internal price



*Select all that apply*

- ☒ Incentivize consideration of climate-related issues in decision making
- ☒ Incentivize consideration of climate-related issues in risk assessment
- ☒ Influence strategy and/or financial planning
- ☒ Setting and/or achieving of climate-related policies and targets

#### **(5.10.1.3) Factors considered when determining the price**

*Select all that apply*

- ☒ Alignment to scientific guidance
- ☒ Alignment with the price of a carbon tax
- ☒ Scenario analysis

#### **(5.10.1.4) Calculation methodology and assumptions made in determining the price**

*Pfizer uses a \$50-\$200/mtCO<sub>2</sub>e internal carbon price to assess certain portfolios of capital projects and opportunities. This price aligns with current and projected international tax schemes that may apply to Pfizer based on its operational locations.*

#### **(5.10.1.5) Scopes covered**

*Select all that apply*

- ☒ Scope 1
- ☒ Scope 2

#### **(5.10.1.6) Pricing approach used – spatial variance**

*Select from:*

- ☒ Differentiated

#### **(5.10.1.7) Indicate how and why the price is differentiated**

*Variable globally and between markets.*

#### **(5.10.1.8) Pricing approach used – temporal variance**

Select from:

☒ Evolutionary

#### (5.10.1.9) Indicate how you expect the price to change over time

*Our strategic modeling assumes a gradual increase in carbon price from 2020 through 2029, reflecting anticipated regulatory and market developments. From 2030 onwards, the model holds the carbon price constant.*

#### (5.10.1.10) Minimum actual price used (currency per metric ton CO2e)

\$50

#### (5.10.1.11) Maximum actual price used (currency per metric ton CO2e)

\$200

#### (5.10.1.12) Business decision-making processes the internal price is applied to

Select all that apply

☒ Capital expenditure

☒ Risk management

☒ Opportunity management

#### (5.10.1.13) Internal price is mandatory within business decision-making processes

Select from:

☒ No

#### (5.10.1.14) % total emissions in the reporting year in selected scopes this internal price covers

23

#### (5.10.1.15) Pricing approach is monitored and evaluated to achieve objectives

Select from:

☒ Yes

#### (5.10.1.16) Details of how the pricing approach is monitored and evaluated to achieve your objectives

*Pfizer continues to apply a shadow carbon price to understand some of the financial implications of decarbonization strategies as part of the overall governance of climate goals at the company. In 2024, this pricing mechanism was used to evaluate the potential costs and cost savings associated with delivering on our Net-Zero (NZ) goal. This included assessing multiple carbon price scenarios and their impacts on the incremental capital and operational expenditures required to meet NZ targets under evolving regulatory, market, and stakeholder expectations.*

#### (5.11) Do you engage with your value chain on environmental issues?

	Engaging with this stakeholder on environmental issues	Environmental issues covered
Suppliers	Select from: <input checked="" type="checkbox"/> Yes	Select all that apply <input checked="" type="checkbox"/> Climate change <input checked="" type="checkbox"/> Water
Customers	Select from: <input checked="" type="checkbox"/> Yes	Select all that apply <input checked="" type="checkbox"/> Climate change <input checked="" type="checkbox"/> Water
Investors and shareholders	Select from: <input checked="" type="checkbox"/> Yes	Select all that apply <input checked="" type="checkbox"/> Climate change
Other value chain stakeholders	Select from: <input checked="" type="checkbox"/> Yes	Select all that apply <input checked="" type="checkbox"/> Climate change <input checked="" type="checkbox"/> Water

## **(5.11.1) Does your organization assess and classify suppliers according to their dependencies and/or impacts on the environment?**

### **Climate change**

#### **(5.11.1.1) Assessment of supplier dependencies and/or impacts on the environment**

Select from:

☒ Yes, we assess the dependencies and/or impacts of our suppliers

#### **(5.11.1.2) Criteria for assessing supplier dependencies and/or impacts on the environment**

Select all that apply

☒ Contribution to supplier-related Scope 3 emissions

#### **(5.11.1.3) % Tier 1 suppliers assessed**

Select from:

☒ 100%

#### **(5.11.1.4) Define a threshold for classifying suppliers as having substantive dependencies and/or impacts on the environment**

*Pfizer uses risk assessment and spend-based GHG emissions estimates to identify suppliers with substantive dependencies or potential impacts on the environment. For climate change, this includes roughly 500 parent suppliers that represent approximately 80% of our scope 3 emissions of purchased goods and services and capital goods.*

#### **(5.11.1.5) % Tier 1 suppliers meeting the threshold for substantive dependencies and/or impacts on the environment**

Select from:

☒ 1-25%

#### **(5.11.1.6) Number of Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment**

## Water

### (5.11.1.1) Assessment of supplier dependencies and/or impacts on the environment

Select from:

☒ Yes, we assess the dependencies and/or impacts of our suppliers

### (5.11.1.2) Criteria for assessing supplier dependencies and/or impacts on the environment

Select all that apply

☒ Impact on pollution levels

### (5.11.1.3) % Tier 1 suppliers assessed

Select from:

☒ 100%

### (5.11.1.4) Define a threshold for classifying suppliers as having substantive dependencies and/or impacts on the environment

*We classify suppliers as having potential substantive environmental dependencies and/or impacts based on their role in our antibiotic supply chain. Specifically, we have evaluated 100% of our antibiotic supply chain against the AMRIA Manufacturing Standard, which includes science-based discharge targets. We actively engage these suppliers to uphold responsible water stewardship, including driving adherence to the AMRIA standard expectations.*

### (5.11.1.5) % Tier 1 suppliers meeting the threshold for substantive dependencies and/or impacts on the environment

Select from:

☒ Less than 1%

### (5.11.1.6) Number of Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment

## (5.11.2) Does your organization prioritize which suppliers to engage with on environmental issues?

### Climate change

#### (5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

- ☒ Yes, we prioritize which suppliers to engage with on this environmental issue

#### (5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ In line with the criteria used to classify suppliers as having substantive dependencies and/or impacts relating to climate change
- ☒ Business risk mitigation
- ☒ Procurement spend
- ☒ Regulatory compliance
- ☒ Supplier performance improvement

#### (5.11.2.4) Please explain

*Pfizer's Scope 3 GHG footprint is approximately four times that associated with the company's direct operations. We recognize action is needed throughout our value chain to address the complex threat of climate change. The procurement of goods and services, essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We are therefore urging all our suppliers to commit to ambitious, science-based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes. We are focusing our engagement efforts on approximately 5% of our suppliers (by number) that account for around 90% of our emissions related to goods and services, including capital goods. We have asked these suppliers to set reduction targets for their Scope 1 and 2 GHG emissions—aligned with SBTi guidance—by the end of 2025. Our Sourcing, External Supply, and EHS colleagues are engaging with many of these suppliers to review their climate commitments and review alignment with Pfizer's expectations. We believe that through our layered approach of influence through competitive bidding, contracting, and supply relationship management we will increase the total number of suppliers engaged, which will help to result in an annual reduction in total emissions.*

### Water

#### (5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

- ☒ Yes, we prioritize which suppliers to engage with on this environmental issue

#### (5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ In line with the criteria used to classify suppliers as having substantive dependencies and/or impacts relating to water
- ☒ Business risk mitigation
- ☒ Regulatory compliance
- ☒ Supplier performance improvement

#### (5.11.2.4) Please explain

*As stated in our Water Stewardship Position Statement, pharmaceuticals in the environment and antimicrobial resistance continue to be important environmental issues for our industry. We remain dedicated to limiting discharge of active pharmaceutical ingredient (API) to wastewater from our manufacturing processes using environmental risk assessment methodologies and discharge control practices and technologies. Aligned with the expectations in the AMRIA Antibiotic Manufacturing Standard, we have conducted approximately 100 risk assessments against science-based discharge targets (known as Predicted No Effect Concentrations or PNECs) at antibiotic supplier locations as part of our commitment to help our suppliers achieve published wastewater PNECs by the end of 2025 and are piloting innovative wastewater management and treatment practices at several sites. In 2024, Pfizer continued to participate in the development and implementation of the certification program designed to demonstrate implementation of AMRIA's Antibiotic Manufacturing Standard through an independent third-party certification body. One of our contract manufacturers obtained the BSI Kitemark quality certification to the Antibiotic Manufacturing Standard for both API and drug product (DP) used to make one of our antibiotics. Pfizer continues to pursue opportunities with our internal API and DP network, suppliers, and contract manufacturers to seek certification of our antibiotic products.*

#### (5.11.5) Do your suppliers have to meet environmental requirements as part of your organization's purchasing process?

##### Climate change

#### (5.11.5.1) Suppliers have to meet specific environmental requirements related to this environmental issue as part of the purchasing process

Select from:

☒ Yes, environmental requirements related to this environmental issue are included in our supplier contracts

#### **(5.11.5.2) Policy in place for addressing supplier non-compliance**

Select from:

☒ Yes, we have a policy in place for addressing non-compliance

#### **(5.11.5.3) Comment**

*Through our contracts, we require our suppliers to establish a science based GHG emissions reduction target for their operations (i.e., covering Scope 1 and 2) or provide evidence of a comparable alternative in effect and, during the duration of the agreement, demonstrate progress in achieving the target.*

### **Water**

#### **(5.11.5.1) Suppliers have to meet specific environmental requirements related to this environmental issue as part of the purchasing process**

Select from:

☒ Yes, environmental requirements related to this environmental issue are included in our supplier contracts

#### **(5.11.5.2) Policy in place for addressing supplier non-compliance**

Select from:

☒ Yes, we have a policy in place for addressing non-compliance

#### **(5.11.5.3) Comment**

*Pfizer is a founding member of the Pharmaceutical Supply Chain Initiative (PSCI), a collaboration of pharma companies with a purpose to define, implement and champion responsible supply chain practices. The PSCI Principles for Responsible Supply Chain Management articulate the members' expectations for suppliers to operate in a manner that minimizes adverse impacts on the environment, including ensuring the safe handling of wastewater discharge and preventing and mitigating releases to the environment. Pfizer has incorporated the PSCI Principles into our supply agreement templates and our Supplier Conduct Principles. Additionally, Pfizer is committed to limiting discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes. Pfizer has incorporated into our supply agreement templates requirements for suppliers to assess and mitigate, if needed, discharges of API.*



**(5.11.6) Provide details of the environmental requirements that suppliers have to meet as part of your organization's purchasing process, and the compliance measures in place.**

## **Climate change**

### **(5.11.6.1) Environmental requirement**

*Select from:*

☒ Setting a science-based emissions reduction target

### **(5.11.6.2) Mechanisms for monitoring compliance with this environmental requirement**

*Select all that apply*

☒ Certification

☒ First-party verification

### **(5.11.6.3) % tier 1 suppliers by procurement spend required to comply with this environmental requirement**

*Select from:*

☒ 51-75%

### **(5.11.6.4) % tier 1 suppliers by procurement spend in compliance with this environmental requirement**

*Select from:*

☒ 51-75%

### **(5.11.6.7) % tier 1 supplier-related scope 3 emissions attributable to the suppliers required to comply with this environmental requirement**

*Select from:*

☒ 51-75%

#### (5.11.6.8) % tier 1 supplier-related scope 3 emissions attributable to the suppliers in compliance with this environmental requirement

Select from:

☒ 51-75%

#### (5.11.6.9) Response to supplier non-compliance with this environmental requirement

Select from:

☒ Retain and engage

#### (5.11.6.10) % of non-compliant suppliers engaged

Select from:

☒ 76-99%

#### (5.11.6.11) Procedures to engage non-compliant suppliers

Select all that apply

☒ Providing information on appropriate actions that can be taken to address non-compliance

#### (5.11.6.12) Comment

*Responses to this question are based on suppliers of purchased goods and services (Scope 3 Category 1) only and based on spend. Emissions from this category represent 78% of Pfizer's total Scope 3 emissions. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have embedded environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes. Pfizer continues our work to catalyze climate action in our supply chain. In 2024, we hosted the Pharmaceutical Supply Chain Initiative (PSCI) annual meeting, engaged suppliers through a third supplier summit, and launched a Pfizer-sponsored training academy for suppliers seeking assistance in measuring and reducing GHG emissions.*

## Water

#### (5.11.6.1) Environmental requirement

Select from:

- ☒ Setting and monitoring water pollution-related targets

#### **(5.11.6.2) Mechanisms for monitoring compliance with this environmental requirement**

*Select all that apply*

- ☒ First-party verification
- ☒ Supplier self-assessment

#### **(5.11.6.3) % tier 1 suppliers by procurement spend required to comply with this environmental requirement**

*Select from:*

- ☒ 1-25%

#### **(5.11.6.4) % tier 1 suppliers by procurement spend in compliance with this environmental requirement**

*Select from:*

- ☒ 1-25%

#### **(5.11.6.5) % tier 1 suppliers with substantive environmental dependencies and/or impacts related to this environmental issue required to comply with this environmental requirement**

*Select from:*

- ☒ 100%

#### **(5.11.6.6) % tier 1 suppliers with substantive environmental dependencies and/or impacts related to this environmental issue that are in compliance with this environmental requirement**

*Select from:*

- ☒ 76-99%

#### **(5.11.6.9) Response to supplier non-compliance with this environmental requirement**

*Select from:*

- ☒ Retain and engage

#### (5.11.6.10) % of non-compliant suppliers engaged

Select from:

☒ 100%

#### (5.11.6.11) Procedures to engage non-compliant suppliers

Select all that apply

☒ Developing quantifiable, time-bound targets and milestones to bring suppliers back into compliance

#### (5.11.6.12) Comment

*In 2024, Pfizer continued to participate in the development and implementation of the certification program designed to demonstrate implementation of AMRIA's Antibiotic Manufacturing Standard through an independent third-party certification body. One of our contract manufacturers obtained the BSI Kitemark quality certification to the Antibiotic Manufacturing Standard for both API and DP used to make one of our antibiotics. Pfizer continues to pursue opportunities with our internal API and DP network, suppliers, and contract manufacturers to seek certification of our antibiotic products.*

### (5.11.7) Provide further details of your organization's supplier engagement on environmental issues.

#### Climate change

#### (5.11.7.2) Action driven by supplier engagement

Select from:

☒ Emissions reduction

#### (5.11.7.3) Type and details of engagement

Capacity building

☒ Provide training, support and best practices on how to mitigate environmental impact

☒ Support suppliers to set their own environmental commitments across their operations

## Innovation and collaboration

- ☒ Collaborate with suppliers on innovative business models and corporate renewable energy sourcing mechanisms

### (5.11.7.4) Upstream value chain coverage

Select all that apply

- ☒ Tier 1 suppliers

### (5.11.7.5) % of tier 1 suppliers by procurement spend covered by engagement

Select from:

- ☒ 76-99%

### (5.11.7.6) % of tier 1 supplier-related scope 3 emissions covered by engagement

Select from:

- ☒ 76-99%

### (5.11.7.9) Describe the engagement and explain the effect of your engagement on the selected environmental action

*Recognizing that our Scope 3 (value chain) GHG footprint is approximately four times that associated with our direct operations, Pfizer has been driving action throughout our value chain to help address the complex threat of climate change. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes. To advance our work with our partners, we held our virtual Supplier Summit again in 2024, which focused on accelerating the transition to net-zero. The company also continues to promote excellence in sustainable supply chain management by participating in recognition events, including one organized by the Sustainable Procurement Pledge in December and Pfizer's own showcase that same month. To support suppliers in their decarbonization journey, we encouraged energy PPA education through the Energize program and offered sponsorships for the Activate program, a collective initiative that targets sustainability / GHG emission improvements at active pharmaceutical ingredient (API) suppliers including Contract Manufacturing Organizations. The measure of success for our supplier engagement program is the percentage of purchased goods and services spend with suppliers that have obtained or have publicly committed to obtain Science Based Targets initiative (SBTi) approval of their emission reduction targets and companies with scope 1 and 2 targets set at a level equivalent to SBTi criteria. Our aim is to drive 64% of our suppliers of goods and services by spend to set science-based GHG emission reduction goals by 2025. As a result of our engagement efforts, 65% of our suppliers of goods and services by spend have committed to science-based emission reduction targets, an increase of 27% compared to 2023.*

#### **(5.11.7.10) Engagement is helping your tier 1 suppliers meet an environmental requirement related to this environmental issue**

*Select from:*

☒ Yes, please specify the environmental requirement :Setting a science-based emission reduction target

#### **(5.11.7.11) Engagement is helping your tier 1 suppliers engage with their own suppliers on the selected action**

*Select from:*

☒ Yes

### **Water**

#### **(5.11.7.2) Action driven by supplier engagement**

*Select from:*

☒ Emissions reduction

#### **(5.11.7.3) Type and details of engagement**

Capacity building

☒ Provide training, support and best practices on how to mitigate environmental impact

#### **(5.11.7.4) Upstream value chain coverage**

*Select all that apply*

☒ Tier 1 suppliers

#### **(5.11.7.5) % of tier 1 suppliers by procurement spend covered by engagement**

*Select from:*

☒ 1-25%

#### **(5.11.7.7) % tier 1 suppliers with substantive impacts and/or dependencies related to this environmental issue covered by engagement**

Select from:

☒ 100%

#### **(5.11.7.9) Describe the engagement and explain the effect of your engagement on the selected environmental action**

*As stated in our Water Stewardship Position Statement, pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be important environmental issues for our industry. We remain dedicated to limiting discharge of active pharmaceutical ingredient (API) to wastewater from our manufacturing processes using environmental risk assessment methodologies and discharge control practices and technologies. We have conducted approximately 100 risk assessments against science-based discharge targets (known as Predicted No Effect Concentrations or PNECs) at antibiotic supplier locations as part of our commitment to help our suppliers achieve published wastewater PNECs by the end of 2025 and are piloting innovative wastewater management and treatment practices at several sites. In 2024, Pfizer continued to participate in the development and implementation of the certification program designed to demonstrate implementation of AMRIA's Antibiotic Manufacturing Standard through an independent third-party certification body. One of our contract manufacturers obtained the BSI Kitemark quality certification to the Antibiotic Manufacturing Standard for both API and drug product (DP) used to make one of our antibiotics. Pfizer continues to pursue opportunities with our internal API and DP network, suppliers, and contract manufacturers to seek certification of our antibiotic products.*

#### **(5.11.7.10) Engagement is helping your tier 1 suppliers meet an environmental requirement related to this environmental issue**

Select from:

☒ Yes, please specify the environmental requirement :Setting and monitoring water pollution-related targets

#### **(5.11.7.11) Engagement is helping your tier 1 suppliers engage with their own suppliers on the selected action**

Select from:

☒ Yes

#### **(5.11.9) Provide details of any environmental engagement activity with other stakeholders in the value chain.**

**Climate change**

### (5.11.9.1) Type of stakeholder

Select from:

☒ Customers

### (5.11.9.2) Type and details of engagement

Education/Information sharing

☒ Share information on environmental initiatives, progress and achievements

Innovation and collaboration

☒ Align your organization's goals to support customers' targets and ambitions

☒ Engage with stakeholders to advocate for policy or regulatory change

### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ 100%

### (5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

☒ Less than 1%

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pfizer recognizes that environmental sustainability issues are increasingly a priority to certain stakeholders, including customers and shareholders. We proactively share information on our climate change performance and strategy with current and prospective customers through our annual Impact Report, postings on our Pfizer.com website, press releases, and social media posts. We frequently respond to requests from our customers for details of our environmental sustainability program and performance data and in 2024 provided information to support Scope 3 reporting for customers representing over \$2B in revenue. We are committed to continue collaborating with our customers to identify opportunities to reduce emissions. Pfizer is also working with our peers in the pharma industry, many of which are also our customers, to identify opportunities to drive emissions reductions in the pharmaceutical supply chain. Pfizer is proud to be part of Energize, a first-of-its-kind collaboration launched in November 2021 between 10 global pharmaceutical companies to engage suppliers in decarbonization of the pharmaceutical value chain through renewable energy procurement. The program, which is designed and delivered by Schneider Electric, enables pharmaceutical suppliers to learn more about renewable energy adoption and contracting. This offers suppliers which may not otherwise have the internal resources or expertise available the opportunity to*



participate in the market for PPAs. In November 2022, Pfizer also joined a collective action initiative, Activate, to support the decarbonization of a major source of GHG emissions in the pharmaceutical value chain. Through Activate, Pfizer partners with peer pharma companies, many of which are also our customers, to accelerate decarbonization in active pharmaceutical ingredient (API) supply chains. Activate targets sustainability / GHG emission improvements at API suppliers including Contract Manufacturing Organizations. Furthermore, Pfizer is a founding member and active participant in the Pharmaceutical Supply Chain Initiative (PSCI). Pfizer colleagues currently sit on PSCI's board and several working committees. In 2024, Pfizer hosted the PSCI Spring Member Meeting at our NYC headquarters and co-hosted the PSCI India Annual Conference and Exhibition in Goa. The percentage of stakeholder-associated Scope 3 emissions was calculated based on downstream transportation emissions.

#### (5.11.9.6) Effect of engagement and measures of success

Pfizer shares climate-related information through our annual Impact Report, CDP Climate Change Response, and Pfizer.com. In 2024 we provided information to support Scope 3 reporting for customers representing over \$2B in revenue. As of the end of 2024, over 309 suppliers have registered for Energize as a result of Pfizer's invitations, and 39 Pfizer supplier organizations—representing 68 facilities—are participating in Activate.

### Water

#### (5.11.9.1) Type of stakeholder

Select from:

☒ Customers

#### (5.11.9.2) Type and details of engagement

Innovation and collaboration

☒ Collaborate with stakeholders on innovations to reduce environmental impacts in products and services

#### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ Less than 1%

#### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

Pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be priority environmental issues for our industry. Pfizer is committed to limiting discharge of active pharmaceutical ingredients to wastewater from our manufacturing processes, using environmental risk assessment methodologies and emission

control practices and technologies. As a founding member of the AMR Industry Alliance Manufacturing Working Group, Pfizer has partnered with peer companies, many of whom are also our customers, and key stakeholders to establish and implement a common framework for managing antibiotic discharge. As a result, the AMR Industry Alliance in June 2022 published its Antibiotic Manufacturing Standard: Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics.

#### (5.11.9.6) Effect of engagement and measures of success

Pfizer engages peer customers on antibiotic and active pharmaceutical ingredient (API) emissions by sharing environmental risk data upon request to support transparency and alignment on responsible manufacturing practices. As a founding member of the AMR Industry Alliance Manufacturing Working Group, Pfizer collaborated with other pharmaceutical companies—many of whom are also our customers—to develop the Antibiotic Manufacturing Standard. This standard aims to minimize the risk of antimicrobial resistance and aquatic toxicity from antibiotic production. In 2024, Pfizer continued its leadership by participating in the pilot of an independent third-party certification program to verify implementation of the standard. The effectiveness of our engagement is measured by customer uptake of data, participation in joint initiatives, and progress toward meeting discharge targets across the value chain.

### Climate change

#### (5.11.9.1) Type of stakeholder

Select from:

☒ Investors and shareholders

#### (5.11.9.2) Type and details of engagement

Education/Information sharing

☒ Share information on environmental initiatives, progress and achievements

#### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ 1-25%

#### (5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

☒ None

#### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*We engage investors on relevant issues, such as corporate strategy, board composition, risk oversight, patient access and affordability, executive compensation, human capital, environmental goals, corporate political spending and lobbying activities through ongoing one-on-one conversations, targeted communications, content in our annual Impact Report, and on our Responsible Business webpage (<https://www.pfizer.com/about/responsibility/responsible-business>).*

#### (5.11.9.6) Effect of engagement and measures of success

*Pfizer engages investors on climate-related topics through a structured and proactive outreach strategy. Investors have expressed appreciation for our transparency, particularly around KPIs, and encouraged further action on renewable energy access and Scope 3 emissions reduction. As a result of this feedback, Pfizer continues active engagement with the Science Based Targets initiative (SBTi) regarding planned revisions to the Net-Zero Standard. While measuring success is inherently qualitative, the absence of shareholder proposals related to our climate strategy and the positive feedback received during engagements are indicators of effective alignment and responsiveness to investor expectations.*

### Climate change

#### (5.11.9.1) Type of stakeholder

Select from:

☒ Other value chain stakeholder, please specify :Employees

#### (5.11.9.2) Type and details of engagement

Education/Information sharing

☒ Educate and work with stakeholders on understanding and measuring exposure to environmental risks

☒ Share information on environmental initiatives, progress and achievements

#### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ 100%

#### (5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

☒ 1-25%

#### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pfizer recognizes that addressing climate change requires collective action across the value chain, including the active engagement of colleagues. As part of our goal to achieve net-zero greenhouse gas (GHG) emissions across our value chain by 2040, we engage colleagues globally to support climate-related initiatives that reduce emissions, build resilience, and foster a culture of environmental responsibility. Colleagues are central to Pfizer's climate strategy. Their decisions—ranging from energy use and travel to procurement and logistics—directly influence our Scope 1, 2, and 3 emissions. Engaging colleagues empowers them to contribute to our climate goals and supports alignment with Pfizer's Purpose Blueprint and values. Pfizer fosters a network of sustainability-focused groups and champions who lead climate-related initiatives, share best practices, and promote awareness across functions and geographies. This engagement model helps ensure that colleagues are not only informed but also equipped and motivated to drive climate action in their daily work. Colleagues are encouraged to identify and implement energy-saving projects at manufacturing and R&D sites. These initiatives are supported by site-level master plans and capital investment processes. The percentage of stakeholder-associated Scope 3 emissions was calculated based on business travel and employee commuting emissions.*

#### (5.11.9.6) Effect of engagement and measures of success

*Pfizer integrates climate awareness and action into colleague engagement through multiple channels. We've implemented tools to help business travelers make informed decisions, including digital platforms to limit travel and preferred carriers aligned with GHG reduction goals. In 2024, travel-related GHG emissions were 55% lower than the 2019 baseline. We continue progressing toward our goal to reduce upstream transportation emissions 10% by 2025 (vs. 2019). In 2024, we focused on empowering supply chain and logistics teams to understand the emissions impact of their decisions. Pfizer developed a visual tool that provides transparency on emissions by customer, lane, and transport mode, helping identify key reduction opportunities. Through close collaboration with carriers and logistics providers, we continue to implement emission-reducing strategies. Additionally, Pfizer fosters colleague engagement through its Safety and Sustainability STAR Awards program, which recognizes projects that advance environmental performance. In 2024, the program received 127 nominations, with several focused on GHG reductions. Winning teams were celebrated during a virtual Earth Day event, reinforcing a culture of shared learning and recognition.*

## Water

#### (5.11.9.1) Type of stakeholder

Select from:

☒ Other value chain stakeholder, please specify :Employees

#### (5.11.9.2) Type and details of engagement

Education/Information sharing

☒ Educate and work with stakeholders on understanding and measuring exposure to environmental risks

- ☒ Share information on environmental initiatives, progress and achievements

### (5.11.9.3) % of stakeholder type engaged

Select from:

- ☒ 100%

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pfizer recognizes access to clean and safe water as a fundamental human right and a critical component of environmental stewardship. We remain committed to conserving this natural resource, with particular attention in water-stressed areas. We engage colleagues across the organization as key stakeholders in advancing our water stewardship goals, aligning with our Water Stewardship Position Statement and broader environmental strategy. The rationale for engaging colleagues stems from their integral role in implementing Pfizer's water conservation and quality initiatives. Colleagues not only are responsible for executing site-level water management practices but also serve as champions of sustainability within their local communities and work environments. Their engagement helps ensure that water-related risks and opportunities are addressed through both operational excellence and cultural alignment. The scope of engagement includes awareness, training, and action. Colleagues receive resource conservation training and are encouraged to identify and implement water-saving initiatives in their daily tasks and processes. Additionally, Pfizer promotes collective action and community involvement through local sustainability groups and initiatives, where colleagues collaborate on water-related projects and share best practices. These efforts are supported by Pfizer's internal environmental standards, which require sites to evaluate water usage, assess local water stress, and develop mitigation plans. Action plans developed from site-level water risk assessments often include colleague-led initiatives. By empowering colleagues to take ownership of water stewardship, Pfizer fosters a culture of environmental responsibility that extends beyond compliance—driving innovation, resilience, and long-term impact across our value chain.*

### (5.11.9.6) Effect of engagement and measures of success

*Pfizer engages colleagues in water stewardship by promoting awareness, accountability, and innovation across its global operations. In 2024, the company strengthened baseline requirements for responsible water management at all sites, emphasizing efficient water use in pharmaceutical development and manufacturing, minimizing environmental impacts from withdrawal and discharge, and protecting local ecosystems and human health. To further drive engagement, Pfizer's annual Safety and Sustainability STAR Awards program recognized projects that advanced environmental performance, including water conservation. Of the 127 nominations received in 2024, several focused on strategies such as optimizing cooling tower operations, implementing closed-loop systems, and reducing process water use. These efforts supported Pfizer's sustainability goals while fostering a culture of innovation and accountability. Winning teams were recognized during Earth Week and shared their approaches with the Environmental, Health, and Safety (EHS) community, reinforcing Pfizer's commitment to continuous improvement and peer learning.*

**(5.13) Has your organization already implemented any mutually beneficial environmental initiatives due to CDP Supply Chain member engagement?**

	Environmental initiatives implemented due to CDP Supply Chain member engagement	Primary reason for not implementing environmental initiatives	Explain why your organization has not implemented any environmental initiatives
	<p>Select from:</p> <p><input checked="" type="checkbox"/> No, and we do not plan to within the next two years</p>	<p>Select from:</p> <p><input checked="" type="checkbox"/> Other, please specify :Pfizer already engages with pharma peers on beneficial environmental initiatives</p>	<p><i>Pfizer already engages with pharma peers on beneficial environmental initiatives</i></p>

## C6. Environmental Performance - Consolidation Approach

(6.1) Provide details on your chosen consolidation approach for the calculation of environmental performance data.

### Climate change

#### (6.1.1) Consolidation approach used

Select from:

☒ Operational control

#### (6.1.2) Provide the rationale for the choice of consolidation approach

*The operational control boundary best represents sites and activities over which Pfizer has full authority to introduce and implement operating policies and can therefore drive reductions in emissions.*

### Water

#### (6.1.1) Consolidation approach used

Select from:

☒ Operational control

#### (6.1.2) Provide the rationale for the choice of consolidation approach

*The operational control boundary best represents sites and activities over which Pfizer has full authority to introduce and implement operating policies and can therefore best manage water use and wastewater discharge quality.*

## C7. Environmental performance - Climate Change

### (7.1) Is this your first year of reporting emissions data to CDP?

Select from:

☒ No

### (7.1.1) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data?

#### (7.1.1.1) Has there been a structural change?

Select all that apply

☒ Yes, an acquisition

☒ Yes, other structural change, please specify

#### (7.1.1.2) Name of organization(s) acquired, divested from, or merged with

*Pfizer completed the acquisition of Seagen in December 2023. As a result, emissions associated with Seagen's operations have been incorporated into Pfizer's footprint. Pfizer's manufacturing site in Karachi, Pakistan was sold to Lucky Core Industries (LCI) in 2024.*

#### (7.1.1.3) Details of structural change(s), including completion dates

*Pfizer's former headquarters building in New York, New York was sold to 219/235 East LLC in 2018 and leased back until lease expiry in July 2024, at which point Pfizer exited the site. Pfizer's commercial office in Berlin, Germany was vacated following lease termination at expiry in November 2023, with operations relocated to a new facility in Berlin, Germany.*

### (7.1.2) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year?



### **(7.1.2.1) Change(s) in methodology, boundary, and/or reporting year definition?**

*Select all that apply*

☒ Yes, a change in methodology

### **(7.1.2.2) Details of methodology, boundary, and/or reporting year definition change(s)**

*Emission factors for Scope 1&2 have been updated to reflect the latest releases from issuing bodies. Methodological enhancements included refinements in how logistics and tertiary packaging material weights are accounted for in upstream transportation and distribution emissions, and the inclusion of well-to-wheel (WTW) emissions for air travel associated with business travel, in alignment with the GHG Protocol. Three remediation sites previously classified under Pfizer's operational control have been reclassified as Scope 3, Category 1: Purchased Goods and Services, reflecting their management by third parties under service contracts.*

### **(7.1.3) Have your organization's base year emissions and past years' emissions been recalculated as a result of any changes or errors reported in 7.1.1 and/or 7.1.2?**

#### **(7.1.3.1) Base year recalculation**

*Select from:*

☒ Yes

#### **(7.1.3.2) Scope(s) recalculated**

*Select all that apply*

☒ Scope 1

☒ Scope 2, location-based

☒ Scope 2, market-based

☒ Scope 3

#### **(7.1.3.3) Base year emissions recalculation policy, including significance threshold**

*Pfizer's base year emissions are reviewed at least annually and adjusted for any changes to footprint, including acquisitions, divestitures, and closures. Emission factors for Scope 1&2 are updated annually to reflect any changes from issuing bodies and are applied retroactively from the effective date which may impact the baseline year. These adjustments are applied for all changes regardless of significance. Additionally, base year emissions, including Scope 3 emissions, may be recalculated to reflect changes in methodology if the change increases or decreases emissions by 5% or more by category.*

#### **(7.1.3.4) Past years' recalculation**

Select from:

☒ Yes

### **(7.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.**

Select all that apply

- ☒ IEA CO2 Emissions from Fuel Combustion
- ☒ The Greenhouse Gas Protocol: Scope 2 Guidance
- ☒ US EPA Mandatory Greenhouse Gas Reporting Rule
- ☒ The Greenhouse Gas Protocol: Public Sector Standard
- ☒ US EPA Emissions & Generation Resource Integrated Database (eGRID)
- ☒ The Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Standard
- ☒ Smart Freight Centre: GLEC Framework for Logistics Emissions Methodologies
- ☒ 2019 Refinement to the 2006 IPCC Guidelines for National Greenhouse Gas Inventories
- ☒ The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)
- ☒ US EPA Center for Corporate Climate Leadership: Direct Emissions from Mobile Combustion Sources
- ☒ Defra Environmental Reporting Guidelines: Including streamlined energy and carbon reporting guidance, 2019

### **(7.3) Describe your organization's approach to reporting Scope 2 emissions.**

	Scope 2, location-based	Scope 2, market-based	Comment
	<i>Select from:</i> <input checked="" type="checkbox"/> We are reporting a Scope 2, location-based figure	<i>Select from:</i> <input checked="" type="checkbox"/> We are reporting a Scope 2, market-based figure	<i>We report both location and market-based figures</i>

**(7.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure?**

*Select from:*

☒ Yes

**(7.4.1) Provide details of the sources of Scope 1, Scope 2, or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure.**

**Row 1**

#### **(7.4.1.1) Source of excluded emissions**

*Emissions associated with in-market local transportation globally except for the United States.*

#### **(7.4.1.2) Scope(s) or Scope 3 category(ies)**

*Select all that apply*

☒ Scope 3: Upstream transportation and distribution

#### **(7.4.1.6) Relevance of Scope 3 emissions from this source**

*Select from:*

☒ Emissions are not relevant

#### (7.4.1.9) Estimated percentage of total Scope 3 emissions this excluded source represents

2

#### (7.4.1.10) Explain why this source is excluded

*Emissions from in-market local transportation globally (excluding the U.S.) are currently not included in 2024 Scope 3 reporting due to data limitations. However, we developed and piloted a methodology in 2024 to address this gap. We plan to apply this methodology to 2025 data and expect to report Category 4 emissions without exclusions in our next disclosure. In accordance with the GHG Protocol Scope 3 Standard, these emissions are considered not relevant for the current reporting year because they do not contribute significantly to our overall Scope 3 footprint. In addition, reductions from these activities would not meaningfully advance our emissions reduction goals or influence investor decision-making.*

#### (7.4.1.11) Explain how you estimated the percentage of emissions this excluded source represents

*Using the US market as a benchmark, we estimate all other markets would collectively emit approximately 1.5 times the amount of the US market emissions for category 4 in 2023 ( $39,971 \text{ mt CO}_2\text{e} * 1.5 = 59,957 \text{ mt CO}_2\text{e}$ ). To ensure a conservative approach, we based our estimates on the 2023 US results.*

### Row 2

#### (7.4.1.1) Source of excluded emissions

*Emissions associated with the downstream transportation and distribution of products globally except for parts of Europe and the USA.*

#### (7.4.1.2) Scope(s) or Scope 3 category(ies)

*Select all that apply*

☒ Scope 3: Downstream transportation and distribution

#### (7.4.1.6) Relevance of Scope 3 emissions from this source

*Select from:*

☒ Emissions are relevant and calculated, but not disclosed

#### (7.4.1.9) Estimated percentage of total Scope 3 emissions this excluded source represents

#### (7.4.1.10) Explain why this source is excluded

*Emissions from downstream transportation and distribution globally (with the exception of parts of Europe and the U.S.) are excluded from our 2024 Scope 3 inventory. In 2024, we established a methodology to estimate these emissions and are preparing to scale it globally. We anticipate full inclusion of Category 9 emissions in our 2025 reporting.*

#### (7.4.1.11) Explain how you estimated the percentage of emissions this excluded source represents

*Our preliminary estimates suggest that emissions from this category are less than 3% of our total Scope 3 emissions for 2024.*

### (7.5) Provide your base year and base year emissions.

#### Scope 1

##### (7.5.1) Base year end

12/31/2019

##### (7.5.2) Base year emissions (metric tons CO<sub>2</sub>e)

695,112

##### (7.5.3) Methodological details

*Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: [https://cdn.pfizer.com/pfizercom/GHG\\_Calculation\\_Methodology\\_JUL2023.pdf](https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf).*

#### Scope 2 (location-based)

##### (7.5.1) Base year end

12/31/2019

## **(7.5.2) Base year emissions (metric tons CO2e)**

558,958

## **(7.5.3) Methodological details**

*Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: [https://cdn.pfizer.com/pfizercom/GHG\\_Calculation\\_Methodology\\_JUL2023.pdf](https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf).*

## **Scope 2 (market-based)**

## **(7.5.1) Base year end**

12/31/2019

## **(7.5.2) Base year emissions (metric tons CO2e)**

571,233

## **(7.5.3) Methodological details**

*Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: [https://cdn.pfizer.com/pfizercom/GHG\\_Calculation\\_Methodology\\_JUL2023.pdf](https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_JUL2023.pdf).*

## **Scope 3 category 1: Purchased goods and services**

## **(7.5.1) Base year end**

12/31/2019

## **(7.5.2) Base year emissions (metric tons CO2e)**

1,900,504

## **(7.5.3) Methodological details**

*Emissions calculated based on 2019 spend data after removing spend from divested business units to the extent possible. Cradle-to-grave emissions for purchased goods and services are estimated based on spend using secondary emission factors. Spend data is extracted from Pfizer's accounting systems (i.e., SAP) by material category and material group (e.g., material category: IT Hardware, Supplies & Software; material group: Software and Licenses) and uploaded into Pfizer's Category 1&2 GHG emissions calculation tool. Spend associated with purchased goods and services with an associated GHG footprint is multiplied by the most appropriate emission factor to estimate emissions (CO2e). Spend not considered to have a significant Scope 3 GHG footprint (e.g., colleague wages, customer rebates, taxes, etc.) is excluded from the calculation. US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS6 adjusted for inflation are used to estimate emissions. Inflation adjustments are based on data from the US Bureau of Labor Statistics.*

### **Scope 3 category 2: Capital goods**

## **(7.5.1) Base year end**

12/31/2019

## **(7.5.2) Base year emissions (metric tons CO2e)**

101,679

## **(7.5.3) Methodological details**

*Emissions calculated based on 2019 spend data after removing spend from divested business units to the extent possible. Cradle-to-grave emissions for capital goods are estimated based on spend using secondary emission factors. Spend data is extracted from Pfizer's accounting systems (i.e., SAP) by material category and material group and uploaded into Pfizer's Category 1&2 GHG emissions calculation tool. Spend associated with capital goods is multiplied by the most appropriate emission factor to estimate emissions (CO2e). US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS6 adjusted for inflation are used. Inflation adjustments are based on data from the US Bureau of Labor Statistics.*

### **Scope 3 category 3: Fuel-and-energy-related activities (not included in Scope 1 or 2)**

## **(7.5.1) Base year end**

12/31/2019

## **(7.5.2) Base year emissions (metric tons CO2e)**

252,909

## **(7.5.3) Methodological details**

*Emissions calculated using electricity, heat, and steam as well as stationary and mobile fuels consumption reported by operations within Pfizer's control. For fuels, consumption by fuel type (in MWh) was multiplied by the appropriate emission factors to determine GHG emissions. Emissions from UK sources calculated using UK Government GHG Conversion Factors for Company Reporting (2020) and include CO<sub>2</sub>, CH<sub>4</sub> and N<sub>2</sub>O (CO<sub>2</sub>eq). For electricity, heat and steam, WTT emissions globally were calculated using UK Government Conversion Factors for Company Reporting Emissions associated with transportation and distribution losses for the UK were calculated using UK factors for sites in the UK and using IEA CO<sub>2</sub> emissions from fuel combustion 2017 for the rest of the world. T&D losses calculated using IEA factors include CO<sub>2</sub> emissions only. T&D losses associated with chilled water were excluded due to unavailability of an emission factor but are anticipated to be <0.1% of total.*

## **Scope 3 category 4: Upstream transportation and distribution**

## **(7.5.1) Base year end**

12/31/2019

## **(7.5.2) Base year emissions (metric tons CO2e)**

200,873

## **(7.5.3) Methodological details**

*Emissions estimates related to upstream transportation include international transportation, market transportation within the US. 1. Emissions associated with international transportation and distribution services are calculated by our Global Logistics Network Services (GL&NS) team using transportation mode, distance, shipment weight, and average emission factors from the GLEC Framework from Smart Freight Center. Primary operational data from our Enterprise Resource Planning tools are leveraged by the GL&NS team to obtain origin, destination, and shipment weight data. 2. Emissions data for US market transportation is obtained directly from our main vendors (FedEx-Parcel, UPS-Parcel). Additionally, for other US vendors, fuel surcharge data is used to estimate gallons of diesel fuel consumed by full truckload shipments, and GLEC v3 emission factors are applied to estimate GHG emissions. Due to lack of access to accurate 2019 US in-market data, we used 2020 data instead. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services. Additionally, emissions associated with market logistics outside the US and emissions associated with the operations of third-party logistics centers are not included in the calculation. Historical upstream transportation and distribution emissions have been recalculated as the result of improvements in our methodology accounting for logistics and tertiary packaging material weights.*



## Scope 3 category 5: Waste generated in operations

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

9512

### (7.5.3) Methodological details

*Emissions (CO2eq) calculated using waste disposal and wastewater discharge data reported by operations within Pfizer's control and UK Government GHG Conversion Factors for Company Reporting (2020). Emission factors include collection, transportation and landfill emissions ('gate to grave') for waste sent to landfill. For combustion and recycling, the factors consider transport to an energy recovery or material reclamation facility only. Because most of the waste reported by sites as "other disposal" by Pfizer locations was sent to wastewater treatment, the wastewater treatment emission factor was used to estimate emissions for all waste reported in this category.*

## Scope 3 category 6: Business travel

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

421,399

### (7.5.3) Methodological details

*Emissions associated with air travel, hotel stays, car use (rental and personal), and rail travel booked within Pfizer's travel system are calculated by Pfizer's travel partner using detailed primary data such as distance, aircraft type, cabin class, etc. plus secondary data when primary data is not available. Air travel emission factors include radiative force. Personal and rental car travel emissions include WTT emissions. Emissions associated with personal car by the field force in the US are calculated using data from the company's reimbursement service provider and US EPA emission factors. Air travel booked outside Pfizer's travel system is estimated using spend data, and leakage rates for other forms of travel are estimated based on industry averages as reported in the paper "Data Dive: How 2021 Priorities Can Be Guided by Leakage Data" by Emburse. Emissions associated with this travel are estimated by Pfizer's travel partner.*

## Scope 3 category 7: Employee commuting

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

60,645

### (7.5.3) Methodological details

*Emissions estimated based on Pfizer's employee headcount as of June 30, 2019. Commuting distance for all colleagues estimated based on data published by NationMaster using the median distance per region to estimate for countries not covered by the source data. Commuting methods for North American colleagues estimated based on a study published by Bloomberg in 2019. Commuting method assumptions for colleagues outside North America were made based on general knowledge of the region. Emissions associated with employee commuting in North America were calculated using US EPA Climate Leaders GHG 2020 emission factors. Emissions for all other regions were calculated using DEFRA emission factors (average car, unknown fuel type; national rail; light rail and tram; and average local bus).*

## Scope 3 category 8: Upstream leased assets

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

36,273

### (7.5.3) Methodological details

*Leased facility square footage for sites not within Pfizer's operational control derived from Pfizer's corporate real estate database. Emissions estimated using the Greenhouse Gas Protocol/Quantis Scope 3 Evaluator.*

## Scope 3 category 9: Downstream transportation and distribution

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

99,576

#### (7.5.3) Methodological details

*Emissions estimated based on number of products sold and average distance of travel to medical offices, pharmacies and retailers in the US only using DEFRA emission factors.*

### Scope 3 category 10: Processing of sold products

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

#### (7.5.3) Methodological details

*Not Applicable*

### Scope 3 category 11: Use of sold products

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

### **(7.5.3) Methodological details**

*Not Applicable*

## **Scope 3 category 12: End of life treatment of sold products**

### **(7.5.1) Base year end**

12/31/2019

### **(7.5.2) Base year emissions (metric tons CO2e)**

0

### **(7.5.3) Methodological details**

*Not Applicable*

## **Scope 3 category 13: Downstream leased assets**

### **(7.5.1) Base year end**

12/31/2019

### **(7.5.2) Base year emissions (metric tons CO2e)**

0

### **(7.5.3) Methodological details**

*Not Applicable*

## **Scope 3 category 14: Franchises**

### **(7.5.1) Base year end**

12/31/2019

**(7.5.2) Base year emissions (metric tons CO2e)**

0

**(7.5.3) Methodological details**

*Not Applicable*

**Scope 3 category 15: Investments**

**(7.5.1) Base year end**

12/31/2019

**(7.5.2) Base year emissions (metric tons CO2e)**

33,892

**(7.5.3) Methodological details**

*Emissions data provided by Pfizer's joint venture operations where we had influence and/or operational control.*

**Scope 3: Other (upstream)**

**(7.5.1) Base year end**

12/31/2019

**(7.5.2) Base year emissions (metric tons CO2e)**

0

**(7.5.3) Methodological details**

Not Applicable

### Scope 3: Other (downstream)

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

#### (7.5.3) Methodological details

Not Applicable

### (7.6) What were your organization's gross global Scope 1 emissions in metric tons CO2e?

	Gross global Scope 1 emissions (metric tons CO2e)	End date	Methodological details
Reporting year	613218	NA	Emission factors for scope 1 have been updated to reflect the latest releases from issuing bodies.
Past year 1	617404	12/31/2023	Emission factors for scope 1 have been updated to reflect the latest releases from issuing bodies.

### (7.7) What were your organization's gross global Scope 2 emissions in metric tons CO2e?

#### Reporting year

#### **(7.7.1) Gross global Scope 2, location-based emissions (metric tons CO2e)**

450,093

#### **(7.7.2) Gross global Scope 2, market-based emissions (metric tons CO2e)**

465,128

#### **(7.7.4) Methodological details**

*Emission factors for scope 2 have been updated to reflect the latest releases from issuing bodies.*

### **Past year 1**

#### **(7.7.1) Gross global Scope 2, location-based emissions (metric tons CO2e)**

461,084

#### **(7.7.2) Gross global Scope 2, market-based emissions (metric tons CO2e)**

490,632

#### **(7.7.3) End date**

12/31/2023

#### **(7.7.4) Methodological details**

*Emission factors for scope 2 have been updated to reflect the latest releases from issuing bodies.*

### **(7.8) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions.**

#### **Purchased goods and services**

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

2,786,489

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Spend-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### (7.8.5) Please explain

*Cradle-to-grave emissions for purchased goods and services are estimated based on spend using secondary emission factors. Spend data is extracted from Pfizer's accounting systems (i.e., SAP) by material category and material group (e.g., material category: IT Hardware, Supplies & Software; material group: Software and Licenses) and uploaded into Pfizer's Category 1&2 GHG emissions calculation tool. Spend associated with purchased goods and services with an associated GHG footprint is multiplied by the most appropriate emission factor to estimate emissions (CO2e). Spend not considered to have a significant Scope 3 GHG footprint (e.g., colleague wages, customer rebates, taxes, etc.) is excluded from the calculation. US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS6 adjusted for inflation are used to estimate emissions. Inflation adjustments are based on data from the US Bureau of Labor Statistics.*

## Capital goods

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)



119,357

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Spend-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### (7.8.5) Please explain

*Cradle-to-grave emissions for capital goods are estimated based on spend using secondary emission factors. Spend data is extracted from Pfizer's accounting systems (i.e., SAP) by material category and material group and uploaded into Pfizer's Category 1&2 GHG emissions calculation tool. Spend associated with capital goods is multiplied by the most appropriate emission factor to estimate emissions (CO<sub>2</sub>e). US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS6 adjusted for inflation are used. Inflation adjustments are based on data from the US Bureau of Labor Statistics.*

## Fuel-and-energy-related activities (not included in Scope 1 or 2)

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO<sub>2</sub>e)

254,803

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Average data method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

### (7.8.5) Please explain

*Emissions for this category are calculated using Pfizer's GHG reporting tool. a. Emissions associated with the production of stationary and mobile fuels are calculated by multiplying consumption by fuel type (gross CV in MWh) by appropriate emission factors. The emission factors used for this subcategory are the UK Government GHG Conversion Factors for Company Reporting (current year) and include CO<sub>2</sub>, CH<sub>4</sub> and N<sub>2</sub>O (CO<sub>2</sub>e). b. Emissions associated with the production of electricity (i.e., WTT-Generation and WTT-T&D) for the UK are calculated using UK Government GHG Conversion Factors for Company Reporting (current year) Emissions associated with the production of electricity (i.e., WTT-Generation and WTT-T&D) for non-UK countries are calculated using UK Government GHG Conversion Factors for Company Reporting (2021). These emissions include CO<sub>2</sub>, CH<sub>4</sub> and N<sub>2</sub>O (CO<sub>2</sub>e). Emissions associated with electricity T&D losses for the UK sites are calculated using UK Government GHG Conversion Factors for Company Reporting (current year) and include CO<sub>2</sub>, CH<sub>4</sub> and N<sub>2</sub>O (CO<sub>2</sub>e). Emissions associated with electricity T&D losses for non-UK countries are calculated using IEA Emission Factors (latest publication) and include CO<sub>2</sub> emissions only. c. Emissions associated with the production (i.e., WTT-Generation and WTT-T&D) as well as T&D losses of heat and steam are calculated for all countries using UK Government Conversion Factors for Company Reporting (current year) and include CO<sub>2</sub>, CH<sub>4</sub> and N<sub>2</sub>O (CO<sub>2</sub>e). d. T&D losses associated with chilled water are excluded from reporting due to unavailability of an emission factor but are anticipated to be <0.1% of the total emissions for this category.*

## Upstream transportation and distribution

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO<sub>2</sub>e)

154,001

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Fuel-based method

☒ Distance-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

### (7.8.5) Please explain

*Emissions estimates for upstream transportation and distribution include international transportation, market (i.e., domestic) transportation in the US (Pfizer's largest market) and emissions associated with the use of dry ice in COVID-19 vaccine transportation globally. a. Emissions for all international transportation and distribution services are calculated by our Global Logistics & Network Services (GL&NS) team using transportation mode, distance, shipment weight and average emission factors from the GLEC Framework by the Smart Freight Center. Primary operational data from our Enterprise Resource Planning tools are leveraged by the GL&NS team to obtain origin, destination, and shipment weight data. Emissions are reduced through the application of low emissions fuels certificates provided by logistics suppliers, ensuring that the claimed reductions do not surpass the calculated maximum allowable limit. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services. b. Emissions associated with US market transportation are obtained directly from three main vendors. Additionally, for full truckload providers, fuel surcharge data is used to estimate gallons of diesel fuel consumed and GLEC emission factors are applied to estimate GHG emissions. For less than truckload providers, weight, average distance/shipment and average freight emission factors from the GLEC Framework are applied to estimate GHG emissions. Activity data is provided by the US market logistics team. c. Pfizer's sites report purchased liquid CO2 and dry ice in Pfizer's internal EHS reporting system. Emissions are calculated using emission factors developed by an external engineering consulting firm. For the conversion of liquid CO2 to dry ice, an emission factor of 0.55kgCO2/kg liquid CO2 is applied to calculate scope 1 emissions, and a factor of 0.45kgCO2/kg liquid CO2 is applied for scope 3. For purchased dry ice, a factor of 1kg CO2/1Kg dry ice is applied to estimate scope 3 emissions.*

## Waste generated in operations

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

5435

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Waste-type-specific method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

99

### (7.8.5) Please explain

*Emissions for this category are calculated using Pfizer's GHG reporting tool. Emissions (CO2e) associated with the disposal of waste generated by Pfizer are calculated using waste disposal and wastewater discharge data reported by operations within Pfizer's control and UK Government GHG Conversion Factors for Company Reporting (current year). Waste disposal includes waste recycled, incinerated, heat recovery/fuel blending, landfilled and other treatments; it does not include waste reused or waste avoided. Emission factors include collection, transportation, and landfill emissions ('gate to grave') for waste sent to landfill. For combustion and recycling, the factors consider transport to an energy recovery or material reclamation facility only. Other treatment is typically a mixture of treatments, however, because most waste reported as "other disposal" by Pfizer locations is sent to wastewater treatment, the wastewater treatment emission factor is used to estimate emissions for all waste reported in this category.*

## Business travel

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

188,309

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Hybrid method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

93

### (7.8.5) Please explain

*Emissions associated with air travel, hotel stays, car use (rental and personal) and rail travel booked within Pfizer's travel system are calculated by Pfizer's travel partner using detailed primary data such as distance, aircraft type, cabin class, etc., plus secondary data when primary data is not available. Air travel emission factors include radiative force. Air, car use and rail emissions include well-to-wheel (WTW) emissions. Emissions associated with personal car use by US Field Force colleagues are calculated by the company's reimbursement service provider using vehicle type and US EPA vehicle emission ratings. Air travel and hotel booked*

outside Pfizer's travel system is estimated using spend data. If the air leakage rate for the reporting year is unavailable, the previous year's rate is used. Leakage rates for other forms of travel are estimated based on industry averages as reported in the paper: "Data Dive: How 2021 Priorities Can Be Guided By Leakage Data" by Emburse. Emissions associated with this travel are estimated by Pfizer's travel partner. Historical air travel emissions have been adjusted to include well-to-wheel (WTW) emissions in accordance with the GHG Protocol.

## Employee commuting

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO<sub>2</sub>e)

20564

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Average data method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### (7.8.5) Please explain

Emissions associated with employee commuting are estimated using the average method described in the GHG Protocol Scope 3 Technical Guidance and are based on Pfizer's employee headcount at the end of the year. A corporate headcount report is used to determine the number of colleagues working onsite full time, colleagues eligible for the company's flexible working program, and colleagues assigned to work remotely full time. Site-based manufacturing and R&D colleagues are assumed to commute 200 days per year. Colleagues eligible for flexible working arrangements are expected to be onsite an average of 2.5 days per week and are therefore assumed to commute 100 days per year. Emissions associated with remote working are excluded from reporting. Commuting distance for all colleagues is estimated based on data published by NationMaster; for countries not included in the NationMaster list, the median distance per region is estimated. Average distance per region is then used in final calculation by region. Commuting methods for North American colleagues are estimated based on a study published by Bloomberg in 2019. Commuting method assumptions for colleagues outside North America are made based on general knowledge of the region. Emissions associated with employee commuting in North America are calculated using US EPA GHG Emission Factors Hub emission factors. Emissions for all other regions are

calculated using DEFRA emission factors (average car, unknown fuel type; national rail; light rail and tram; and average local bus). There may be double counting of emissions generated by commuters using company owned vehicles, which is reported in Scope 1. Pfizer is working to enhance its calculation methodology.

## Upstream leased assets

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

15,511

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Fuel-based method

☒ Asset-specific method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

44

### (7.8.5) Please explain

Emissions associated with Pfizer's occupancy of leased building areas not covered by Scopes 1 & 2 are calculated based on occupied square footage obtained from Pfizer's real estate database. For most locations between 10,000 ft<sup>2</sup> and 100,000 ft<sup>2</sup>, emissions are calculated in Pfizer's internal EHS reporting system using actual energy consumption data. For the remaining locations under 100,000 ft<sup>2</sup>, emissions are estimated in accordance with GHG Protocol Scope 3 Category 8 Technical Guidance hybrid method (asset-specific and average data method) using average emission factors derived from data from sites under Pfizer's operational control. Leased facility square footage for sites not within Pfizer's operational control is derived from Pfizer's corporate real estate database.

## Downstream transportation and distribution

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

3397

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Distance-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### (7.8.5) Please explain

*Data for downstream US domestic transportation and distribution services for parts of US and Europe is obtained from Pfizer's Network and Site Analytics team and includes origin and destination, mass of goods, and total distance travelled. Emissions are estimated using the distance, shipment weight, and GLEC emission factors for road transportation for the US and Europe.*

## Processing of sold products

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*Pfizer products are not typically subjected to further processing.*

## Use of sold products

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*Pfizer products are not likely to create significant emissions in normal use.*

## End of life treatment of sold products

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*GHG emissions associated with the normal use of Pfizer products are negligible. Products returned to Pfizer for destruction by Pfizer are accounted for in waste treatment estimate.*

## Downstream leased assets

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*Pfizer is not a significant lessor of real estate. Emissions from real estate assets within Pfizer sites that are leased to third parties are included in Scope 1+2 emissions.*

## Franchises



### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*Pfizer does not operate franchises.*

## Investments

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

7342

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Fuel-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

### (7.8.5) Please explain

*Pfizer has an interest in a joint venture (ZHOPL) located in India. The site reports energy consumption data directly in Pfizer's GHG tracking tool and the system is used to calculate Scope 1+2 emissions for the site. Our Category 15 emissions inventory includes only those investments with operational activities—such as our joint ventures—that are not already covered in our Scope 1 and 2 reporting.*

## Other (upstream)

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*Pfizer does not have other upstream emissions.*

## Other (downstream)

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Please explain

*Pfizer does not have other downstream emissions.*

## (7.8.1) Disclose or restate your Scope 3 emissions data for previous years.

### Past year 1

#### (7.8.1.1) End date

12/31/2023

#### (7.8.1.2) Scope 3: Purchased goods and services (metric tons CO2e)

3,401,334

**(7.8.1.3) Scope 3: Capital goods (metric tons CO2e)**

126,588

**(7.8.1.4) Scope 3: Fuel and energy-related activities (not included in Scopes 1 or 2) (metric tons CO2e)**

263,780

**(7.8.1.5) Scope 3: Upstream transportation and distribution (metric tons CO2e)**

257,319

**(7.8.1.6) Scope 3: Waste generated in operations (metric tons CO2e)**

8795

**(7.8.1.7) Scope 3: Business travel (metric tons CO2e)**

186,396

**(7.8.1.8) Scope 3: Employee commuting (metric tons CO2e)**

21,745

**(7.8.1.9) Scope 3: Upstream leased assets (metric tons CO2e)**

26,497

**(7.8.1.10) Scope 3: Downstream transportation and distribution (metric tons CO2e)**

4446

**(7.8.1.11) Scope 3: Processing of sold products (metric tons CO2e)**

0

#### (7.8.1.12) Scope 3: Use of sold products (metric tons CO2e)

0

#### (7.8.1.13) Scope 3: End of life treatment of sold products (metric tons CO2e)

0

#### (7.8.1.14) Scope 3: Downstream leased assets (metric tons CO2e)

0

#### (7.8.1.15) Scope 3: Franchises (metric tons CO2e)

0

#### (7.8.1.16) Scope 3: Investments (metric tons CO2e)

6754

#### (7.8.1.17) Scope 3: Other (upstream) (metric tons CO2e)

0

#### (7.8.1.18) Scope 3: Other (downstream) (metric tons CO2e)

0

#### (7.8.1.19) Comment

*Historical upstream transportation and distribution emissions for 2023 have been recalculated as the result of improvements in our methodology accounting for logistics and tertiary packaging material weights, resulting in a 16% decrease from the previously reported value. Air travel emissions for 2023 have been adjusted to include well-to-wheel (WTW) emissions in accordance with the GHG Protocol, resulting in a 8% increase from the previously reported value for Business Travel. Upstream leased assets emissions for 2023 were recalculated due to a minor error identified in the original calculations, resulting in a 3% decrease from the previously reported value.*

**(7.9) Indicate the verification/assurance status that applies to your reported emissions.**

	Verification/assurance status
Scope 1	<i>Select from:</i> <input checked="" type="checkbox"/> Third-party verification or assurance process in place
Scope 2 (location-based or market-based)	<i>Select from:</i> <input checked="" type="checkbox"/> Third-party verification or assurance process in place
Scope 3	<i>Select from:</i> <input checked="" type="checkbox"/> Third-party verification or assurance process in place

**(7.9.1) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.**

**Row 1**

**(7.9.1.1) Verification or assurance cycle in place**

*Select from:*

☒ Annual process

**(7.9.1.2) Status in the current reporting year**

*Select from:*

☒ Complete

**(7.9.1.3) Type of verification or assurance**

Select from:

☒ Reasonable assurance

#### (7.9.1.4) Attach the statement

*ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf*

#### (7.9.1.5) Page/section reference

*Full document*

#### (7.9.1.6) Relevant standard

Select from:

☒ ISAE3000

#### (7.9.1.7) Proportion of reported emissions verified (%)

100

**(7.9.2) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements.**

#### Row 1

#### (7.9.2.1) Scope 2 approach

Select from:

☒ Scope 2 location-based

#### (7.9.2.2) Verification or assurance cycle in place

Select from:

☒ Annual process

### (7.9.2.3) Status in the current reporting year

Select from:

☒ Complete

### (7.9.2.4) Type of verification or assurance

Select from:

☒ Reasonable assurance

### (7.9.2.5) Attach the statement

*ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf*

### (7.9.2.6) Page/ section reference

*Full document*

### (7.9.2.7) Relevant standard

Select from:

☒ ISAE3000

### (7.9.2.8) Proportion of reported emissions verified (%)

100

## Row 2

### (7.9.2.1) Scope 2 approach

Select from:

☒ Scope 2 market-based

#### (7.9.2.2) Verification or assurance cycle in place

Select from:

☒ Annual process

#### (7.9.2.3) Status in the current reporting year

Select from:

☒ Complete

#### (7.9.2.4) Type of verification or assurance

Select from:

☒ Reasonable assurance

#### (7.9.2.5) Attach the statement

*ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf*

#### (7.9.2.6) Page/ section reference

*Full document*

#### (7.9.2.7) Relevant standard

Select from:

☒ ISAE3000

#### (7.9.2.8) Proportion of reported emissions verified (%)

100



**(7.9.3) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements.**

**Row 1**

**(7.9.3.1) Scope 3 category**

*Select all that apply*

- |   |   |
|---|---|
| <input checked="" type="checkbox"/> Scope 3: Investments            | <input checked="" type="checkbox"/> Scope 3: Purchased goods and services                                       |
| <input checked="" type="checkbox"/> Scope 3: Capital goods          | <input checked="" type="checkbox"/> Scope 3: Waste generated in operations                                      |
| <input checked="" type="checkbox"/> Scope 3: Business travel        | <input checked="" type="checkbox"/> Scope 3: Upstream transportation and distribution                           |
| <input checked="" type="checkbox"/> Scope 3: Employee commuting     | <input checked="" type="checkbox"/> Scope 3: Fuel and energy-related activities (not included in Scopes 1 or 2) |
| <input checked="" type="checkbox"/> Scope 3: Upstream leased assets |   |

**(7.9.3.2) Verification or assurance cycle in place**

*Select from:*

- ☒ Annual process

**(7.9.3.3) Status in the current reporting year**

*Select from:*

- ☒ Complete

**(7.9.3.4) Type of verification or assurance**

*Select from:*

- ☒ Limited assurance

**(7.9.3.5) Attach the statement**

*ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf*

**(7.9.3.6) Page/section reference**

### **(7.9.3.7) Relevant standard**

Select from:

☒ ISAE3000

### **(7.9.3.8) Proportion of reported emissions verified (%)**

100

**(7.10) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?**

Select from:

☒ Decreased

**(7.10.1) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year.**

**Change in renewable energy consumption**

### **(7.10.1.1) Change in emissions (metric tons CO2e)**

3809

### **(7.10.1.2) Direction of change in emissions**

Select from:

☒ Decreased

### **(7.10.1.3) Emissions value (percentage)**

0.34

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1 & scope 2 market-based emissions in reporting year, multiplied by 100  $((-3,809/1,108,036)*100)$*

### Other emissions reduction activities

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

32,292

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

#### (7.10.1.3) Emissions value (percentage)

2.91

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1 & scope 2 market-based emissions in reporting year, multiplied by 100  $((-32,292/1,108,036)*100)$*

### Divestment

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

4868

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

### (7.10.1.3) Emissions value (percentage)

0.44

### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1& scope 2 market-based emissions in reporting year, multiplied by 100  $((-4,868/1,108,036)*100)$*

## Acquisitions

### (7.10.1.1) Change in emissions (metric tons CO2e)

1285

### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

### (7.10.1.3) Emissions value (percentage)

0.12

### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1& scope 2 market-based emissions in reporting year, multiplied by 100  $((-1,285/1,108,036)*100)$*

## Change in output

### (7.10.1.1) Change in emissions (metric tons CO2e)

13,861

### (7.10.1.2) Direction of change in emissions

Select from:

☒ Increased

#### (7.10.1.3) Emissions value (percentage)

1.25

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1& scope 2 market-based emissions in reporting year, multiplied by 100  $((13,861/1,108,036)*100)$*

#### Change in boundary

#### (7.10.1.1) Change in emissions (metric tons CO2e)

1297

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

#### (7.10.1.3) Emissions value (percentage)

0.12

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1& scope 2 market-based emissions in reporting year, multiplied by 100  $((-1,297/1,108,036)*100)$*

#### (7.10.2) Are your emissions performance calculations in 7.10 and 7.10.1 based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?

Select from:

☒ Market-based

**(7.12) Are carbon dioxide emissions from biogenic carbon relevant to your organization?**

Select from:

☒ Yes

**(7.12.1) Provide the emissions from biogenic carbon relevant to your organization in metric tons CO2.**

	CO2 emissions from biogenic carbon (metric tons CO2)	Comment
	15481	Wood Chips, Wood Pellets, Biodiesel 100 and Ethanol E-100 from Fleet (mobile)

**(7.15) Does your organization break down its Scope 1 emissions by greenhouse gas type?**

Select from:

☒ Yes

**(7.15.1) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used global warming potential (GWP).**

**Row 1**

**(7.15.1.1) Greenhouse gas**

Select from:

☒ CO2

### (7.15.1.2) Scope 1 emissions (metric tons of CO2e)

567,934

### (7.15.1.3) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

### Row 2

### (7.15.1.1) Greenhouse gas

Select from:

☒ CH4

### (7.15.1.2) Scope 1 emissions (metric tons of CO2e)

344

### (7.15.1.3) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

### Row 3

### (7.15.1.1) Greenhouse gas

Select from:

☒ N2O

### (7.15.1.2) Scope 1 emissions (metric tons of CO2e)

1243

### (7.15.1.3) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

### Row 4

### (7.15.1.1) Greenhouse gas

Select from:

☒ HFCs

### (7.15.1.2) Scope 1 emissions (metric tons of CO<sub>2</sub>e)

33,982

### (7.15.1.3) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

### Row 5

### (7.15.1.1) Greenhouse gas

Select from:

☒ SF<sub>6</sub>

### (7.15.1.2) Scope 1 emissions (metric tons of CO<sub>2</sub>e)

621

### (7.15.1.3) GWP Reference

Select from:



☒ IPCC Sixth Assessment Report (AR6 - 100 year)

## Row 6

### (7.15.1.1) Greenhouse gas

Select from:

☒ Other, please specify :Acetylene

### (7.15.1.2) Scope 1 emissions (metric tons of CO2e)

1

### (7.15.1.3) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

## Row 7

### (7.15.1.1) Greenhouse gas

Select from:

☒ Other, please specify :VOC

### (7.15.1.2) Scope 1 emissions (metric tons of CO2e)

9117

### (7.15.1.3) GWP Reference

Select from:

☒ Other, please specify :Internal calculation method

**(7.16) Break down your total gross global Scope 1 and 2 emissions by country/area.**

**Algeria**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

497

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

1754

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

1754

**Argentina**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

1874

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

2833

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

2833

**Australia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

3264

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

7637

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

7637

**Austria**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

297

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

2816

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

1833

**Belarus**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

30

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

## Belgium

### (7.16.1) Scope 1 emissions (metric tons CO2e)

24,222

### (7.16.2) Scope 2, location-based (metric tons CO2e)

11,573

### (7.16.3) Scope 2, market-based (metric tons CO2e)

8149

## Brazil

### (7.16.1) Scope 1 emissions (metric tons CO2e)

4311

### (7.16.2) Scope 2, location-based (metric tons CO2e)

1166

### (7.16.3) Scope 2, market-based (metric tons CO2e)

62

## Bulgaria

### (7.16.1) Scope 1 emissions (metric tons CO2e)

158

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Canada

(7.16.1) Scope 1 emissions (metric tons CO2e)

4845

(7.16.2) Scope 2, location-based (metric tons CO2e)

22

(7.16.3) Scope 2, market-based (metric tons CO2e)

22

## Chile

(7.16.1) Scope 1 emissions (metric tons CO2e)

308

(7.16.2) Scope 2, location-based (metric tons CO2e)

36

(7.16.3) Scope 2, market-based (metric tons CO2e)

36

## China

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

23

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

5161

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

5161

**Colombia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

380

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

43

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

43

**Costa Rica**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

776

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Croatia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

2836

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

1712

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Czechia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

437

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Denmark**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Ecuador****(7.16.1) Scope 1 emissions (metric tons CO2e)**

28

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Egypt****(7.16.1) Scope 1 emissions (metric tons CO2e)**

631

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**



0

## Estonia

(7.16.1) Scope 1 emissions (metric tons CO2e)

49

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Finland

(7.16.1) Scope 1 emissions (metric tons CO2e)

150

(7.16.2) Scope 2, location-based (metric tons CO2e)

354

(7.16.3) Scope 2, market-based (metric tons CO2e)

831

## France

(7.16.1) Scope 1 emissions (metric tons CO2e)

1408

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Germany**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

11,293

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

10,796

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

1439

**Greece**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

860

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

186

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

270

## Hungary

### (7.16.1) Scope 1 emissions (metric tons CO2e)

304

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## India

### (7.16.1) Scope 1 emissions (metric tons CO2e)

7087

### (7.16.2) Scope 2, location-based (metric tons CO2e)

34,686

### (7.16.3) Scope 2, market-based (metric tons CO2e)

34,686

## Indonesia

### (7.16.1) Scope 1 emissions (metric tons CO2e)

705

### (7.16.2) Scope 2, location-based (metric tons CO2e)

4304

(7.16.3) Scope 2, market-based (metric tons CO2e)

4304

Ireland

(7.16.1) Scope 1 emissions (metric tons CO2e)

70,368

(7.16.2) Scope 2, location-based (metric tons CO2e)

24,105

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Israel

(7.16.1) Scope 1 emissions (metric tons CO2e)

553

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Italy

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

27,846

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

4757

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

7631

**Japan**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

6925

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

16,367

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

15,544

**Kazakhstan**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

77

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Latvia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

40

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Lithuania**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

116

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Luxembourg**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Mexico****(7.16.1) Scope 1 emissions (metric tons CO2e)**

3990

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

2809

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

2809

**Morocco****(7.16.1) Scope 1 emissions (metric tons CO2e)**

608

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

1389

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

1389

## Netherlands

(7.16.1) Scope 1 emissions (metric tons CO2e)

474

(7.16.2) Scope 2, location-based (metric tons CO2e)

95

(7.16.3) Scope 2, market-based (metric tons CO2e)

126

## New Zealand

(7.16.1) Scope 1 emissions (metric tons CO2e)

20

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Norway

(7.16.1) Scope 1 emissions (metric tons CO2e)

23



(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Pakistan

(7.16.1) Scope 1 emissions (metric tons CO2e)

235

(7.16.2) Scope 2, location-based (metric tons CO2e)

4371

(7.16.3) Scope 2, market-based (metric tons CO2e)

4371

## Peru

(7.16.1) Scope 1 emissions (metric tons CO2e)

109

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Philippines

### (7.16.1) Scope 1 emissions (metric tons CO2e)

807

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Poland

### (7.16.1) Scope 1 emissions (metric tons CO2e)

681

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Portugal

### (7.16.1) Scope 1 emissions (metric tons CO2e)

1109

### (7.16.2) Scope 2, location-based (metric tons CO2e)

(7.16.3) Scope 2, market-based (metric tons CO2e)

668

Puerto Rico

(7.16.1) Scope 1 emissions (metric tons CO2e)

121

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Republic of Korea

(7.16.1) Scope 1 emissions (metric tons CO2e)

9

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Romania

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

438

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Russian Federation**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

1388

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Saudi Arabia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

680

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

4056

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

4056

**Serbia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

158

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Singapore**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

31,331

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

13,095

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

13,095

**Slovakia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Slovenia****(7.16.1) Scope 1 emissions (metric tons CO2e)**

131

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**South Africa****(7.16.1) Scope 1 emissions (metric tons CO2e)**

21

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

## Spain

### (7.16.1) Scope 1 emissions (metric tons CO2e)

4695

### (7.16.2) Scope 2, location-based (metric tons CO2e)

1759

### (7.16.3) Scope 2, market-based (metric tons CO2e)

272

## Sweden

### (7.16.1) Scope 1 emissions (metric tons CO2e)

262

### (7.16.2) Scope 2, location-based (metric tons CO2e)

847

### (7.16.3) Scope 2, market-based (metric tons CO2e)

730

## Switzerland

### (7.16.1) Scope 1 emissions (metric tons CO2e)

258

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

**Taiwan, China**

(7.16.1) Scope 1 emissions (metric tons CO2e)

716

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

**Thailand**

(7.16.1) Scope 1 emissions (metric tons CO2e)

32

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0



## Tunisia

### (7.16.1) Scope 1 emissions (metric tons CO2e)

371

### (7.16.2) Scope 2, location-based (metric tons CO2e)

409

### (7.16.3) Scope 2, market-based (metric tons CO2e)

409

## Turkey

### (7.16.1) Scope 1 emissions (metric tons CO2e)

2608

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Ukraine

### (7.16.1) Scope 1 emissions (metric tons CO2e)

178

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

**United Kingdom of Great Britain and Northern Ireland**

(7.16.1) Scope 1 emissions (metric tons CO2e)

821

(7.16.2) Scope 2, location-based (metric tons CO2e)

2695

(7.16.3) Scope 2, market-based (metric tons CO2e)

1117

**United States of America**

(7.16.1) Scope 1 emissions (metric tons CO2e)

387,750

(7.16.2) Scope 2, location-based (metric tons CO2e)

288,065

(7.16.3) Scope 2, market-based (metric tons CO2e)

343,852

**Viet Nam**

### (7.16.1) Scope 1 emissions (metric tons CO2e)

3

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## (7.17) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.

Select all that apply

☒ By business division

### (7.17.1) Break down your total gross global Scope 1 emissions by business division.

	Business division	Scope 1 emissions (metric ton CO2e)
Row 1	<i>Pfizer Global Supply (Manufacturing)</i>	<i>405,866</i>
Row 2	<i>Research and Development</i>	<i>127,055</i>
Row 3	<i>Fleet</i>	<i>71,495</i>
Row 4	<i>Logistics</i>	<i>3656</i>
Row 5	<i>Other Sites</i>	<i>0</i>
Row 6	<i>Commercial Offices</i>	<i>5147</i>

**(7.20) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.**

Select all that apply

☒ By business division

**(7.20.1) Break down your total gross global Scope 2 emissions by business division.**

	Business division	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Row 1	<i>Pfizer Global Supply (Manufacturing)</i>	361,615	359,596
Row 2	<i>Commercial Offices</i>	18,695	20,122
Row 3	<i>Logistics</i>	8994	9376
Row 4	<i>Other Sites</i>	1	1
Row 5	<i>Research and Development</i>	60,788	76,033

**(7.22) Break down your gross Scope 1 and Scope 2 emissions between your consolidated accounting group and other entities included in your response.**

**Consolidated accounting group**

**(7.22.1) Scope 1 emissions (metric tons CO2e)**

613218

**(7.22.2) Scope 2, location-based emissions (metric tons CO2e)**

450093

#### (7.22.3) Scope 2, market-based emissions (metric tons CO2e)

465128

#### (7.22.4) Please explain

*All business units for each scope are included under Pfizer, Inc.*

#### All other entities

#### (7.22.1) Scope 1 emissions (metric tons CO2e)

0

#### (7.22.2) Scope 2, location-based emissions (metric tons CO2e)

0

#### (7.22.3) Scope 2, market-based emissions (metric tons CO2e)

0

#### (7.22.4) Please explain

*Pfizer has not included emissions data for any other entities in our response.*

#### (7.23) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response?

Select from:

☒ Not relevant as we do not have any subsidiaries

(7.27) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges?

Row 1

(7.27.1) Allocation challenges

Select from:  
☒ Other, please specify :Lack of customer-specific information

(7.27.2) Please explain what would help you overcome these challenges

Many of our customers, especially in the United States, purchase Pfizer products through wholesalers. We therefore do not have access to data to enable us to allocate emissions.

(7.28) Do you plan to develop your capabilities to allocate emissions to your customers in the future?

	Do you plan to develop your capabilities to allocate emissions to your customers in the future?	Describe how you plan to develop your capabilities
	Select from: <input checked="" type="checkbox"/> Yes	We are working to develop product-specific environmental footprint data that will enable us to more accurately allocate emissions for some customers.

(7.29) What percentage of your total operational spend in the reporting year was on energy?

Select from:  
☒ More than 0% but less than or equal to 5%

**(7.30) Select which energy-related activities your organization has undertaken.**

	Indicate whether your organization undertook this energy-related activity in the reporting year
Consumption of fuel (excluding feedstocks)	Select from: <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired electricity	Select from: <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired heat	Select from: <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired steam	Select from: <input checked="" type="checkbox"/> Yes
Consumption of purchased or acquired cooling	Select from: <input checked="" type="checkbox"/> Yes
Generation of electricity, heat, steam, or cooling	Select from: <input checked="" type="checkbox"/> Yes

**(7.30.1) Report your organization's energy consumption totals (excluding feedstocks) in MWh.**

**Consumption of fuel (excluding feedstock)**

**(7.30.1.1) Heating value**

Select from:

☒ HHV (higher heating value)

### (7.30.1.2) MWh from renewable sources

48,581

### (7.30.1.3) MWh from non-renewable sources

2,977,171

### (7.30.1.4) Total (renewable + non-renewable) MWh

3,025,752.00

## Consumption of purchased or acquired electricity

### (7.30.1.1) Heating value

Select from:

☒ Unable to confirm heating value

### (7.30.1.2) MWh from renewable sources

194,087

### (7.30.1.3) MWh from non-renewable sources

999,200

### (7.30.1.4) Total (renewable + non-renewable) MWh

1,193,287.00

## Consumption of purchased or acquired heat

### (7.30.1.1) Heating value

Select from:



☒ Unable to confirm heating value

#### (7.30.1.2) MWh from renewable sources

0

#### (7.30.1.3) MWh from non-renewable sources

7598

#### (7.30.1.4) Total (renewable + non-renewable) MWh

7598.00

### Consumption of purchased or acquired steam

#### (7.30.1.1) Heating value

Select from:

☒ Unable to confirm heating value

#### (7.30.1.2) MWh from renewable sources

0

#### (7.30.1.3) MWh from non-renewable sources

111,607

#### (7.30.1.4) Total (renewable + non-renewable) MWh

111,607.00

### Consumption of purchased or acquired cooling

### (7.30.1.1) Heating value

Select from:

☒ Unable to confirm heating value

### (7.30.1.2) MWh from renewable sources

0

### (7.30.1.3) MWh from non-renewable sources

74,779

### (7.30.1.4) Total (renewable + non-renewable) MWh

74,779.00

## Consumption of self-generated non-fuel renewable energy

### (7.30.1.1) Heating value

Select from:

☒ Unable to confirm heating value

### (7.30.1.2) MWh from renewable sources

24,511

### (7.30.1.4) Total (renewable + non-renewable) MWh

24,511.00

## Total energy consumption

### (7.30.1.1) Heating value

Select from:

☒ Unable to confirm heating value

#### (7.30.1.2) MWh from renewable sources

267,179

#### (7.30.1.3) MWh from non-renewable sources

4,170,355

#### (7.30.1.4) Total (renewable + non-renewable) MWh

4,437,534.00

#### (7.30.6) Select the applications of your organization's consumption of fuel.

	Indicate whether your organization undertakes this fuel application
Consumption of fuel for the generation of electricity	Select from: <input checked="" type="checkbox"/> Yes
Consumption of fuel for the generation of heat	Select from: <input checked="" type="checkbox"/> No
Consumption of fuel for the generation of steam	Select from: <input checked="" type="checkbox"/> Yes
Consumption of fuel for the generation of cooling	Select from: <input checked="" type="checkbox"/> No

	Indicate whether your organization undertakes this fuel application
Consumption of fuel for co-generation or tri-generation	<i>Select from:</i> <input checked="" type="checkbox"/> Yes

**(7.30.7) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.**

### **Sustainable biomass**

#### **(7.30.7.1) Heating value**

*Select from:*

☒ LHV

#### **(7.30.7.2) Total fuel MWh consumed by the organization**

0

#### **(7.30.7.3) MWh fuel consumed for self-generation of electricity**

0

#### **(7.30.7.4) MWh fuel consumed for self-generation of heat**

0

#### **(7.30.7.5) MWh fuel consumed for self-generation of steam**

0

**(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.8) Comment**

*No certificates for Biomass*

**Other biomass**

**(7.30.7.1) Heating value**

*Select from:*

☒ LHV

**(7.30.7.2) Total fuel MWh consumed by the organization**

47,886

**(7.30.7.3) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.4) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.5) MWh fuel consumed for self-generation of steam**

47,886

**(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.8) Comment**

N/A

## Other renewable fuels (e.g. renewable hydrogen)

### (7.30.7.1) Heating value

Select from:

☒ LHV

### (7.30.7.2) Total fuel MWh consumed by the organization

662

### (7.30.7.3) MWh fuel consumed for self-generation of electricity

0

### (7.30.7.4) MWh fuel consumed for self-generation of heat

0

### (7.30.7.5) MWh fuel consumed for self-generation of steam

0

### (7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

### (7.30.7.8) Comment

N/A

## Coal

### (7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

0

(7.30.7.3) MWh fuel consumed for self-generation of electricity

0

(7.30.7.4) MWh fuel consumed for self-generation of heat

0

(7.30.7.5) MWh fuel consumed for self-generation of steam

0

(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.8) Comment

N/A

**Oil**

(7.30.7.1) Heating value

Select from:

☒ LHV

(7.30.7.2) Total fuel MWh consumed by the organization

99,772

**(7.30.7.3) MWh fuel consumed for self-generation of electricity**

18,023

**(7.30.7.4) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.5) MWh fuel consumed for self-generation of steam**

15,704

**(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.8) Comment**

N/A

**Gas**

**(7.30.7.1) Heating value**

Select from:

☒ LHV

**(7.30.7.2) Total fuel MWh consumed by the organization**

2,668,282

**(7.30.7.3) MWh fuel consumed for self-generation of electricity**

0



**(7.30.7.4) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.5) MWh fuel consumed for self-generation of steam**

1,725,349

**(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration**

942,933

**(7.30.7.8) Comment**

N/A

**Other non-renewable fuels (e.g. non-renewable hydrogen)**

**(7.30.7.1) Heating value**

Select from:

☒ LHV

**(7.30.7.2) Total fuel MWh consumed by the organization**

209,151

**(7.30.7.3) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.4) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.5) MWh fuel consumed for self-generation of steam**

0

**(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.8) Comment**

N/A

**Total fuel**

**(7.30.7.1) Heating value**

Select from:

☒ LHV

**(7.30.7.2) Total fuel MWh consumed by the organization**

3,025,752

**(7.30.7.3) MWh fuel consumed for self-generation of electricity**

18,023

**(7.30.7.4) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.5) MWh fuel consumed for self-generation of steam**

1,788,939

**(7.30.7.7) MWh fuel consumed for self- cogeneration or self-trigeneration**

942,933

#### **(7.30.7.8) Comment**

N/A

**(7.30.9) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.**

#### **Electricity**

##### **(7.30.9.1) Total Gross generation (MWh)**

330,888

##### **(7.30.9.2) Generation that is consumed by the organization (MWh)**

322,176

##### **(7.30.9.3) Gross generation from renewable sources (MWh)**

25,452

##### **(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

24,510

#### **Heat**

##### **(7.30.9.1) Total Gross generation (MWh)**

0

##### **(7.30.9.2) Generation that is consumed by the organization (MWh)**

0

**(7.30.9.3) Gross generation from renewable sources (MWh)**

0

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

0

## **Steam**

**(7.30.9.1) Total Gross generation (MWh)**

0

**(7.30.9.2) Generation that is consumed by the organization (MWh)**

0

**(7.30.9.3) Gross generation from renewable sources (MWh)**

0

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

0

## **Cooling**

**(7.30.9.1) Total Gross generation (MWh)**

0

**(7.30.9.2) Generation that is consumed by the organization (MWh)**

0

**(7.30.9.3) Gross generation from renewable sources (MWh)**

0

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

0

**(7.30.16) Provide a breakdown by country/area of your electricity/heat/steam/cooling consumption in the reporting year.**

**Algeria**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

3442

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

3442.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

**Argentina**

(7.30.16.1) Consumption of purchased electricity (MWh)

9084

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

9084.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Australia

### (7.30.16.1) Consumption of purchased electricity (MWh)

12,514

### (7.30.16.2) Consumption of self-generated electricity (MWh)

344

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

12858.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Austria

### (7.30.16.1) Consumption of purchased electricity (MWh)

7774

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

8089

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

15,863.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Belarus**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0



**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Belgium**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

77911

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

22,124

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

100,035.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Brazil**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

15621

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

576

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

16,197.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Bulgaria

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Canada**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

13324

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

13,324.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Chile**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

112

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

112.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**China**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

6650

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

5410

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

12060.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Colombia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

287

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

45

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

332.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

**Costa Rica**

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Croatia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

9234

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**



9234.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Czechia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## Denmark

### (7.30.16.1) Consumption of purchased electricity (MWh)

0

### (7.30.16.2) Consumption of self-generated electricity (MWh)

0

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Ecuador

### (7.30.16.1) Consumption of purchased electricity (MWh)

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Egypt**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

**Estonia**

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## **Finland**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

961

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

1269

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

2230.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**France**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## Germany

### (7.30.16.1) Consumption of purchased electricity (MWh)

29,371

### (7.30.16.2) Consumption of self-generated electricity (MWh)

291

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

59

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

29,721.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Greece

### (7.30.16.1) Consumption of purchased electricity (MWh)

547

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

547.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Hungary**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0



**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**India**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

42,784

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

3123

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

4400

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

50,307.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Indonesia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

5435

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

5435.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Ireland**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

83,081

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

73,364

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

156,445.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Israel**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Italy**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

15,207

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

37,581

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

52,788.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Japan**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

30,878

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

8777

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

39,655.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Kazakhstan**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Latvia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Lithuania**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**



0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Luxembourg**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## Mexico

### (7.30.16.1) Consumption of purchased electricity (MWh)

7626

### (7.30.16.2) Consumption of self-generated electricity (MWh)

474

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

8100.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Morocco

### (7.30.16.1) Consumption of purchased electricity (MWh)

1833

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

143

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

1976.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Netherlands**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

332

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

332.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

**New Zealand**

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Norway**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Pakistan**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

11,045

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

11,045.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## Peru

### (7.30.16.1) Consumption of purchased electricity (MWh)

0

### (7.30.16.2) Consumption of self-generated electricity (MWh)

0

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Philippines

### (7.30.16.1) Consumption of purchased electricity (MWh)

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Poland**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0



**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Portugal**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

1237

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

1237.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Puerto Rico**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

**Republic of Korea**

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Romania**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Russian Federation**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Saudi Arabia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

6519

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

6519.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Serbia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Singapore**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

34,429

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

35,966

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

70,395.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Slovakia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**



0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Slovenia**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## South Africa

### (7.30.16.1) Consumption of purchased electricity (MWh)

0

### (7.30.16.2) Consumption of self-generated electricity (MWh)

0

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Spain

### (7.30.16.1) Consumption of purchased electricity (MWh)

10,275

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

1957

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

12,232.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Sweden**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

10,361

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

17,820

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

28,181.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Switzerland**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Taiwan, China**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Thailand**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

## Tunisia

### (7.30.16.1) Consumption of purchased electricity (MWh)

1020

### (7.30.16.2) Consumption of self-generated electricity (MWh)

0

### (7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

1020.00

### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

## Turkey

### (7.30.16.1) Consumption of purchased electricity (MWh)

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**Ukraine**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

0

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0



**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**United Kingdom of Great Britain and Northern Ireland**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

11,206

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

7246

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

18452.00

**(7.30.16.7) Provide details of the electricity consumption excluded**

N/A

**United States of America**

**(7.30.16.1) Consumption of purchased electricity (MWh)**

733,187

**(7.30.16.2) Consumption of self-generated electricity (MWh)**

146,188

**(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)**

140,914

**(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

1,020,289.00

(7.30.16.7) Provide details of the electricity consumption excluded

N/A

**Viet Nam**

(7.30.16.1) Consumption of purchased electricity (MWh)

0

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

#### (7.30.16.7) Provide details of the electricity consumption excluded

N/A

#### (7.30.17) Provide details of your organization's renewable electricity purchases in the reporting year by country/area.

##### Row 1

#### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Austria

#### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

#### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Hydropower (capacity unknown)

#### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

7774

#### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

#### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Austria

**(7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?**

Select from:

☒ No

**(7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)**

Select from:

☒ Before 2020

**(7.30.17.10) Supply arrangement start year**

2022

**(7.30.17.11) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Other, please specify :No brand, label or certification

**(7.30.17.12) Comment**

*Year of commissioning unknown, origin assumed to be Austria*

**Row 2**

**(7.30.17.1) Country/area of consumption of purchased renewable electricity**

Select from:

☒ Belgium

**(7.30.17.2) Sourcing method**

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Wind

### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

29525

### (7.30.17.5) Tracking instrument used

Select from:

☒ GO

### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Belgium

### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ Yes

### (7.30.17.8) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2013

### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ 2024

### (7.30.17.10) Supply arrangement start year

2023

### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :Guarantee of Origin

### Row 3

### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Croatia

### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :is not detailed in contract

### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

9234

### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

#### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Croatia

#### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

#### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ Before 2020

#### (7.30.17.10) Supply arrangement start year

2023

#### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

#### (7.30.17.12) Comment

*Multiple commissioning years and technologies; country of origin is assumed to be Croatia*

### Row 4

#### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Germany



### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Hydropower (capacity unknown)

### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

27,407

### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Germany

### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ Before 2020

### (7.30.17.10) Supply arrangement start year

**(7.30.17.11) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Other, please specify :No brand, label or certification

**(7.30.17.12) Comment**

*Country of origin is assumed to be Germany*

**Row 5****(7.30.17.1) Country/area of consumption of purchased renewable electricity**

Select from:

☒ Ireland

**(7.30.17.2) Sourcing method**

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

**(7.30.17.3) Renewable electricity technology type**

Select from:

☒ Renewable electricity mix, please specify :is not detailed in contract

**(7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)**

83,081

**(7.30.17.5) Tracking instrument used**

Select from:

☒ Contract

#### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Ireland

#### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ Yes

#### (7.30.17.8) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2020

#### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ 2020

#### (7.30.17.10) Supply arrangement start year

2021

#### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :European Energy Certificate System

#### (7.30.17.12) Comment

*Certificates were generated from onshore wind installations commissioned between 1988 and 2023, with the highest share (12%) coming from a single installation commissioned in 2020. Vintage of all certificates 2023. Countries of origin include Denmark, Finland, Hungary, and Portugal.*

## Row 6

### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Spain

### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :is not detailed in contract

### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

9316

### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Spain

### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

#### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ Before 2020

#### (7.30.17.10) Supply arrangement start year

2021

#### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

#### (7.30.17.12) Comment

*Year of commissioning unknown, origin assumed to be Spain*

### Row 7

#### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Sweden

#### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

#### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :is not detailed in contract

#### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

10361

#### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

#### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Sweden

#### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

#### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ Before 2020

#### (7.30.17.10) Supply arrangement start year

2021

#### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

#### (7.30.17.12) Comment

Year of commissioning unknown, origin assumed to be Sweden

## Row 8

### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ United Kingdom of Great Britain and Northern Ireland

### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.17.3) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :is not detailed in contract

### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

2600

### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ United Kingdom of Great Britain and Northern Ireland

### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ No

#### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ Before 2020

#### (7.30.17.10) Supply arrangement start year

2021

#### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :No brand, label or certification

#### (7.30.17.12) Comment

*Year of commissioning unknown, origin assumed to be United Kingdom of Great Britain and Northern Ireland*

### Row 9

#### (7.30.17.1) Country/area of consumption of purchased renewable electricity

Select from:

☒ Brazil

#### (7.30.17.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

#### (7.30.17.3) Renewable electricity technology type



Select from:

☒ Hydropower (capacity unknown)

#### (7.30.17.4) Renewable electricity consumed via selected sourcing method in the reporting year (MWh)

14789

#### (7.30.17.5) Tracking instrument used

Select from:

☒ Contract

#### (7.30.17.6) Country/area of origin (generation) of purchased renewable electricity

Select from:

☒ Brazil

#### (7.30.17.7) Are you able to report the commissioning or re-powering year of the energy generation facility?

Select from:

☒ Yes

#### (7.30.17.8) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2019

#### (7.30.17.9) Vintage of the renewable energy/attribute (i.e. year of generation)

Select from:

☒ 2024

#### (7.30.17.10) Supply arrangement start year

2023

### (7.30.17.11) Ecolabel associated with purchased renewable electricity

Select from:

☒ Other, please specify :IREC

### (7.30.17.12) Comment

*Country of origin is assumed to be Brazil*

**(7.30.18) Provide details of your organization's low-carbon heat, steam, and cooling purchases in the reporting year by country/area.**

**Row 1**

### (7.30.18.1) Sourcing method

Select from:

☒ Other, please specify :Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.18.2) Country/area of consumption of low-carbon heat, steam or cooling

Select from:

☒ Sweden

### (7.30.18.3) Energy carrier

Select from:

☒ Heat

### (7.30.18.4) Low-carbon technology type

Select from:

☒ Other biomass

#### (7.30.18.5) Low-carbon heat, steam, or cooling consumed (MWh)

6329

#### (7.30.18.6) Comment

*Contract*

#### Row 2

#### (7.30.18.1) Sourcing method

*Select from:*

☒ Other, please specify :Retail supply contract with an electricity supplier (retail green electricity)

#### (7.30.18.2) Country/area of consumption of low-carbon heat, steam or cooling

*Select from:*

☒ Sweden

#### (7.30.18.3) Energy carrier

*Select from:*

☒ Steam

#### (7.30.18.4) Low-carbon technology type

*Select from:*

☒ Other biomass

#### (7.30.18.5) Low-carbon heat, steam, or cooling consumed (MWh)

11491

#### (7.30.18.6) Comment

**(7.30.19) Provide details of your organization's renewable electricity generation by country/area in the reporting year.**

**Row 1**

**(7.30.19.1) Country/area of generation**

Select from:

☒ Morocco

**(7.30.19.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

0.21

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

143

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

143

**(7.30.19.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.19.8) Comment**

None

## Row 2

### (7.30.19.1) Country/area of generation

Select from:

☒ Australia

### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

### (7.30.19.3) Facility capacity (MW)

0.48

### (7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

344

### (7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

344

### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

### (7.30.19.8) Comment

None

Row 3

(7.30.19.1) Country/area of generation

Select from:

☒ India

(7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.19.3) Facility capacity (MW)

0.24

(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

2641

(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

1798

(7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

None

Row 4

#### (7.30.19.1) Country/area of generation

Select from:

☒ Singapore

#### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.19.3) Facility capacity (MW)

1

#### (7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

1542

#### (7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

1542

#### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.19.8) Comment

None

#### Row 5

#### (7.30.19.1) Country/area of generation

Select from:

☒ Belgium

#### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Wind

#### (7.30.19.3) Facility capacity (MW)

4.6

#### (7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

7632

#### (7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

7632

#### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.19.8) Comment

None

### Row 6

#### (7.30.19.1) Country/area of generation

Select from:

☒ Belgium



#### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.19.3) Facility capacity (MW)

0.47

#### (7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

407

#### (7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

407

#### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.19.8) Comment

None

### Row 7

#### (7.30.19.1) Country/area of generation

Select from:

☒ Germany

#### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Geothermal

#### (7.30.19.3) Facility capacity (MW)

0.11

#### (7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

181

#### (7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

181

#### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.19.8) Comment

None

### Row 8

#### (7.30.19.1) Country/area of generation

Select from:

☒ Germany

#### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

0.1

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

133

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

110

**(7.30.19.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.19.8) Comment**

None

**Row 9**

**(7.30.19.1) Country/area of generation**

Select from:

☒ Ireland

**(7.30.19.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

0.19

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

132

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

132

**(7.30.19.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.19.8) Comment**

None

**Row 10**

**(7.30.19.1) Country/area of generation**

Select from:

☒ Italy

**(7.30.19.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

1.6

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

2145

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

2145

**(7.30.19.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.19.8) Comment**

None

**Row 11**

**(7.30.19.1) Country/area of generation**

Select from:

☒ Spain

**(7.30.19.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

1.4

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

1957

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

1957

**(7.30.19.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.19.8) Comment**

None

**Row 12**

**(7.30.19.1) Country/area of generation**

Select from:

☒ Brazil

**(7.30.19.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

1.21

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

576

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

576

**(7.30.19.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.19.8) Comment**

None

**Row 13**

**(7.30.19.1) Country/area of generation**

Select from:

☒ Colombia

**(7.30.19.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.19.3) Facility capacity (MW)**

0.07

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

48

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

**(7.30.19.6) Energy attribute certificates issued for this generation***Select from:*☒ No**(7.30.19.8) Comment***None***Row 14****(7.30.19.1) Country/area of generation***Select from:*☒ Mexico**(7.30.19.2) Renewable electricity technology type***Select from:*☒ Solar**(7.30.19.3) Facility capacity (MW)**

0.2

**(7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

388

**(7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

388



#### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.19.8) Comment

None

### Row 15

#### (7.30.19.1) Country/area of generation

Select from:

☒ United States of America

#### (7.30.19.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.19.3) Facility capacity (MW)

0.24

#### (7.30.19.4) Total renewable electricity generated by this facility in the reporting year (MWh)

7184

#### (7.30.19.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

7110

#### (7.30.19.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.19.8) Comment

None

(7.30.20) Describe how your organization’s renewable electricity sourcing strategy directly or indirectly contributes to bringing new capacity into the grid in the countries/areas in which you operate.

*Pfizer invests in no- and low-carbon technologies at our sites and through VPPAs that enable sourcing of renewable energy. VPPAs covering solar projects in Spain and the United States, came online in first semester 2025, are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe.*

(7.30.21) In the reporting year, has your organization faced barriers or challenges to sourcing renewable electricity?

	Challenges to sourcing renewable electricity	Challenges faced by your organization which were not country/area-specific
	Select from: <input checked="" type="checkbox"/> Yes, both in specific countries/areas and in general	<i>There is a limited supply of renewable electricity across all markets and the cost of VPPAs in many markets can be prohibitive.</i>

(7.30.22) Provide details of the country/area-specific challenges to sourcing renewable electricity faced by your organization in the reporting year.

Row 1

### (7.30.22.1) Country/area

Select from:

☒ India

### (7.30.22.2) Reason why it was challenging to source renewable electricity within selected country/area

Select all that apply

☒ Limited supply of renewable electricity in the market

### (7.30.22.3) Provide additional details of the barriers faced within this country/area

*The availability of national-level VPPAs is limited and unlikely to meet demand.*

## Row 2

### (7.30.22.1) Country/area

Select from:

☒ Singapore

### (7.30.22.2) Reason why it was challenging to source renewable electricity within selected country/area

Select all that apply

☒ Limited supply of renewable electricity in the market

### (7.30.22.3) Provide additional details of the barriers faced within this country/area

*Limited land availability for the development of new renewable energy infrastructure.*

**(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.**

## Row 1

### (7.45.1) Intensity figure

0.000017

### (7.45.2) Metric numerator (Gross global combined Scope 1 and 2 emissions, metric tons CO2e)

1,078,346

### (7.45.3) Metric denominator

Select from:

☒ unit total revenue

### (7.45.4) Metric denominator: Unit total

63,627,000,000

### (7.45.5) Scope 2 figure used

Select from:

☒ Market-based

### (7.45.6) % change from previous year

11

### (7.45.7) Direction of change

Select from:

☒ Decreased

### (7.45.8) Reasons for change

Select all that apply

- ☒ Change in renewable energy consumption
- ☒ Other emissions reduction activities
- ☒ Change in revenue

### (7.45.9) Please explain

*Pfizer's 2024 Scope 1 & 2 GHG emissions decreased 3% compared to 2023 while our procurement of renewable energy increased by 4.5%. Our 2024 revenue was 9% higher than 2023.*

## (7.52) Provide any additional climate-related metrics relevant to your business.

### Row 1

#### (7.52.1) Description

Select from:

- ☒ Energy usage

#### (7.52.2) Metric value

4,437,907

#### (7.52.3) Metric numerator

*megawatt hours (MWh)*

#### (7.52.5) % change from previous year

1

#### (7.52.6) Direction of change

Select from:

☒ Decreased

### (7.52.7) Please explain

*Pfizer is committed to reducing greenhouse gas (GHG) emissions by implementing targeted energy efficiency initiatives across our operations. Each of our manufacturing sites establishes annual energy reduction goals and actively pursues projects to achieve them. Progress is tracked through a structured operational excellence framework, ensuring continuous improvement and accountability.*

## Row 2

### (7.52.1) Description

Select from:

☒ Waste

### (7.52.2) Metric value

121,740

### (7.52.3) Metric numerator

*metric tons*

### (7.52.5) % change from previous year

34

### (7.52.6) Direction of change

Select from:

☒ Decreased

### (7.52.7) Please explain

*Pfizer's waste management strategy is guided by an internal performance metric based on hierarchy of control principles (avoid, reduce, reuse, recycle, dispose). Our manufacturing sites establish annual internal targets to reduce the volume of waste sent to landfill. Progress toward these goals is systematically tracked through our operational excellence framework, supporting continuous improvement in waste management practices.*

## **(7.53) Did you have an emissions target that was active in the reporting year?**

*Select all that apply*

☒ Absolute target

### **(7.53.1) Provide details of your absolute emissions targets and progress made against those targets.**

#### **Row 1**

##### **(7.53.1.1) Target reference number**

*Select from:*

☒ Abs 3

##### **(7.53.1.2) Is this a science-based target?**

*Select from:*

☒ Yes, and this target has been approved by the Science Based Targets initiative

##### **(7.53.1.3) Science Based Targets initiative official validation letter**

*PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf*

##### **(7.53.1.4) Target ambition**

*Select from:*

☒ 1.5°C aligned

##### **(7.53.1.5) Date target was set**

11/23/2020

#### (7.53.1.6) Target coverage

Select from:

☒ Organization-wide

#### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Carbon dioxide (CO2)

☒ Methane (CH4)

☒ Nitrous oxide (N2O)

☒ Hydrofluorocarbons (HFCs)

☒ Sulphur hexafluoride (SF6)

#### (7.53.1.8) Scopes

Select all that apply

☒ Scope 1

☒ Scope 2

#### (7.53.1.9) Scope 2 accounting method

Select from:

☒ Market-based

#### (7.53.1.11) End date of base year

12/31/2019

#### (7.53.1.12) Base year Scope 1 emissions covered by target (metric tons CO2e)

695,112



**(7.53.1.13) Base year Scope 2 emissions covered by target (metric tons CO2e)**

571,233

**(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

0.000

**(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

1,266,345.000

**(7.53.1.33) Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1**

100

**(7.53.1.34) Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2**

100

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

100

**(7.53.1.54) End date of target**

12/31/2030

**(7.53.1.55) Targeted reduction from base year (%)**

46

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

683,826.300

#### (7.53.1.57) Scope 1 emissions in reporting year covered by target (metric tons CO2e)

613,218

#### (7.53.1.58) Scope 2 emissions in reporting year covered by target (metric tons CO2e)

465,128

#### (7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

1,078,346.000

#### (7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

#### (7.53.1.79) % of target achieved relative to base year

32.27

#### (7.53.1.80) Target status in reporting year

Select from:

☒ Underway

#### (7.53.1.82) Explain target coverage and identify any exclusions

*Pfizer's near-term Scope 1+2 GHG emissions reduction goal is company-wide, covering all owned sites and leased sites where Pfizer has operational control, and includes biogenic emissions and removals from bioenergy feedstocks. Pfizer's biogenic emissions are limited to the burning of wood pellets and chips at two of our manufacturing facilities and comprise approximately 1% of our Scope 1+2 footprint.*

#### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by*

the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.

#### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

Pfizer is making progress toward our near-term goal although emission reductions will vary from year to year as we work to implement emission reduction projects and transition to renewable electricity sources. Our manufacturing and R&D sites have long-term environmental sustainability master plans to reduce impact, including actions ranging in scale and complexity. We seek opportunities to design new facility or renovation projects with reduced environmental impact (such as energy consumption, water usage and waste management) so we can deliver greener buildings, invest in no/low carbon technologies at our sites and in contractual agreements that enable sourcing of clean energy from renewable sources, and undertake process enhancements within our product manufacturing to reduce the number of steps and resources required. VPPAs covering solar projects in Spain and the United States, coming online in 2025, are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe. As of the end of 2024, Pfizer has reduced scope 1 and 2 GHG emissions by 15% from our 2019 baseline.

#### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

### Row 2

#### (7.53.1.1) Target reference number

Select from:

☒ Abs 4

#### (7.53.1.2) Is this a science-based target?

Select from:

☒ Yes, and this target has been approved by the Science Based Targets initiative

#### (7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf

#### (7.53.1.4) Target ambition

Select from:

- ☒ Well-below 2°C aligned

#### (7.53.1.5) Date target was set

11/23/2020

#### (7.53.1.6) Target coverage

Select from:

- ☒ Organization-wide

#### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

- ☒ Carbon dioxide (CO2)
- ☒ Methane (CH4)
- ☒ Nitrous oxide (N2O)
- ☒ Hydrofluorocarbons (HFCs)
- ☒ Sulphur hexafluoride (SF6)

#### (7.53.1.8) Scopes

Select all that apply

- ☒ Scope 3

#### (7.53.1.10) Scope 3 categories

Select all that apply

- ☒ Scope 3, Category 4 – Upstream transportation and distribution

#### (7.53.1.11) End date of base year

12/31/2019

**(7.53.1.17) Base year Scope 3, Category 4: Upstream transportation and distribution emissions covered by target (metric tons CO2e)**

200,873

**(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

200,873.000

**(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

200,873.000

**(7.53.1.38) Base year Scope 3, Category 4: Upstream transportation and distribution covered by target as % of total base year emissions in Scope 3, Category 4: Upstream transportation and distribution (metric tons CO2e)**

100

**(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)**

6.4

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

6.4

**(7.53.1.54) End date of target**

12/31/2025

**(7.53.1.55) Targeted reduction from base year (%)**

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

180,785.700

**(7.53.1.62) Scope 3, Category 4: Upstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)**

154,001

**(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)**

154,001.000

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

154,001.000

**(7.53.1.78) Land-related emissions covered by target**

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

**(7.53.1.79) % of target achieved relative to base year**

233.34

**(7.53.1.80) Target status in reporting year**

Select from:

☒ Underway

**(7.53.1.82) Explain target coverage and identify any exclusions**

Upstream transportation and distribution emissions represent approximately 7% of Pfizer's current Scope 3 footprint and are our second largest source of Scope 3 emissions. Target coverage includes Pfizer-paid transportation and distribution of Pfizer products.

### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

*We have continued to make progress toward our goal to reduce our upstream transportation emissions 10% by 2025 compared to 2019 levels. In 2024, we focused on empowering our supply chain and logistics teams to better understand the emissions impact of their decisions. Pfizer has developed a visual tool that provides our colleagues with transparency on emissions for each transportation route to identify the largest contributors by customer, lane, and mode of transport. Collaborating closely with our carriers and logistics providers, we continue to identify and implement emission reduction opportunities. In 2024, we advanced a number of our own initiatives, including switching shipments from air to ocean where possible, working to enhance circularity, adopting biofuels, and rolling out electric vehicles to deliver our products. As of the end of 2024, Pfizer's emissions in this category were 23% lower than the 2019 baseline.*

### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

## Row 3

### (7.53.1.1) Target reference number

Select from:

☒ Abs 5

### (7.53.1.2) Is this a science-based target?

Select from:

☒ Yes, and this target has been approved by the Science Based Targets initiative

### (7.53.1.3) Science Based Targets initiative official validation letter

*PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf*

### (7.53.1.4) Target ambition

*Select from:*

☒ Well-below 2°C aligned

### (7.53.1.5) Date target was set

*11/23/2020*

### (7.53.1.6) Target coverage

*Select from:*

☒ Organization-wide

### (7.53.1.7) Greenhouse gases covered by target

*Select all that apply*

☒ Carbon dioxide (CO<sub>2</sub>)

☒ Methane (CH<sub>4</sub>)

☒ Nitrous oxide (N<sub>2</sub>O)

☒ Hydrofluorocarbons (HFCs)

☒ Sulphur hexafluoride (SF<sub>6</sub>)

### (7.53.1.8) Scopes

*Select all that apply*

☒ Scope 3

### (7.53.1.10) Scope 3 categories



Select all that apply

☒ Scope 3, Category 6 – Business travel

**(7.53.1.11) End date of base year**

12/31/2019

**(7.53.1.19) Base year Scope 3, Category 6: Business travel emissions covered by target (metric tons CO2e)**

421,399

**(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

421,399.000

**(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

421,399.000

**(7.53.1.40) Base year Scope 3, Category 6: Business travel emissions covered by target as % of total base year emissions in Scope 3, Category 6: Business travel (metric tons CO2e)**

100.0

**(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)**

13.5

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

13.5

**(7.53.1.54) End date of target**

12/31/2025

**(7.53.1.55) Targeted reduction from base year (%)**

25

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

316,049.250

**(7.53.1.64) Scope 3, Category 6: Business travel emissions in reporting year covered by target (metric tons CO2e)**

188,309

**(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)**

188,309.000

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

188,309.000

**(7.53.1.78) Land-related emissions covered by target**

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

**(7.53.1.79) % of target achieved relative to base year**

221.25

**(7.53.1.80) Target status in reporting year**

Select from:

☒ Underway

### (7.53.1.82) Explain target coverage and identify any exclusions

*Business travel has historically represented approximately 6% of Pfizer's Scope 3 footprint. The target covers emissions from air travel, hotel stays, automobile use (rental as well as business use of personal vehicles), and rail transportation associated with Pfizer business.*

### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

*Travel-related GHG emissions were 55% lower than the 2019 baseline. We have implemented tools to help business travelers make informed decisions about travel options. This includes using digital tools to limit travel and using preferred carriers that are advancing GHG reduction targets.*

### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

## Row 4

### (7.53.1.1) Target reference number

Select from:

☒ Abs 6

### (7.53.1.2) Is this a science-based target?

Select from:

☒ No, but we are reporting another target that is science-based

### (7.53.1.5) Date target was set

06/30/2022

#### (7.53.1.6) Target coverage

Select from:

☒ Organization-wide

#### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Carbon dioxide (CO2)

☒ Methane (CH4)

☒ Nitrous oxide (N2O)

☒ Hydrofluorocarbons (HFCs)

☒ Sulphur hexafluoride (SF6)

#### (7.53.1.8) Scopes

Select all that apply

☒ Scope 1

☒ Scope 2

#### (7.53.1.9) Scope 2 accounting method

Select from:

☒ Market-based

#### (7.53.1.11) End date of base year

12/31/2019

#### (7.53.1.12) Base year Scope 1 emissions covered by target (metric tons CO2e)

695,112

**(7.53.1.13) Base year Scope 2 emissions covered by target (metric tons CO2e)**

571,233

**(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

0.000

**(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

1,266,345.000

**(7.53.1.33) Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1**

100

**(7.53.1.34) Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2**

98

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

100

**(7.53.1.54) End date of target**

12/31/2040

**(7.53.1.55) Targeted reduction from base year (%)**

95

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

63,317.250

#### (7.53.1.57) Scope 1 emissions in reporting year covered by target (metric tons CO2e)

613,218

#### (7.53.1.58) Scope 2 emissions in reporting year covered by target (metric tons CO2e)

465,128

#### (7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

1,078,346.000

#### (7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

#### (7.53.1.79) % of target achieved relative to base year

15.63

#### (7.53.1.80) Target status in reporting year

Select from:

☒ Underway

#### (7.53.1.82) Explain target coverage and identify any exclusions

*Pfizer's long-term Scope 1+2 GHG emissions reduction goal is company-wide, covering all owned sites and leased sites where Pfizer has operational control, and includes biogenic emissions and removals from bioenergy feedstocks. Pfizer's biogenic emissions are limited to the burning of wood pellets and chips at two of our manufacturing facilities and comprise approximately 1% of our Scope 1+2 footprint.*

#### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by*

the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.

#### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

Pfizer aims to decrease our company's GHG emissions by 95% by reducing energy demand from our own operations and transitioning to renewable energy sources. Scope 1 & 2 GHG emissions in 2024 were 3% lower than in 2023. Emissions for 2024 were 15% lower than the 2019 baseline.

#### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

#### Row 5

#### (7.53.1.1) Target reference number

Select from:

☒ Abs 7

#### (7.53.1.2) Is this a science-based target?

Select from:

☒ No, but we are reporting another target that is science-based

#### (7.53.1.5) Date target was set

06/30/2022

#### (7.53.1.6) Target coverage

Select from:

☒ Organization-wide

#### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Carbon dioxide (CO2)

### (7.53.1.8) Scopes

Select all that apply

☒ Scope 3

### (7.53.1.10) Scope 3 categories

Select all that apply

☒ Scope 3, Category 15 – Investments

☒ Scope 3, Category 2 – Capital goods

☒ Scope 3, Category 6 – Business travel

☒ Scope 3, Category 7 – Employee commuting

☒ Scope 3, Category 8 - Upstream leased assets  
Scope 1 or 2)

☒ Scope 3, Category 1 – Purchased goods and services

☒ Scope 3, Category 5 – Waste generated in operations

☒ Scope 3, Category 4 – Upstream transportation and distribution

☒ Scope 3, Category 9 – Downstream transportation and distribution

☒ Scope 3, Category 3 – Fuel- and energy- related activities (not included in

### (7.53.1.11) End date of base year

12/31/2019

### (7.53.1.14) Base year Scope 3, Category 1: Purchased goods and services emissions covered by target (metric tons CO2e)

1,900,504

### (7.53.1.15) Base year Scope 3, Category 2: Capital goods emissions covered by target (metric tons CO2e)

101,679

### (7.53.1.16) Base year Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions covered by target (metric tons CO2e)

252,909



**(7.53.1.17) Base year Scope 3, Category 4: Upstream transportation and distribution emissions covered by target (metric tons CO2e)**

200,873

**(7.53.1.18) Base year Scope 3, Category 5: Waste generated in operations emissions covered by target (metric tons CO2e)**

9512

**(7.53.1.19) Base year Scope 3, Category 6: Business travel emissions covered by target (metric tons CO2e)**

421,399

**(7.53.1.20) Base year Scope 3, Category 7: Employee commuting emissions covered by target (metric tons CO2e)**

60,645

**(7.53.1.21) Base year Scope 3, Category 8: Upstream leased assets emissions covered by target (metric tons CO2e)**

36,273

**(7.53.1.22) Base year Scope 3, Category 9: Downstream transportation and distribution emissions covered by target (metric tons CO2e)**

99,576

**(7.53.1.28) Base year Scope 3, Category 15: Investments emissions covered by target (metric tons CO2e)**

33,892

**(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

3,117,262.000

**(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

3,117,262.000

**(7.53.1.35) Base year Scope 3, Category 1: Purchased goods and services emissions covered by target as % of total base year emissions in Scope 3, Category 1: Purchased goods and services (metric tons CO2e)**

100

**(7.53.1.36) Base year Scope 3, Category 2: Capital goods emissions covered by target as % of total base year emissions in Scope 3, Category 2: Capital goods (metric tons CO2e)**

100

**(7.53.1.37) Base year Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions covered by target as % of total base year emissions in Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) (metric tons CO2e)**

100

**(7.53.1.38) Base year Scope 3, Category 4: Upstream transportation and distribution covered by target as % of total base year emissions in Scope 3, Category 4: Upstream transportation and distribution (metric tons CO2e)**

100

**(7.53.1.39) Base year Scope 3, Category 5: Waste generated in operations emissions covered by target as % of total base year emissions in Scope 3, Category 5: Waste generated in operations (metric tons CO2e)**

100

**(7.53.1.40) Base year Scope 3, Category 6: Business travel emissions covered by target as % of total base year emissions in Scope 3, Category 6: Business travel (metric tons CO2e)**

100

**(7.53.1.41) Base year Scope 3, Category 7: Employee commuting covered by target as % of total base year emissions in Scope 3, Category 7: Employee commuting (metric tons CO2e)**

100

**(7.53.1.42) Base year Scope 3, Category 8: Upstream leased assets emissions covered by target as % of total base year emissions in Scope 3, Category 8: Upstream leased assets (metric tons CO2e)**

100

**(7.53.1.43) Base year Scope 3, Category 9: Downstream transportation and distribution emissions covered by target as % of total base year emissions in Scope 3, Category 9: Downstream transportation and distribution (metric tons CO2e)**

100

**(7.53.1.49) Base year Scope 3, Category 15: Investments emissions covered by target as % of total base year emissions in Scope 3, Category 15: Investments (metric tons CO2e)**

100

**(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)**

100

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

100

**(7.53.1.54) End date of target**

12/31/2040

**(7.53.1.55) Targeted reduction from base year (%)**

90

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

311,726.200

**(7.53.1.59) Scope 3, Category 1: Purchased goods and services emissions in reporting year covered by target (metric tons CO2e)**

2,786,489

**(7.53.1.60) Scope 3, Category 2: Capital goods emissions in reporting year covered by target (metric tons CO2e)**

119,357

**(7.53.1.61) Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions in reporting year covered by target (metric tons CO2e)**

254,803

**(7.53.1.62) Scope 3, Category 4: Upstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)**

154,001

**(7.53.1.63) Scope 3, Category 5: Waste generated in operations emissions in reporting year covered by target (metric tons CO2e)**

5435

**(7.53.1.64) Scope 3, Category 6: Business travel emissions in reporting year covered by target (metric tons CO2e)**

188,309

**(7.53.1.65) Scope 3, Category 7: Employee commuting emissions in reporting year covered by target (metric tons CO2e)**

20,564

**(7.53.1.66) Scope 3, Category 8: Upstream leased assets emissions in reporting year covered by target (metric tons CO2e)**

15,511

**(7.53.1.67) Scope 3, Category 9: Downstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)**

3397

**(7.53.1.73) Scope 3, Category 15: Investments emissions in reporting year covered by target (metric tons CO2e)**

7342

**(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)**

3,555,208.000

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

3,555,208.000

**(7.53.1.78) Land-related emissions covered by target**

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

**(7.53.1.79) % of target achieved relative to base year**

-15.61

### (7.53.1.80) Target status in reporting year

Select from:

☒ Underway

### (7.53.1.82) Explain target coverage and identify any exclusions

*Pfizer's long-term Scope 3 GHG emissions reduction target is company-wide, covering all Scope 3 emissions relevant to Pfizer's operations.*

### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

*Pfizer's value chain GHG emissions are roughly four times greater than those associated with our direct operations. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have embedded environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes.*

### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

## (7.54) Did you have any other climate-related targets that were active in the reporting year?

Select all that apply

☒ Targets to increase or maintain low-carbon energy consumption or production

☒ Net-zero targets

☒ Other climate-related targets

## (7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production.

### Row 1

#### (7.54.1.1) Target reference number

Select from:

☒ Low 1

#### (7.54.1.2) Date target was set

11/23/2020

#### (7.54.1.3) Target coverage

Select from:

☒ Organization-wide

#### (7.54.1.4) Target type: energy carrier

Select from:

☒ Electricity

#### (7.54.1.5) Target type: activity

Select from:

☒ Consumption

#### (7.54.1.6) Target type: energy source

Select from:

☒ Renewable energy source(s) only

#### (7.54.1.7) End date of base year

12/31/2019

**(7.54.1.8) Consumption or production of selected energy carrier in base year (MWh)**

1,449,163

**(7.54.1.9) % share of low-carbon or renewable energy in base year**

9.5

**(7.54.1.10) End date of target**

12/31/2030

**(7.54.1.11) % share of low-carbon or renewable energy at end date of target**

100

**(7.54.1.12) % share of low-carbon or renewable energy in reporting year**

14.4

**(7.54.1.13) % of target achieved relative to base year**

5.41

**(7.54.1.14) Target status in reporting year**

Select from:

☒ Underway

**(7.54.1.16) Is this target part of an emissions target?**

Yes, Pfizer's commitment to 100% renewable electricity is a component of our Scope 1+2 emissions reduction target (Abs 3).

**(7.54.1.17) Is this target part of an overarching initiative?**



Select all that apply

☒ RE100

☒ Science Based Targets initiative

#### (7.54.1.18) Science Based Targets initiative official validation letter

*PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf*

#### (7.54.1.19) Explain target coverage and identify any exclusions

*This target is company-wide with no exclusions.*

#### (7.54.1.20) Target objective

*The sourcing of renewable electricity is a key component of Pfizer's decarbonization strategy.*

#### (7.54.1.21) Plan for achieving target, and progress made to the end of the reporting year

*Pfizer has entered into virtual power purchase agreements covering North America and the EU. These projects will generate renewable energy credits (RECs) expected to cover approximately 100% of Pfizer's purchased electricity needs in these jurisdictions beginning in 2025. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe.*

### (7.54.2) Provide details of any other climate-related targets, including methane reduction targets.

#### Row 1

#### (7.54.2.1) Target reference number

Select from:

☒ Oth 1

#### (7.54.2.2) Date target was set

*11/23/2020*

### (7.54.2.3) Target coverage

Select from:

☒ Organization-wide

### (7.54.2.4) Target type: absolute or intensity

Select from:

☒ Intensity

### (7.54.2.5) Target type: category & metric (target numerator if reporting an intensity target)

Engagement with suppliers

☒ Percentage of suppliers (by procurement spend) with a science-based target

### (7.54.2.6) Target denominator (intensity targets only)

Select from:

☒ Other, please specify :Total procurement spend

### (7.54.2.7) End date of base year

12/31/2019

### (7.54.2.8) Figure or percentage in base year

0

### (7.54.2.9) End date of target

12/31/2025

### (7.54.2.10) Figure or percentage at end of date of target

**(7.54.2.11) Figure or percentage in reporting year****(7.54.2.12) % of target achieved relative to base year**

101.5625000000

**(7.54.2.13) Target status in reporting year**

Select from:

☒ Underway**(7.54.2.15) Is this target part of an emissions target?**

No

**(7.54.2.16) Is this target part of an overarching initiative?**

Select all that apply

☒ Science Based Targets initiative – approved supplier engagement target**(7.54.2.17) Science Based Targets initiative official validation letter**

PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf

**(7.54.2.18) Please explain target coverage and identify any exclusions**

*Pfizer currently estimates GHG emissions associated with purchased goods and services based on spend and aligned with the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Estimated emissions for this category currently represent 78% of Pfizer's Scope 3 footprint. Pfizer is committed to accelerating change across our supply chain and aims to drive 64% of our suppliers of goods and services by spend to set their own science-based emission reduction goals by 2025. Emissions associated with purchased goods and services are calculated using spend-based emission factors.*

**(7.54.2.19) Target objective**

*Procurement of goods and services, which are essential to producing medicines and vaccines, is the most significant contributor to our scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes.*

#### **(7.54.2.20) Plan for achieving target, and progress made to the end of the reporting year**

*Pfizer continues our work to catalyze climate action in our supply chain. In 2024, we hosted the Pharmaceutical Supply Chain Initiative (PSCI) annual meeting, engaged suppliers through a third supplier summit, and launched a Pfizer-sponsored training academy for suppliers seeking assistance in measuring and reducing GHG emissions. We continue to promote excellence in sustainable supply chain management by participating in recognition events, including one organized by the Sustainable Procurement Pledge in December and Pfizer's own showcase that same month. As a result of our engagement efforts, 65% of our suppliers of goods and services by spend have committed to science-based emission reduction targets, an increase of 27% compared to 2023.*

### **(7.54.3) Provide details of your net-zero target(s).**

#### **Row 1**

#### **(7.54.3.1) Target reference number**

Select from:

☒ NZ1

#### **(7.54.3.2) Date target was set**

06/30/2022

#### **(7.54.3.3) Target Coverage**

Select from:

☒ Organization-wide

#### **(7.54.3.4) Targets linked to this net zero target**

Select all that apply

☒ Abs3

- ☒ Abs4
- ☒ Abs5
- ☒ Low1

#### (7.54.3.5) End date of target for achieving net zero

12/31/2040

#### (7.54.3.6) Is this a science-based target?

Select from:

- ☒ Yes, we consider this a science-based target, and we have committed to seek validation of this target by the Science Based Targets initiative in the next two years

#### (7.54.3.8) Scopes

Select all that apply

- ☒ Scope 1
- ☒ Scope 2
- ☒ Scope 3

#### (7.54.3.9) Greenhouse gases covered by target

Select all that apply

- ☒ Carbon dioxide (CO2)
- ☒ Methane (CH4)
- ☒ Nitrous oxide (N2O)
- ☒ Hydrofluorocarbons (HFCs)
- ☒ Sulphur hexafluoride (SF6)

#### (7.54.3.10) Explain target coverage and identify any exclusions

Pfizer's Net-Zero target covers at least 95% of total scope 1 and 2 emissions and at least 90% of total scope 3 emissions.

### (7.54.3.11) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

### (7.54.3.12) Do you intend to neutralize any residual emissions with permanent carbon removals at the end of the target?

Select from:

☒ Yes

### (7.54.3.13) Do you plan to mitigate emissions beyond your value chain?

Select from:

☒ No, we do not plan to mitigate emissions beyond our value chain

### (7.54.3.14) Do you intend to purchase and cancel carbon credits for neutralization and/or beyond value chain mitigation?

Select all that apply

☒ No, we do not plan to purchase and cancel carbon credits for neutralization and/or beyond value chain mitigation

### (7.54.3.15) Planned milestones and/or near-term investments for neutralization at the end of the target

*While Pfizer's focus is driving absolute GHG reductions, we anticipate that a carbon removal strategy may be necessary to address hard-to-abate emissions as we progress towards the target end dates.*

### (7.54.3.17) Target status in reporting year

Select from:

☒ Underway

### (7.54.3.19) Process for reviewing target

*Environmental sustainability has been integrated into the overarching Pfizer strategy and GHG emissions reduction is monitored as a key performance indicator (KPI). Performance against targets is monitored throughout the year by the PGS Executive Leadership Team.*

**(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.**

Select from:

☒ Yes

**(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.**

	Number of initiatives	Total estimated annual CO2e savings in metric tonnes CO2e
Under investigation	6	<i>`Numeric input</i>
To be implemented	0	0
Implementation commenced	4	796
Implemented	266	32292
Not to be implemented	68	<i>`Numeric input</i>

**(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below.**

Row 1

**(7.55.2.1) Initiative category & Initiative type**

Energy efficiency in buildings

☒ Other, please specify :Energy and efficiency in buildings

#### (7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

32292

#### (7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

*Select all that apply*

☒ Scope 1

☒ Scope 2 (location-based)

☒ Scope 2 (market-based)

#### (7.55.2.4) Voluntary/Mandatory

*Select from:*

☒ Voluntary

#### (7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

\$9,341,663

#### (7.55.2.6) Investment required (unit currency – as specified in 1.2)

\$36,298,134

#### (7.55.2.7) Payback period

*Select from:*

☒ 4-10 years

#### (7.55.2.8) Estimated lifetime of the initiative



Select from:

☒ 6-10 years

### (7.55.2.9) Comment

*Multiple initiatives across Pfizer*

## (7.55.3) What methods do you use to drive investment in emissions reduction activities?

### Row 1

#### (7.55.3.1) Method

Select from:

☒ Internal incentives/recognition programs

#### (7.55.3.2) Comment

*Pfizer's internal "Safety and Sustainability STAR Awards" program recognizes projects advanced by colleagues across Pfizer related to driving sustainability improvements including GHG reductions and innovations in sustainable medicines. These awards encourage sites to implement sustainability initiatives. In 2024, two emissions reduction projects and three sustainable medicines projects were recognized with STAR awards.*

### Row 2

#### (7.55.3.1) Method

Select from:

☒ Lower return on investment (ROI) specification

#### (7.55.3.2) Comment

*Projects with environmental benefits may be approved for funding despite not meeting internally established financial hurdle rates.*

### Row 3

#### (7.55.3.1) Method

Select from:

☒ Compliance with regulatory requirements/standards

#### (7.55.3.2) Comment

*Pfizer prioritizes funding for projects that reduce energy demand and GHG emissions associated with regulatory compliance requirements.*

### (7.73) Are you providing product level data for your organization's goods or services?

Select from:

☒ No, I am not providing data

### (7.74) Do you classify any of your existing goods and/or services as low-carbon products?

Select from:

☒ Yes

#### (7.74.1) Provide details of your products and/or services that you classify as low-carbon products.

### Row 1

#### (7.74.1.1) Level of aggregation

Select from:

☒ Product or service

#### (7.74.1.2) Taxonomy used to classify product(s) or service(s) as low-carbon

Select from:

☒ Other, please specify :Life Cycle Assessment (LCA) using in-house collaborative tools

#### (7.74.1.3) Type of product(s) or service(s)

Chemicals and plastics

☒ Other, please specify :Elimination of materials used in manufacturing of product

#### (7.74.1.4) Description of product(s) or service(s)

*The product, Enviero® progesterone, is now synthesized using a plant sterols pathway which uses fewer natural resources (than the original synthesis pathway) during its manufacture, reducing waste, GHG emissions, and use of hazardous solvents. The product can be used as a final active pharmaceutical ingredient or as an intermediate for more advanced steroidal products based on the customers intentions.*

#### (7.74.1.5) Have you estimated the avoided emissions of this low-carbon product(s) or service(s)

Select from:

☒ Yes

#### (7.74.1.6) Methodology used to calculate avoided emissions

Select from:

☒ Other, please specify :Performed in-house using a collaborative LCA tool created by the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR). The tool is underpinned with Life Cycle Inventory (LCI) from the Ecoinvent database.

#### (7.74.1.7) Life cycle stage(s) covered for the low-carbon product(s) or services(s)

Select from:

☒ Cradle-to-gate

#### (7.74.1.8) Functional unit used

*kg of progesterone product sold in its primary form (i.e., not with excipients or in solution, etc.)*

#### (7.74.1.9) Reference product/service or baseline scenario used

*The original and historical longer chemical synthesis route used to manufacture progesterone*

#### **(7.74.1.10) Life cycle stage(s) covered for the reference product/service or baseline scenario**

Select from:

☒ Cradle-to-gate

#### **(7.74.1.11) Estimated avoided emissions (metric tons CO<sub>2</sub>e per functional unit) compared to reference product/service or baseline scenario**

0.18

#### **(7.74.1.12) Explain your calculation of avoided emissions, including any assumptions**

*The emissions (in kg CO<sub>2</sub>e) are determined from the manufacturing process via a cradle to gate LCA using Ecoinvent Life Cycle Inventory (LCI) databases. Based on LCA calculations, the historical chemical synthesis manufacturing process generated approximately 256 kg CO<sub>2</sub>e per kg of progesterone produced. The new process, based on plant sterols, generated approximately 72 kg CO<sub>2</sub>e per kg of progesterone produced, a reduction of approximately 184 kg CO<sub>2</sub>e per kg of progesterone. This equates to a 72% reduction. Key assumptions: 1 ) Where compound-specific LCIs were not available, analogous proxies have been used (or built) within the same tools. 2) The lifecycle tool used (ACS GCIPR PMI-LCA tool) does not include energy for processing. This will lead to a conservative estimate of benefit as the new process is largely at room temperature conditions whereas the original route used several heating and cooling steps. Likewise, the new route is half the number of internal processing steps as the original route. Previous studies show that the GHG emissions associated with energy consumption in chemical synthesis commonly represent 15 to 25% of the carbon footprint when compared to bill of materials.*

#### **(7.74.1.13) Revenue generated from low-carbon product(s) or service(s) as % of total revenue in the reporting year**

0.01

#### **(7.79) Has your organization retired any project-based carbon credits within the reporting year?**

Select from:

☒ No

## C9. Environmental performance - Water security

### (9.1) Are there any exclusions from your disclosure of water-related data?

Select from:

☒ Yes

#### (9.1.1) Provide details on these exclusions.

##### Row 1

##### (9.1.1.1) Exclusion

Select from:

☒ Facilities

##### (9.1.1.2) Description of exclusion

*Withdrawals and discharges of water from logistics centers and office buildings not associated with manufacturing or research activities.*

##### (9.1.1.3) Reason for exclusion

Select from:

☒ Water used for internal WASH services

##### (9.1.1.7) Percentage of water volume the exclusion represents

Select from:

☒ Less than 1%

##### (9.1.1.8) Please explain

*Logistics centers and commercial office buildings comprise <1% of Pfizer's total water withdrawal.*

## **(9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?**

### **Water withdrawals – total volumes**

#### **(9.2.1) % of sites/facilities/operations**

Select from:

☒ 100%

#### **(9.2.2) Frequency of measurement**

Select from:

☒ Monthly

#### **(9.2.3) Method of measurement**

*Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system.*

#### **(9.2.4) Please explain**

*Pfizer collects and reports water withdrawal for all manufacturing and research and development (R&D) locations where we maintain operational control. Manufacturing and R&D sites report monthly withdrawal data (with a few exceptions where water data is only available quarterly). Total water withdrawal is reported annually in our Impact Report.*

### **Water withdrawals – volumes by source**

#### **(9.2.1) % of sites/facilities/operations**

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Monthly

### (9.2.3) Method of measurement

*Water withdrawal volumes are measured and monitored at the site level and are reported centrally by source. Volume data is obtained in a variety of ways depending on site specific factors: purchased water through utility providers' invoices; ground water and fresh water through municipal and internal flow meters; and rainwater through actual measurement with local mechanical flow meters.*

### (9.2.4) Please explain

*Pfizer collects and reports water withdrawal by source for all manufacturing and R&D locations where we maintain operational control. Manufacturing and R&D sites report monthly withdrawal data by source (with a few exceptions where water data is only available quarterly).*

## Water withdrawals quality

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Monthly

### (9.2.3) Method of measurement

*Water withdrawal quality is monitored through sampling and is tested onsite and by external labs analysis and includes all parameters related to the local regulations for potable water.*

### (9.2.4) Please explain

Water quality is monitored at the site level as required by regulation (local potable water standards) and as necessary to help ensure conformance with quality standards for manufacturing by all manufacturing and R&D locations where Pfizer maintains operational control. Water is purified as necessary to support manufacturing and R&D operations.

## Water discharges – total volumes

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Monthly

### (9.2.3) Method of measurement

Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. See Pfizer's website for our calculation methodology.  
[https://cdn.pfizer.com/pfizercom/Waste\\_and\\_Water\\_Methodology\\_MAR2024.pdf](https://cdn.pfizer.com/pfizercom/Waste_and_Water_Methodology_MAR2024.pdf)

### (9.2.4) Please explain

Water discharge volumes are monitored by all manufacturing and R&D locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Manufacturing and R&D locations report monthly discharge volumes. Total water discharge is reported annually in our Impact report.

## Water discharges – volumes by destination

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement



Select from:

☒ Monthly

### (9.2.3) Method of measurement

*Volume data for water discharged to municipal treatment plants is obtained through utility invoices and/or internal flow meters. Discharges to fresh and salt water are monitored through internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. See Pfizer's website for our calculation methodology. [https://cdn.pfizer.com/pfizercom/Waste\\_and\\_Water\\_Methodology\\_MAR2024.pdf](https://cdn.pfizer.com/pfizercom/Waste_and_Water_Methodology_MAR2024.pdf)*

### (9.2.4) Please explain

*Water discharge volumes are monitored by all manufacturing and research and development (R&D) sites under Pfizer's operational control and are reported centrally by discharge destination via our global environmental reporting system. Manufacturing and R&D locations report monthly discharge volumes.*

## Water discharges – volumes by treatment method

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Monthly

### (9.2.3) Method of measurement

*All manufacturing and R&D sites where we maintain operational control monitor their treatment processes and track discharge volumes through invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. Discharges are managed in accordance with the jurisdictional requirements applicable to the location. Pfizer's calculation methodology is available on our website.*

### (9.2.4) Please explain

Pfizer collects information on wastewater treatment technologies and quantities of wastewater discharged at our manufacturing and research and development (R&D) sites via our global environmental reporting system.

## Water discharge quality – by standard effluent parameters

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Monthly

### (9.2.3) Method of measurement

Water is monitored through sampling and is tested onsite and by external labs as required by site permits and applicable regulations. Monitoring data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through our EHS audit program.

### (9.2.4) Please explain

Pfizer requires all manufacturing and R&D sites where we maintain operational control to monitor wastewater discharge quality and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits. Water discharge quality is monitored as frequently as required by local regulations.

## Water discharge quality – emissions to water (nitrates, phosphates, pesticides, and/or other priority substances)

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Other, please specify :as required by local regulations.

### (9.2.3) Method of measurement

*Water discharge quality is monitored through sampling and is tested onsite and by external certified labs as required by site permits and applicable regulations. Monitoring data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through Pfizer's EHS audit program.*

### (9.2.4) Please explain

*Pfizer requires all manufacturing and R&D sites where we maintain operational control to monitor wastewater discharge quality and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits.*

## Water discharge quality – temperature

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Other, please specify :as required by local regulations.

### (9.2.3) Method of measurement

*Water discharge quality, including temperature, is monitored through sampling as required by site permits and applicable regulations. This data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through Pfizer's EHS audit program.*

### (9.2.4) Please explain

*Pfizer requires all manufacturing and R&D sites where we maintain operational control to monitor wastewater discharge quality, including temperature, and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits. Water temperature is monitored as frequently as required by local regulations.*

## Water consumption – total volume

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Yearly

### (9.2.3) Method of measurement

*Aggregated monthly or quarterly data is used to calculate water consumption annually.*

### (9.2.4) Please explain

*Water withdrawal and discharge volumes are monitored by all manufacturing and R&D sites under Pfizer's operational control and are reported monthly.*

## Water recycled/reused

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Monthly

### (9.2.3) Method of measurement

Volume data is obtained through flowmeters and/or estimated based on operations and engineering knowledge and data. Manufacturing and R&D sites report monthly recycled water volumes via our global environmental reporting system.

#### (9.2.4) Please explain

All manufacturing and R&D sites under Pfizer's operational control where recycled water is used monitor volumes and report centrally.

### The provision of fully-functioning, safely managed WASH services to all workers

#### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

#### (9.2.2) Frequency of measurement

Select from:

☒ Continuously

#### (9.2.3) Method of measurement

Pfizer's Global Environment, Health and Safety (EHS) Standards require all facilities to provide safe, fully functioning WASH services for all employees. Compliance to our standard is monitored through our internal audit program. In addition, compliance with WASH standards is also reviewed through the sites' periodic EHS self-assessment program. Finally, colleagues can report any issues through the Compliance Helpline.

#### (9.2.4) Please explain

Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees.

**(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change?**

#### Total withdrawals

### (9.2.2.1) Volume (megaliters/year)

30,801

### (9.2.2.2) Comparison with previous reporting year

Select from:

☒ Lower

### (9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

### (9.2.2.4) Five-year forecast

Select from:

☒ Higher

### (9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

### (9.2.2.6) Please explain

*Water withdrawals decreased by 3% compared to 2023. The decrease was primarily due to production and operational efficiency changes that occurred in 2024. Pfizer collects and reports water withdrawal for all manufacturing and research and development (R&D) locations where we maintain operational control. Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system. Total annual water withdrawal is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Water withdrawal is expected to increase over the next five years due to planned expansions and increased production at our biologics manufacturing sites.*

## Total discharges

#### (9.2.2.1) Volume (megaliters/year)

27,563

#### (9.2.2.2) Comparison with previous reporting year

Select from:

☒ Lower

#### (9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.4) Five-year forecast

Select from:

☒ Higher

#### (9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.6) Please explain

*Pfizer's wastewater discharge decreased by 4% compared to 2023 primarily due to production and operational efficiency changes that occurred in the 2024 calendar year. Water discharge volumes are monitored by all manufacturing and R&D locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed on an ongoing basis. Total annual water discharge is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Water discharge is expected to increase over the next five years due to planned expansions and increased production at our biologics manufacturing sites.*

#### Total consumption

### (9.2.2.1) Volume (megaliters/year)

3239

### (9.2.2.2) Comparison with previous reporting year

Select from:

☒ Much higher

### (9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

### (9.2.2.4) Five-year forecast

Select from:

☒ Higher

### (9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

### (9.2.2.6) Please explain

*Pfizer's total water consumption was much higher than in 2023. Pfizer defines "Much Higher" as an increase of more than 10% when compared to the previous year. The increase was primarily due to decommissioning activities at the Rocky Mount, North Carolina facility which required certain equipment to remain filled with water. Water consumption is calculated at the corporate level by subtracting total water discharged from total water withdrawn. The consumption corresponds to water incorporated in products, as well as water lost through evaporation in cooling towers. Total consumption is expected to increase over the next five years due to planned expansions and increased production at our biologics manufacturing sites.*



**(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change.**

**(9.2.4.1) Withdrawals are from areas with water stress**

Select from:

☒ Yes

**(9.2.4.2) Volume withdrawn from areas with water stress (megaliters)**

1441

**(9.2.4.3) Comparison with previous reporting year**

Select from:

☒ Much higher

**(9.2.4.4) Primary reason for comparison with previous reporting year**

Select from:

☒ Change in accounting methodology

**(9.2.4.5) Five-year forecast**

Select from:

☒ Lower

**(9.2.4.6) Primary reason for forecast**

Select from:

☒ Increase/decrease in business activity

**(9.2.4.7) % of total withdrawals that are withdrawn from areas with water stress**

**(9.2.4.8) Identification tool***Select all that apply*☒ WRI Aqueduct**(9.2.4.9) Please explain**

*Pfizer's methodology used to identify sites located in water-stressed areas is described in the Pfizer Water Stewardship position statement published in Jan 2022 and is based on the UN CEO Water Mandate definition of water stress which considers other physical aspects related to water resources in addition to water scarcity, including water quality, environmental flows, and the accessibility of water. Our methodology uses the WRI Aqueduct tool, considering all indicators outlined in the tool in our assessment, including those related to water quality, environmental flows, and water accessibility. Based on Pfizer's assessment methodology, the use of water from facilities operating in water-stressed areas increased by 26% primarily due to the inclusion of our Sanford, North Carolina facility based on recent assessment. Based on Pfizer's assessment methodology, 14% of our manufacturing and research and development sites are located in "High" or "Extremely High" water-stressed areas. We require these sites to develop water stewardship plans. The percentage of water withdrawn from water-stressed areas in 2024 was 4.68%. Water withdrawal from areas with water stress is expected to decrease in the next five years due to increases in efficiency and implementation of water stewardship projects.*

**(9.2.7) Provide total water withdrawal data by source.****Fresh surface water, including rainwater, water from wetlands, rivers, and lakes****(9.2.7.1) Relevance***Select from:*☒ Relevant**(9.2.7.2) Volume (megaliters/year)**

727

**(9.2.7.3) Comparison with previous reporting year**

Select from:

☒ Lower

#### (9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.7.5) Please explain

*Pfizer's use of fresh surface water is primarily for non-contact cooling water and includes water sources from lakes and a small amount of rain. Pfizer's use of fresh surface water decreased by 6% compared to 2023 due to production changes at our Strangnas, Sweden site (our primary user of surface water) in 2024. Going forward, we anticipate fresh surface water withdrawal to continue to decrease due to changes in business activity. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Brackish surface water/Seawater

#### (9.2.7.1) Relevance

Select from:

☒ Not relevant

#### (9.2.7.5) Please explain

*Pfizer does not currently use brackish surface water in our operations, and we do not anticipate using brackish surface water or seawater in our operations in the coming years.*

### Groundwater – renewable

#### (9.2.7.1) Relevance

Select from:

☒ Relevant

#### (9.2.7.2) Volume (megaliters/year)

**(9.2.7.3) Comparison with previous reporting year**

Select from:

☒ Lower**(9.2.7.4) Primary reason for comparison with previous reporting year**

Select from:

☒ Increase/decrease in business activity**(9.2.7.5) Please explain**

*Pfizer uses ground water for manufacturing operations, non-contact cooling, and potable and sanitary purposes. Pfizer's groundwater withdrawal decreased by 3% compared to 2023 primarily due to decreased production at the Kalamazoo, Michigan site. Going forward, we anticipate water consumption to increase, largely due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

**Groundwater – non-renewable****(9.2.7.1) Relevance**

Select from:

☒ Not relevant**(9.2.7.5) Please explain**

*Pfizer's groundwater use is limited to renewable water from shallow wells. Pfizer's operating sites do not withdraw water from non-renewable groundwater sources, and we do not anticipate doing so in the future.*

**Produced/Entrained water****(9.2.7.1) Relevance**

Select from:

☒ Not relevant

#### (9.2.7.5) Please explain

*Pfizer does not use produced water in operations. Given our need for high quality and very pure water, it is expensive and energy intensive to source produced water. Going forward, we do not anticipate using produced water in our operations.*

### Third party sources

#### (9.2.7.1) Relevance

Select from:

☒ Relevant

#### (9.2.7.2) Volume (megaliters/year)

7413

#### (9.2.7.3) Comparison with previous reporting year

Select from:

☒ About the same

#### (9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.7.5) Please explain

*Pfizer's use of municipal water did not change compared to 2023. Going forward, we anticipate water consumption to increase, largely due to expansions and increased production at our biologics manufacturing sites, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "about the same" as an increase or decrease between 0% and 2% when compared to the previous year.*

## (9.2.8) Provide total water discharge data by destination.

### Fresh surface water

#### (9.2.8.1) Relevance

Select from:

☒ Relevant

#### (9.2.8.2) Volume (megaliters/year)

19593

#### (9.2.8.3) Comparison with previous reporting year

Select from:

☒ Lower

#### (9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.8.5) Please explain

*Pfizer's discharge to surface water decreased by 4% compared to 2023 due to a decrease in non-contact cooling water use at our Kalamazoo, Michigan manufacturing plant related to production mix and production decreases. Going forward, we anticipate some near-term increases in water discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Brackish surface water/seawater

#### (9.2.8.1) Relevance

Select from:

☒ Relevant

#### (9.2.8.2) Volume (megaliters/year)

957

#### (9.2.8.3) Comparison with previous reporting year

Select from:

☒ About the same

#### (9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.8.5) Please explain

*Pfizer's discharges of brackish surface water/sea water did not change compared to 2023. Going forward, we anticipate some near-term increases in the use and discharge of brackish surface water/sea water due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "about the same" as an increase or decrease between 0% and 2% when compared to the previous year.*

### Groundwater

#### (9.2.8.1) Relevance

Select from:

☒ Not relevant

#### (9.2.8.5) Please explain

*Pfizer does not discharge to groundwater.*

### Third-party destinations

### (9.2.8.1) Relevance

Select from:

☒ Relevant

### (9.2.8.2) Volume (megaliters/year)

7013

### (9.2.8.3) Comparison with previous reporting year

Select from:

☒ Lower

### (9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

### (9.2.8.5) Please explain

*Pfizer's discharge to third party (municipal) wastewater treatment facilities decreased by 7% compared to 2023. The decrease was primarily attributed to changes in decreased discharge from our Rocky Mount, North Carolina site due to equipment decommissioning activities which required certain equipment to remain full of water. We do not discharge any wastewater to other organizations for further use. Going forward, we anticipate some near-term increases in water discharge due to increased production, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### (9.2.9) Within your direct operations, indicate the highest level(s) to which you treat your discharge.

#### Tertiary treatment

### (9.2.9.1) Relevance of treatment level to discharge

Select from:



☒ Relevant

#### (9.2.9.2) Volume (megaliters/year)

1037

#### (9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

#### (9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 11-20

#### (9.2.9.6) Please explain

*Eight Pfizer sites provide onsite tertiary treatment of wastewater prior to discharge. The volume of wastewater to which tertiary treatment was applied in 2024 was 10% lower than in 2023 mainly due to variation in production at the Nagoya, Japan, Purrs, Belgium, and Newbridge, Ireland facilities. This volume represents approximately 4% of our total wastewater discharge. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Secondary treatment

#### (9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

#### (9.2.9.2) Volume (megaliters/year)

**(9.2.9.3) Comparison of treated volume with previous reporting year**

Select from:

☒ Much higher**(9.2.9.4) Primary reason for comparison with previous reporting year**

Select from:

☒ Increase/decrease in business activity**(9.2.9.5) % of your sites/facilities/operations this volume applies to**

Select from:

☒ 11-20**(9.2.9.6) Please explain**

*Six Pfizer sites provide onsite secondary treatment of wastewater prior to discharge. The volume of wastewater processed through secondary treatment at Pfizer facilities in 2024 increased by 20% compared to 2023 due to changes in production at our Sanford, North Carolina and Ringaskiddy, Ireland sites. Additionally, our second facility in Tuas, Singapore (Tuas 2) started production in late 2023. This volume represents 3% of our total wastewater discharge. Pfizer defines "much higher" as an increase over 10% when compared to the previous year.*

**Primary treatment only****(9.2.9.1) Relevance of treatment level to discharge**

Select from:

☒ Relevant**(9.2.9.2) Volume (megaliters/year)**

### (9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Much lower

### (9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

### (9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 1-10

### (9.2.9.6) Please explain

*Three Pfizer sites provide onsite primary treatment of wastewater prior to discharge. The volume of wastewater processed through primary treatment at Pfizer facilities in 2024 decreased by 29% compared to 2023 due to changes in production at our Melbourne, Australia facility. This volume represents less than 1% of our total wastewater discharge. Pfizer defines "much lower" as a decrease over 10% when compared to the previous year.*

## Discharge to the natural environment without treatment

### (9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

### (9.2.9.2) Volume (megaliters/year)

19,408

### (9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

#### (9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 61-70

#### (9.2.9.6) Please explain

*Pfizer's discharge to the natural environment includes non-contact cooling water and utility wastewater (e.g., cooling tower blowdown and boiler blowdown). This water is monitored to help ensure compliance with the site's discharge permits (e.g., temperature, turbidity, etc.). The volume of water discharged from Pfizer sites to the natural environment decreased by 4% compared to 2023 primarily due to decrease in non-contact cooling water at the Kalamazoo, Michigan facility related to change in production mix and production decreases. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Discharge to a third party without treatment

#### (9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Relevant

#### (9.2.9.2) Volume (megaliters/year)

6227

#### (9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

#### (9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☒ 21-30

#### (9.2.9.6) Please explain

*Pfizer's discharges to third parties such as municipal wastewater treatment plants without pre-treatment decreased by 8% primarily due to changes in production mix at our Kalamazoo, Michigan manufacturing facility. Pfizer does not discharge any wastewater to other organizations for further use. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

#### Other

#### (9.2.9.1) Relevance of treatment level to discharge

Select from:

☒ Not relevant

#### (9.2.9.6) Please explain

*Pfizer does not treat wastewater using any other techniques.*

**(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year.**

#### (9.2.10.1) Emissions to water in the reporting year (metric tons)

### (9.2.10.2) Categories of substances included

Select all that apply

- ☒ Nitrates
- ☒ Phosphates
- ☒ Priority substances listed under the EU Water Framework Directive

### (9.2.10.3) List the specific substances included

*Nitrates, phosphates and other priority substances are monitored across our network of sites where required by local regulatory requirements and site discharge permits. This data is not aggregated at the corporate level.*

### (9.2.10.4) Please explain

*Nitrates, phosphates and other priority substances are monitored across our network of sites where required by local regulatory requirements and site discharge permits. This data is not aggregated at the corporate level.*

**(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities?**

### Direct operations

#### (9.3.1) Identification of facilities in the value chain stage

Select from:

- ☒ Yes, we have assessed this value chain stage and identified facilities with water-related dependencies, impacts, risks, and opportunities

#### (9.3.2) Total number of facilities identified

### (9.3.3) % of facilities in direct operations that this represents

Select from:

☒ 1-25

### (9.3.4) Please explain

*We have identified our facilities in La Jolla, California, US; Andover, Massachusetts, US; Toluca, Mexico; Ascoli, Italy; Vizag, India; Chennai, India; King Abdullah Economic City (KAEC), Saudi Arabia, and Sanford, North Carolina, US, as facilities exposed to water risks. Although these sites do not present a substantive risk to Pfizer's overall operation, they are important priorities from a water risk perspective and illustrative of the work we are doing to advance water stewardship across our operations.*

## Upstream value chain

### (9.3.1) Identification of facilities in the value chain stage

Select from:

☒ No, we have assessed this value chain stage but did not identify any facilities with water-related dependencies, impacts, risks, and opportunities

### (9.3.4) Please explain

*Pfizer uses natural hazard analysis and mapping tools to monitor short-, medium- and long-term physical threats for more than 5,000 contract manufacturers and material suppliers. We did not identify any contract manufacturers or material suppliers with substantive water-related dependencies, impacts, risks, and opportunities.*

**(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year.**

## Row 1

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 1

#### (9.3.1.2) Facility name (optional)

KAEC, Saudi Arabia

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

Saudi Arabia

☒ Other, please specify :Saudi Arabia; Red Sea, East Coast

#### (9.3.1.8) Latitude

22.5102

#### (9.3.1.9) Longitude

39.1004



**(9.3.1.10) Located in area with water stress**

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

10

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

10

**(9.3.1.21) Total water discharges at this facility (megaliters)**

3

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

3

**(9.3.1.27) Total water consumption at this facility (megaliters)**

7

**(9.3.1.28) Comparison of total consumption with previous reporting year**

Select from:

☒ Lower

### (9.3.1.29) Please explain

*The total water withdrawal at the KAEC, Saudi Arabia facility decreased by 39%, while the total water consumption decreased by 10%. Water discharges decreased by 65%. The decrease in withdrawal and consumption was due to changes in production. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.*

### Row 3

#### (9.3.1.1) Facility reference number

Select from:

☒ Facility 3

#### (9.3.1.2) Facility name (optional)

*La Jolla, California, US*

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

United States of America

☒ Other, please specify :San Diego, California

**(9.3.1.8) Latitude**

32.898

**(9.3.1.9) Longitude**

-117.2287

**(9.3.1.10) Located in area with water stress**

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

99

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ About the same

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

99

**(9.3.1.21) Total water discharges at this facility (megaliters)**

47

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

**(9.3.1.27) Total water consumption at this facility (megaliters)****(9.3.1.28) Comparison of total consumption with previous reporting year***Select from:*☒ Much higher**(9.3.1.29) Please explain**

*The total water withdrawal at the La Jolla, California facility increased by 1%. The site's water discharge decreased by 39% and total water consumption increased by 149% due to a change in the site's calculation methodology. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% compared to the previous year.*

**Row 4****(9.3.1.1) Facility reference number***Select from:*☒ Facility 4**(9.3.1.2) Facility name (optional)***Chennai, India***(9.3.1.3) Value chain stage***Select from:*☒ Direct operations**(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility**

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

India

☒ Other, please specify :India East Coast

#### (9.3.1.8) Latitude

12.9922

#### (9.3.1.9) Longitude

80.2437

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

1

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ About the same

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

1

**(9.3.1.21) Total water discharges at this facility (megaliters)**

0

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.23) Discharges to fresh surface water**

0



#### (9.3.1.24) Discharges to brackish surface water/seawater

0

#### (9.3.1.25) Discharges to groundwater

0

#### (9.3.1.26) Discharges to third party destinations

0

#### (9.3.1.27) Total water consumption at this facility (megaliters)

1

#### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much higher

#### (9.3.1.29) Please explain

Water withdrawal at the Chennai, India site increased by 1% in 2024 compared to 2023. Discharge was reduced by 100% through the implementation of water efficiency and reuse measures at the site. Water consumption at the site increased by 402% due to changes in production activities. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year.

### Row 5

#### (9.3.1.1) Facility reference number

Select from:

☒ Facility 5

#### (9.3.1.2) Facility name (optional)

Vizag, India

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

India

☒ Other, please specify :India East Coast

#### (9.3.1.8) Latitude

13.0494

#### (9.3.1.9) Longitude

80.239

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

302

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

302

**(9.3.1.21) Total water discharges at this facility (megaliters)**

142

#### (9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☒ Much lower

#### (9.3.1.23) Discharges to fresh surface water

0

#### (9.3.1.24) Discharges to brackish surface water/seawater

0

#### (9.3.1.25) Discharges to groundwater

0

#### (9.3.1.26) Discharges to third party destinations

142

#### (9.3.1.27) Total water consumption at this facility (megaliters)

160

#### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much lower

#### (9.3.1.29) Please explain

*Water withdrawal at the Vizag, India plant in 2024 decreased 17% and water discharge decreased 22%. The site's water consumption decreased 12%. The decrease in water withdrawal and discharge is due to water efficiency measure implementation at site. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

## Row 6

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 6

### (9.3.1.2) Facility name (optional)

Ascoli, Italy

### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

### (9.3.1.7) Country/Area & River basin

Italy

☒ Other, please specify :Italy East Coast

### (9.3.1.8) Latitude

42.8446

#### (9.3.1.9) Longitude

13.6541

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

123

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Lower

#### (9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

#### (9.3.1.16) Withdrawals from brackish surface water/seawater

0

#### (9.3.1.17) Withdrawals from groundwater - renewable

87

#### (9.3.1.18) Withdrawals from groundwater - non-renewable

0

#### (9.3.1.19) Withdrawals from produced/entrained water

0

**(9.3.1.20) Withdrawals from third party sources**

36

**(9.3.1.21) Total water discharges at this facility (megaliters)**

123

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Lower

**(9.3.1.23) Discharges to fresh surface water**

73

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

50

**(9.3.1.27) Total water consumption at this facility (megaliters)**

0

**(9.3.1.28) Comparison of total consumption with previous reporting year**

Select from:

☒ About the same

### (9.3.1.29) Please explain

*Water withdrawal and discharges in 2024 at the Ascoli, Italy plant were 7% lower due to changes in the site's production schedule. Water consumption in 2024 remained approximately the same compared to the previous reporting period. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year.*

## Row 7

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 7

### (9.3.1.2) Facility name (optional)

*Toluca, Mexico*

### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges



#### (9.3.1.7) Country/Area & River basin

Mexico

☒ Other, please specify :Río Lerma

#### (9.3.1.8) Latitude

19.2897

#### (9.3.1.9) Longitude

-99.6251

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

33

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Lower

#### (9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

#### (9.3.1.16) Withdrawals from brackish surface water/seawater

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

33

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

0

**(9.3.1.21) Total water discharges at this facility (megaliters)**

26

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Lower

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

### (9.3.1.26) Discharges to third party destinations

26

### (9.3.1.27) Total water consumption at this facility (megaliters)

7

### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Lower

### (9.3.1.29) Please explain

*Water withdrawal and water discharges at the Toluca, Mexico plant were 10% lower in 2024 compared to 2023. The decreases in water withdrawal and discharges were due to the implementation of water efficiency initiatives at the plant. Water consumption decreased by 9%. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.*

## Row 8

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 8

### (9.3.1.2) Facility name (optional)

*Andover, Massachusetts, US*

### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

United States of America

☒ Other, please specify :Atlantic Ocean Seaboard

#### (9.3.1.8) Latitude

42.6135

#### (9.3.1.9) Longitude

-71.1716

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

495

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ About the same

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

495

**(9.3.1.21) Total water discharges at this facility (megaliters)**

390

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Lower

#### (9.3.1.23) Discharges to fresh surface water

0

#### (9.3.1.24) Discharges to brackish surface water/seawater

0

#### (9.3.1.25) Discharges to groundwater

0

#### (9.3.1.26) Discharges to third party destinations

390

#### (9.3.1.27) Total water consumption at this facility (megaliters)

105

#### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Higher

#### (9.3.1.29) Please explain

*Water withdrawal volume at the Andover, Massachusetts plant did not change in 2024 while discharges were 2% lower due to site production changes. Water consumption was 9% higher. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% when compared to the previous year. Pfizer defines "higher" as an increase of 2% to 10% when compared to the previous year.*

### Row 9

#### (9.3.1.1) Facility reference number

Select from:

☒ Facility 9

#### (9.3.1.2) Facility name (optional)

*Sanford, North Carolina, US*

#### (9.3.1.3) Value chain stage

*Select from:*

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

*Select all that apply*

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

*Select from:*

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

United States of America

☒ Cape Fear River

#### (9.3.1.8) Latitude

*35.5351*

#### (9.3.1.9) Longitude

*-79.1758*

**(9.3.1.10) Located in area with water stress**

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

378

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ Higher

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**



378

**(9.3.1.21) Total water discharges at this facility (megaliters)**

342

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Much higher

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

342

**(9.3.1.27) Total water consumption at this facility (megaliters)**

36

**(9.3.1.28) Comparison of total consumption with previous reporting year**

Select from:

☒ Much lower

### (9.3.1.29) Please explain

*Water withdrawal at the Sanford, North Carolina site increased 6% and water discharge increased 20% in 2024 due to changes in production. Water consumption was 50% lower. Pfizer defines "higher" as an increase of 2% to 10% when compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

## (9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified?

### Water withdrawals – total volumes

#### (9.3.2.1) % verified

Select from:

☒ 76-100

#### (9.3.2.2) Verification standard used

*ISAE 3000. 2024 water data is independently verified to the limited assurance level.*

### Water withdrawals – volume by source

#### (9.3.2.1) % verified

Select from:

☒ Not verified

#### (9.3.2.3) Please explain

*Assurance of 2024 water data was limited to water withdrawal, water discharges and water consumption totals.*

### Water withdrawals – quality by standard water quality parameters

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2024 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water discharges – total volumes

### (9.3.2.1) % verified

Select from:

☒ 76-100

### (9.3.2.2) Verification standard used

*ISAE 3000. 2024 water data is independently verified to the limited assurance level.*

## Water discharges – volume by destination

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2024 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water discharges – volume by final treatment level

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2024 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water discharges – quality by standard water quality parameters

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2024 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water consumption – total volume

### (9.3.2.1) % verified

Select from:

☒ 76-100

### (9.3.2.2) Verification standard used

*ISAE 3000. 2024 water data is independently verified to the limited assurance level.*

## (9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member?

Select from:

☒ No, CDP supply chain members do not buy goods or services from facilities listed in 9.3.1

**(9.5) Provide a figure for your organization's total water withdrawal efficiency.**

	Revenue (currency)	Total water withdrawal efficiency	Anticipated forward trend
	63,627,000,000	2,065,744.62	<i>We expect water withdrawal to increase near-term, largely due to planned expansions and increased production.</i>

**(9.13) Do any of your products contain substances classified as hazardous by a regulatory authority?**

**(9.13.1) Products contain hazardous substances**

Select from:

☒ Unknown

**(9.13.2) Comment**

*At Pfizer we produce medicines and vaccines regulated by health authorities around the world for quality, safety, and efficacy. Additional guidance is needed to understand how this question applies to the bio-pharma sector.*

**(9.14) Do you classify any of your current products and/or services as low water impact?**

**(9.14.1) Products and/or services classified as low water impact**

Select from:

☒ No, but we plan to address this within the next two years

### (9.14.3) Primary reason for not classifying any of your current products and/or services as low water impact

Select from:

☒ Other, please specify :Currently working on developing product sustainability criteria.

### (9.14.4) Please explain

*To support environmental footprint reduction efforts, Pfizer is conducting representative life cycle assessments (LCAs) across our small molecule, large molecule, vaccines, and device portfolios. Guided by these assessments, we are working to define environmental sustainability criteria across the product lifecycle. We have conducted over 20 life cycle assessments (LCAs) measuring impacts across a range of product modalities, including small molecules, large molecules, vaccines, and medical devices. These LCAs provide valuable insights into the environmental impacts at each stage of a product's life. We share these insights with our scientists, researchers, and engineers to support sustainable innovation and impact reduction.*

### (9.15) Do you have any water-related targets?

Select from:

☒ Yes

#### (9.15.1) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories.

##### Water pollution

#### (9.15.1.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

#### (9.15.1.2) Please explain

*Pfizer is committed to limiting discharges to wastewater from our manufacturing processes as described within our Water Stewardship Position Statement ([https://cdn.pfizer.com/pfizercom/Pfizer\\_Water\\_Stewardship\\_Public\\_Position\\_Statement\\_2022.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf)).*

## Water withdrawals

### (9.15.1.1) Target set in this category

Select from:

☒ Yes

## Water, Sanitation, and Hygiene (WASH) services

### (9.15.1.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

### (9.15.1.2) Please explain

*Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees and therefore a WASH target is not relevant for our organization.*

## Other

### (9.15.1.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

### (9.15.1.2) Please explain

*Pfizer is committed to limiting discharges to wastewater from our manufacturing processes as described within our Water Stewardship Position Statement ([https://cdn.pfizer.com/pfizercom/Pfizer\\_Water\\_Stewardship\\_Public\\_Position\\_Statement\\_2022.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf)).*

## (9.15.2) Provide details of your water-related targets and the progress made.

### Row 1

#### (9.15.2.1) Target reference number

Select from:

☒ Target 1

#### (9.15.2.2) Target coverage

Select from:

☒ Business division

#### (9.15.2.3) Category of target & Quantitative metric

Water withdrawals

☒ Reduction in total water withdrawals

#### (9.15.2.4) Date target was set

01/01/2020

#### (9.15.2.5) End date of base year

12/31/2019

#### (9.15.2.6) Base year figure

13,344,248

#### (9.15.2.7) End date of target year

12/31/2030



#### (9.15.2.8) Target year figure

12,677,035

#### (9.15.2.9) Reporting year figure

12,118,324

#### (9.15.2.10) Target status in reporting year

Select from:

☒ Underway

#### (9.15.2.11) % of target achieved relative to base year

184

#### (9.15.2.12) Global environmental treaties/initiatives/ frameworks aligned with or supported by this target

Select all that apply

☒ Sustainable Development Goal 6

#### (9.15.2.13) Explain target coverage and identify any exclusions

*Pfizer has established an internal target to reduce water withdrawal, excluding non-contact cooling water, 5% by 2030 compared to a 2019 baseline. This target covers Pfizer's manufacturing sites, which account for approximately 95% of Pfizer's water withdrawal. Water withdrawal data for this target is presented in cubic meters.*

#### (9.15.2.14) Plan for achieving target, and progress made to the end of the reporting year

*Manufacturing sites are required to set annual water withdrawal targets and to maintain site masterplans which include water conservation projects. Pfizer's water withdrawal excluding non-contact cooling water decreased by 2% in 2024 compared to 2023 and remained 9% lower than the 2019 baseline.*

#### (9.15.2.16) Further details of target

*Pfizer anticipates water withdrawal to increase in the next 2-4 years largely due to expansions and increased production at our biologics manufacturing sites, but we will continue to work to offset these increases through improvements in water management and the implementation of conservation projects.*

## C10. Environmental performance - Plastics

### (10.1) Do you have plastics-related targets, and if so what type?

#### (10.1.1) Targets in place

Select from:

☒ Yes

#### (10.1.2) Target type and metric

End-of-life management

- ☒ Increase the proportion of recyclable plastic waste that we collect, sort, and recycle
- ☒ Reduce the proportion of plastic waste which is sent to landfill and/or incinerated

Extended Producer Responsibility (EPR)

- ☒ Ensure compliance with EPR policies and schemes

#### (10.1.3) Please explain

*Pfizer uses an internal performance metric to track site waste management practices as they relate to the hierarchy of control principles: avoid, reduce, reuse, recycle, dispose. This metric covers both hazardous and non-hazardous wastes, including plastic wastes, and is used to drive waste minimization and waste handling decisions to improve circularity. Our manufacturing sites set annual internal improvement targets and review performance quarterly. We are also able to use this metric to benchmark performance against others in the industry and identify opportunities for improvement.*

### (10.2) Indicate whether your organization engages in the following activities.

#### Production/commercialization of plastic polymers (including plastic converters)

### (10.2.1) Activity applies

Select from:

☒ No

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Pfizer does not engage in the production of plastic polymers.*

## Production/commercialization of durable plastic goods and/or components (including mixed materials)

### (10.2.1) Activity applies

Select from:

☒ No

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Pfizer does not engage in the production of plastic components.*

## Usage of durable plastics goods and/or components (including mixed materials)

### (10.2.1) Activity applies

Select from:

☒ Yes

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. We use plastics in equipment required for R&D and manufacturing (especially aseptic manufacturing) but primarily use them in packaging and product delivery systems, where their application is regulated and optimized for safety, efficiency, and minimal environmental impact.*

## Production/commercialization of plastic packaging

### (10.2.1) Activity applies

Select from:

☒ No

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Pfizer does not engage in the production/commercialization of plastic packaging.*

## Production/commercialization of goods/products packaged in plastics

### (10.2.1) Activity applies

Select from:

☒ Yes

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Plastic packaging is a necessary and non-discretionary component of our final products.*

## Provision/commercialization of services that use plastic packaging (e.g., food services)

### (10.2.1) Activity applies

Select from:

☒ Yes

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Plastic packaging is a necessary and non-discretionary component of our final products.*

## Provision of waste management and/or water management services

### (10.2.1) Activity applies

Select from:

☒ No

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Pfizer does not engage in the provision of waste and/or water management services.*

## Provision of financial products and/or services for plastics-related activities

### (10.2.1) Activity applies

Select from:

☒ No

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Pfizer does not provide financial products or services.*

## Other activities not specified

### (10.2.1) Activity applies

Select from:

☒ No

### (10.2.2) Comment

*Pfizer manufactures pharmaceuticals. Plastic packaging is a necessary and non-discretionary component of our pharmaceutical products but Pfizer does not engage in plastics production, commercialization, or other plastics-related activities.*

## (10.4) Provide the total weight of plastic durable goods and durable components produced, sold and/or used, and indicate the raw material content.

### Durable goods and durable components used

### (10.4.2) Raw material content percentages available to report

Select all that apply

☒ None

#### (10.4.7) Please explain

*Pfizer tracks quantities of plastic packaging use and its circularity potential where required by regulation, however this information is not collected at the corporate level.*

**(10.5) Provide the total weight of plastic packaging sold and/or used and indicate the raw material content.**

**Plastic packaging used**

#### (10.5.2) Raw material content percentages available to report

Select all that apply

☒ None

#### (10.5.7) Please explain

*Pfizer tracks quantities of plastic packaging use and its circularity potential where required by regulation, however this information is not collected at the corporate level.*

**(10.5.1) Indicate the circularity potential of the plastic packaging you sold and/or used.**

**Plastic packaging used**

#### (10.5.1.1) Percentages available to report for circularity potential

Select all that apply

☒ None

#### (10.5.1.5) Please explain

*Pfizer tracks quantities of plastic packaging use and its circularity potential where required by regulation, however this information is not collected at the corporate level.*



## C13. Further information & sign off

(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party?

	Other environmental information included in your CDP response is verified and/or assured by a third party
	Select from: <input checked="" type="checkbox"/> Yes

(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used?

### Row 1

#### (13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

#### (13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Base year emissions

#### (13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

#### (13.1.1.4) Further details of the third-party verification/assurance process

*Pfizer obtained limited assurance for its updated 2019 baseline emissions data, covering Scopes 1 and 2, as well as Scope 3 categories 1, 2, 4, 5, and 6. Base year emissions are relevant to targets Abs 3, Abs 6, and Abs 7 in module 7.*

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

*ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf*

### Row 2

#### (13.1.1.1) Environmental issue for which data has been verified and/or assured

*Select all that apply*

☒ Climate change

#### (13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Renewable Electricity/Steam/Heat/Cooling consumption

#### (13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

#### (13.1.1.4) Further details of the third-party verification/assurance process

*Renewable electricity consumption was verified to the limited assurance level. Verification is performed annually. Renewable electricity consumption is relevant to target Low 1 in module 7.*

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf

### Row 3

#### (13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

#### (13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Waste data

☒ Other data point in module 7, please specify :Emissions intensity

#### (13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

#### (13.1.1.4) Further details of the third-party verification/assurance process

Hazardous waste and emissions intensity data for facilities within Pfizer's operational control were verified to the limited assurance level. Verification is performed annually.

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf

### Row 4

#### (13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

#### (13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Other data point in module 7, please specify :Total Scope 3 GHG emissions from categories 1, 2, 3, 4, 5, 6, 7, 8 and 15.

#### (13.1.1.3) Verification/assurance standard

General standards

☒ ISAE 3000

#### (13.1.1.4) Further details of the third-party verification/assurance process

*In addition to obtaining assurance for individual Scope 3 categories as reported in module 7, Pfizer obtains limited assurance of total Scope 3 emissions from categories 1, 2, 3, 4, 5, 6, 7, 8, and 15 annually.*

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

*ERM CVS – CDP Assurance Report for Pfizer 2024\_20 August 2025.pdf*

### (13.3) Provide the following information for the person that has signed off (approved) your CDP response.

#### (13.3.1) Job title

*Executive Vice President, Chief Global Supply and Quality Officer*

#### (13.3.2) Corresponding job category

☒ President